{"e41164020be9e53be8929045dff66d0885e9a188": [["With the arrival of COVID-19, healthcare workers are fighting a lethal virus with PPE shortages and no evidence-based treatment.", [["COVID", "TEST", 20, 25], ["a lethal virus", "TREATMENT", 62, 76], ["PPE shortages", "TREATMENT", 82, 95], ["based treatment", "TREATMENT", 112, 127]]], ["These unprecedented conditions have greatly amplified the sources of emotional distress experienced by healthcare workers [2] [3] [4] .", [["emotional distress", "DISEASE", 69, 87], ["emotional distress", "PROBLEM", 69, 87]]], ["Without adequate PPE protection, the paramount fear expressed by healthcare workers is that they will not only get sick, but also spread the virus to their patients and families.", [["patients", "ORGANISM", 156, 164], ["patients", "SPECIES", 156, 164], ["adequate PPE protection", "TREATMENT", 8, 31], ["adequate", "OBSERVATION_MODIFIER", 8, 16], ["PPE", "OBSERVATION", 17, 20]]], ["Concurrently, healthcare workers are being forced to handle life and death situations on the frontlines, like never before.", [["death", "DISEASE", 69, 74]]], ["While patient care decisions were historically based on patient preferences, during COVID-19, with limited resources, these decisions are being based on triaging protocols, creating moral distress among healthcare workers, as they are being called upon to triage patients knowing there are a limited number of ICU beds and ventilators [6, 7] .", [["patient", "ORGANISM", 6, 13], ["patient", "ORGANISM", 56, 63], ["patients", "ORGANISM", 263, 271], ["patient", "SPECIES", 6, 13], ["patient", "SPECIES", 56, 63], ["patients", "SPECIES", 263, 271], ["triaging protocols", "TEST", 153, 171], ["ventilators", "TREATMENT", 323, 334]]], ["Other sources of A key concern of HCO (hospital) leaders during COVID-19, is their organization's ability to be resilient in adapting to the rapidly evolving pressures of the pandemic, to provide safe and effective care to their patients and communities [25, 26] .", [["HCO", "CHEMICAL", 34, 37], ["patients", "ORGANISM", 229, 237], ["patients", "SPECIES", 229, 237], ["COVID", "TEST", 64, 69], ["pressures", "OBSERVATION_MODIFIER", 158, 167]]], ["Given this primary concern, it is imperative for HCO leaders to recognize that a limited view of worker psychological safety (solely in terms of job security), without due consideration for the broader emotional distress created by the pandemic, could have the effect of severely restricting organizational resilience and adversely impacting patient safety and staff retention during and beyond the pandemic.", [["emotional distress", "DISEASE", 202, 220], ["patient", "ORGANISM", 342, 349], ["patient", "SPECIES", 342, 349], ["the broader emotional distress", "PROBLEM", 190, 220], ["staff retention", "PROBLEM", 361, 376]]], ["The purpose of this paper is to use the organizational resilience framework to discuss the potential impact of a stoic approach to healthcare worker support on resilience, patient safety and staff retention within a hospital ICU context, during the COVID-19 pandemic.", [["patient", "ORGANISM", 172, 179], ["patient", "SPECIES", 172, 179], ["a stoic approach", "TREATMENT", 111, 127], ["the COVID", "TEST", 245, 254], ["pandemic", "PROBLEM", 258, 266]]], ["The discussion, in turn, helps to develop recommendations for HCO leaders to overcome these challenges, ensure patient safety, and retain a resilient healthcare workforce during and beyond the pandemic period.Framework for Organizational Resilience in HCOsOn the frontlines of healthcare, resilience has been described as the ability to improvise with materials at hand to develop solutions to unexpected problems, thereby enabling patient care to be delivered safely despite obstacles [27] .", [["patient", "ORGANISM", 111, 118], ["patient", "ORGANISM", 432, 439], ["patient", "SPECIES", 111, 118], ["patient", "SPECIES", 432, 439], ["HCO leaders", "TREATMENT", 62, 73], ["these challenges", "TREATMENT", 86, 102], ["unexpected problems", "PROBLEM", 394, 413]]], ["Organizational resilience is known to have three interconnected levels: (i) the individual level, for example, individual healthcare workers who use workarounds to temporarily resolve recurring safety problems on the frontlines, and then communicate their safety concerns to managers, in an effort to prevent problem recurrence; (ii) the team level, for example, managers who encourage frontline healthcare workers to freely communicate their safety concerns, with a view to addressing underlying issues and preventing problem recurrence; and (iii) the organizational level, for example, senior leadership commitment to patient safety and lasting improvement (change) [28, 29] .", [["patient", "ORGANISM", 620, 627], ["patient", "SPECIES", 620, 627], ["recurring safety problems", "PROBLEM", 184, 209], ["problem recurrence", "PROBLEM", 309, 327], ["underlying issues", "PROBLEM", 486, 503], ["problem recurrence", "PROBLEM", 519, 537]]], ["Each of these elements in turn, can occur at each of the three levels outlined above (individual, team, and organization) [27] [28] [29] [30] [31] .", [["[27] [28] [29] [30] [31]", "SIMPLE_CHEMICAL", 122, 146]]], ["On the face of it, first-order problem solving appears successful because it allows patient care continues in the short term, however, its downside is the lack of communication about failures which keeps managers unaware of the need for change and prevents problems from being investigated, making it likely for problems to recur [27] .", [["patient", "ORGANISM", 84, 91], ["patient", "SPECIES", 84, 91]]], ["Second-order problem solving is necessary for the organization to learn from individual error recovery and ensure lasting improvement, i.e., apply safety standards for all patients, with minimal variation [27] [28] [29] [30] .Framework for Organizational Resilience in HCOsA resilient organization is one whose workers are supported in the key elements of foresight, coping, and recovery across the three levels (individual, team, and organization), so that safety is promoted at an organizational level, by anticipating failures, by learning how to adapt to circumstances of failure, and by restoring safe conditions after failure.", [["patients", "ORGANISM", 172, 180], ["patients", "SPECIES", 172, 180], ["failure", "PROBLEM", 576, 583], ["failure", "PROBLEM", 624, 631], ["failure", "OBSERVATION", 576, 583]]], ["The patient care process of clinical handover has been used to illustrate the concept of resilience in HCOs [31, 32] .", [["HCOs", "DISEASE", 103, 107], ["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11]]], ["Clinical handover is internationally recognized as a patient safety priority since it represents a disruption to the continuity of care and so may be especially prone to errors leading to patient harm.", [["patient", "ORGANISM", 53, 60], ["patient", "ORGANISM", 188, 195], ["patient", "SPECIES", 53, 60], ["patient", "SPECIES", 188, 195]]], ["When considering foresight, coping, and recovery elements in clinical handover across the three levels, an example of foresight at an individual level, would be a clinician contacting their replacement before shift change.", [["their replacement", "TREATMENT", 184, 201]]], ["At an organizational level, it would be workforce training and standard operating procedures about handover.", [["workforce training", "TREATMENT", 40, 58], ["standard operating procedures", "TREATMENT", 63, 92]]], ["Likewise, an example of coping at the individual level would be a clinician agreeing to stay on until a replacement is found.", [["a replacement", "TREATMENT", 102, 115]]], ["At an organizational level, it would be extensive documentation of clinical care by the day people identifying high-risk situations overnight.", [["people", "SPECIES", 92, 98]]], ["Lastly, an example of recovery at the individual level would be the clinician making the effort to ensure that supervisors are aware of the situation, as well as any patient care concerns emanating from that shift.", [["patient", "ORGANISM", 166, 173], ["patient", "SPECIES", 166, 173]]], ["They also help to understand that if resilience is restricted to individual level without advancing to team and organizational levels, it could leave the organization suspended in a reactive or brittle stage of resilience (as opposed to proactive or full resilience).", [["organizational levels", "TEST", 112, 133]]], ["In such a scenario, individual workers are left to deal with failures that are likely to recur, in the absence of systems for learning from individual error recovery at the organizational level, which, in turn, allows variation to persist in individual practices, creating room for error.", [["failures", "PROBLEM", 61, 69]]], ["Such a scenario, in turn, could force an organization to be easily overwhelmed even by minor disruptions, thereby restricting organizational resilience under challenging conditions [27, 31, 32] .", [["minor disruptions", "PROBLEM", 87, 104]]], ["On the other hand, when systems for learning from individual error recovery (problem-solving) are developed at the organizational level, it allows resilience to advance from individual to organizational levels, which, in turn, helps to prevent problem recurrence and ensure lasting improvement [27, 31] .", [["organizational levels", "TEST", 188, 209], ["problem recurrence", "PROBLEM", 244, 262]]], ["In the case of clinical handover therefore, advancing from individual to organizational resilience, has the potential to transform clinical handover from a source of vulnerability, to a source of patient safety, with proactive mechanisms in place to recover from errors and prevent future process failures.Worker Trust and Psychological Safety are Pre-Requisites for Organizational Resilience in HCOsAs discussed earlier, healthcare workers on the frontlines often need to make trade-offs to deal with mismatches between demand and capacity, and manage competing priorities.", [["patient", "ORGANISM", 196, 203], ["patient", "SPECIES", 196, 203], ["proactive mechanisms", "TREATMENT", 217, 237], ["future process failures", "PROBLEM", 282, 305]]], ["This requires negotiation with coworkers and flexible interpretation of organizational protocols [27, 33, 34] .", [["organizational protocols", "TREATMENT", 72, 96]]], ["For the individual healthcare worker, this involves taking interpersonal risks, i.e., trusting coworkers and managers to work towards a shared goal, and feeling safe in flexible interpretation of protocols to provide safe patient care [33] .", [["patient", "ORGANISM", 222, 229], ["patient", "SPECIES", 222, 229]]], ["In a similar vein, psychological safety has been defined as individuals' perceptions about the consequences of taking interpersonal risks in their work environment [34] .", [["vein", "ANATOMY", 13, 17], ["vein", "MULTI-TISSUE_STRUCTURE", 13, 17], ["similar vein", "ANATOMY", 5, 17]]], ["Under normal circumstances (as opposed to COVID-19), psychological safety may be viewed in terms of the ultimate fear of losing one's job or license, if one puts oneself on the line by asking a question, reporting a mistake, or proposing a new idea.", [["COVID", "TEST", 42, 47], ["normal", "OBSERVATION", 6, 12]]], ["When employees trust they will be supported, they are likely to feel psychologically safe and empowered to communicate safety concerns to managers, which, in turn, enables patient safety to improve in everyday practice for all patients [27, 33] .", [["patient", "ORGANISM", 172, 179], ["patients", "ORGANISM", 227, 235], ["patient", "SPECIES", 172, 179], ["patients", "SPECIES", 227, 235]]], ["Clearly, both trust and psychological safety are essential for healthcare workers to make tradeoffs and communicate safety concerns to managers, who are in a position to address underlying causes of errors and prevent problem recurrence.", [["problem recurrence", "PROBLEM", 218, 236]]], ["The latter, in turn, is essential for resilience to advance from individual to organizational levels.", [["organizational levels", "TEST", 79, 100]]], ["Correspondingly, the literature has underscored the importance of worker trust and psychological safety in serving as pre-requisites for organizational resilience [33] .Need for a Holistic Consideration of Worker Psychological Safety during COVID-19 to Provide for the Broader Impact of Emotional Distress and BurnoutIt is important for HCO leaders to recognize that emotional distress emanating from a broad array of fears during COVID-19 can supersede the psychological safety of having just one fear addressed, of losing one's job or license.", [["emotional distress", "DISEASE", 367, 385], ["Emotional Distress", "PROBLEM", 287, 305], ["emotional distress", "PROBLEM", 367, 385]]], ["Therefore, while it may be reasonable to view worker psychological safety primarily from the perspective of job security during normal times, it is essential to adopt a more holistic consideration of psychological safety during unprecedented times like COVID-19, to provide for the broader impact of emotional distress and worker burnout [12] [13] [14] [15] 35, 36] .", [["emotional distress", "DISEASE", 300, 318], ["psychological safety", "TREATMENT", 200, 220], ["emotional distress", "PROBLEM", 300, 318]]], ["This line of reasoning is echoed by a growing stream of pandemic literature calling attention to the heightened risk of worker burnout during the pandemic [2] [3] [4] [12] [13] [14] [15] .", [["burnout", "DISEASE", 127, 134], ["[2] [3] [4] [12] [13] [14] [15]", "CHEMICAL", 155, 186], ["[2] [3] [4] [12] [13] [14] [15]", "SIMPLE_CHEMICAL", 155, 186]]], ["For example, a recent opinion article in JAMA discusses a strategy for supporting the emotional well-being of healthcare workers during the pandemic, to prevent burnout [12] .", [["burnout", "DISEASE", 161, 168]]], ["The article underscores the importance of listening to the specific concerns and needs of healthcare workers and responding in a meaningful way, by facilitating access to essential services to meet those needs, along with emotional and social support.", [["social support", "TREATMENT", 236, 250]]], ["The article also cautions against recycling wellness offerings of the past (e.g., teaching generic approaches to stress reduction) during the unprecedented conditions created by COVID-19 [12, 13] .Need for a Holistic Consideration of Worker Psychological Safety during COVID-19 to Provide for the Broader Impact of Emotional Distress and BurnoutWorker burnout, which has been described as one of the leading concerns for patient safety, refers to the human response to chronic emotional and interpersonal stress at work, defined by exhaustion, cynicism and inefficiency [37] [38] [39] [40] [41] .", [["stress reduction", "DISEASE", 113, 129], ["BurnoutWorker burnout", "DISEASE", 338, 359], ["COVID-19", "CHEMICAL", 178, 186], ["[37] [38] [39] [40]", "CHEMICAL", 570, 589], ["patient", "ORGANISM", 421, 428], ["human", "ORGANISM", 451, 456], ["[37] [38] [39] [40] [41]", "SIMPLE_CHEMICAL", 570, 594], ["patient", "SPECIES", 421, 428], ["human", "SPECIES", 451, 456], ["human", "SPECIES", 451, 456], ["stress reduction", "TREATMENT", 113, 129], ["COVID", "TEST", 178, 183], ["Emotional Distress", "PROBLEM", 315, 333], ["chronic emotional and interpersonal stress at work", "PROBLEM", 469, 519], ["cynicism", "PROBLEM", 544, 552]]], ["A 2017 literature review on nurse burnout showed that a key factor contributing to burnout was exclusion from the decision-making process [42] .", [["burnout", "DISEASE", 83, 90], ["burnout", "PROBLEM", 83, 90]]], ["According to this literature, HCOs that implement resilience-training may experience reduced burnout, increased patient safety, and increased staff retention [38, 46] .", [["burnout", "DISEASE", 93, 100], ["patient", "ORGANISM", 112, 119], ["patient", "SPECIES", 112, 119], ["reduced burnout", "PROBLEM", 85, 100], ["increased", "OBSERVATION_MODIFIER", 102, 111]]], ["However, resilience-training by itself cannot effectively address burnout, unless the leadership strives to create a work environment of mutual trust and psychological safety, to empower healthcare workers to communicate safety concerns and participate in the decision-making process.", [["burnout", "DISEASE", 66, 73]]], ["The latter, in turn, is required for resilience to progress from individual (reactive/brittle) to organizational (proactive/full) levels [43] [44] [45] .Absence of Leadership Support for Emotional Distress during COVID-19 Could Adversely Impact Organizational Resilience, Patient Safety, and Staff RetentionAt the outset of the COVID-19 pandemic, Stanford Medicine (California, USA) conducted multiple listening sessions with groups of healthcare professionals (69 total), including physicians, nurses, and advanced practice providers, to explore what healthcare workers were most concerned about and what messages and behaviors they needed most from their leaders [12, 13] .", [["individual (reactive/brittle)", "PROBLEM", 65, 94], ["organizational (proactive/full) levels", "TEST", 98, 136], ["Leadership Support", "TREATMENT", 164, 182], ["Emotional Distress", "PROBLEM", 187, 205]]], ["These discussions identified eight sources of anxiety: (1) adequate access to PPE; (2) exposure to COVID-19 at work and taking the infection home to family, (3) inadequate access to COVID-19 testing if symptoms develop since the infection could be propagated at work, (4) uncertainty about whether their organization would support their needs if they develop infection, (5) access to childcare during school closures and increased work hours, (6) support for additional needs as work hours increase (food, lodging, transportation), (7) ability to provide competent care in a new area (e.g., non-ICU nurses deployed to serve as ICU nurses), and (8) inadequate communication and information.", [["anxiety", "DISEASE", 46, 53], ["COVID-19", "CHEMICAL", 99, 107], ["infection", "DISEASE", 131, 140], ["infection", "DISEASE", 229, 238], ["infection", "DISEASE", 359, 368], ["anxiety", "PROBLEM", 46, 53], ["COVID", "TREATMENT", 99, 104], ["COVID-19 testing", "TEST", 182, 198], ["symptoms", "PROBLEM", 202, 210], ["the infection", "PROBLEM", 225, 238], ["infection", "PROBLEM", 359, 368], ["infection", "OBSERVATION", 359, 368]]], ["To summarize, the focus group sessions found that healthcare workers need unambiguous assurance that their organizations will support their well-being during COVID-19.", [["COVID", "TEST", 158, 163]]], ["Above all, healthcare workers needed to be able to trust their organizations and leaders to have their backs during the COVID-19 pandemic [12, 13, 47, 48] .Absence of Leadership Support for Emotional Distress during COVID-19 Could Adversely Impact Organizational Resilience, Patient Safety, and Staff RetentionThe above discussion provides a broad understanding of how a stoic approach to healthcare worker support, i.e., the absence of leadership support for the broader emotional distress and burnout created by COVID-19, could lead to the erosion of trust and psychological safety needed for healthcare workers to freely communicate patient safety concerns to their managers.", [["emotional distress", "DISEASE", 472, 490], ["burnout", "DISEASE", 495, 502], ["backs", "ORGANISM_SUBDIVISION", 103, 108], ["patient", "ORGANISM", 636, 643], ["patient", "SPECIES", 636, 643], ["Leadership Support", "TREATMENT", 167, 185], ["Emotional Distress", "PROBLEM", 190, 208], ["leadership support", "TREATMENT", 437, 455], ["the broader emotional distress", "PROBLEM", 460, 490], ["burnout", "PROBLEM", 495, 502], ["COVID", "TEST", 514, 519], ["the erosion of trust", "PROBLEM", 538, 558], ["erosion", "OBSERVATION", 542, 549]]], ["The latter, in turn, has the potential to severely restrict organizational resilience and adversely impact patient safety and staff retention, during and beyond the pandemic period.Application of Organizational Resilience Framework to the Hospital ICU ContextThis section applies the organizational resilience framework to the hospital ICU context, to provide a more nuanced illustration of the potential impact of a stoic approach to healthcare worker support (i.e., absence of leadership support for emotional distress during COVID-19), on organizational resilience, patient safety and staff retention, during and beyond the pandemic.", [["emotional distress", "DISEASE", 502, 520], ["patient", "ORGANISM", 107, 114], ["patient", "ORGANISM", 569, 576], ["patient", "SPECIES", 107, 114], ["patient", "SPECIES", 569, 576], ["a stoic approach", "TREATMENT", 415, 431], ["leadership support", "TREATMENT", 479, 497], ["emotional distress", "PROBLEM", 502, 520], ["COVID", "TEST", 528, 533]]], ["The application in turn, helps to develop recommendations for HCOs to overcome these challenges, ensure patient safety, and retain a resilient healthcare workforce during and beyond the pandemic.Application of Organizational Resilience Framework to the Hospital ICU ContextPotential Impact of the \"Stoic Approach\" on Resilience, Patient Safety, and Staff Retention in ICUsApplication of Organizational Resilience Framework to the Hospital ICU ContextIn areas most affected by pandemic, hospital ICUs are experiencing rapid changes in practice environments to meet the pressures of increased demands for ICU beds, with limited resources, e.g., conversion of observation units into makeshift ICUs, use of \"float-pool\" (non-ICU) nurses to function as ICU nurses, and in some cases, placing two patients on a single ventilator, all within the context of acute shortage (limited supply) of essential PPE [6, 21, 22] .", [["patient", "ORGANISM", 104, 111], ["patients", "ORGANISM", 791, 799], ["patient", "SPECIES", 104, 111], ["patients", "SPECIES", 791, 799], ["HCOs", "TREATMENT", 62, 66], ["these challenges", "TREATMENT", 79, 95], ["rapid changes in practice environments", "PROBLEM", 517, 555], ["ICU beds", "TREATMENT", 603, 611], ["a single ventilator", "TREATMENT", 803, 822]]], ["In this scenario, frontline ICU nurses are faced with having to implement dynamic tradeoffs and workarounds to patient care processes on a daily basis, to resolve problems and ensure patient safety under challenging conditions [22] .Application of Organizational Resilience Framework to the Hospital ICU ContextFor example, during COVID-19, a number of ICU patients are placed on medications (such as fentanyl, propofol, and pressor drugs) that require titration (dose adjustment) on an ongoing basis, sometimes every 5, 10, or 15 mins, to ensure effective dosage and prevent side effects.", [["fentanyl", "CHEMICAL", 401, 409], ["propofol", "CHEMICAL", 411, 419], ["fentanyl", "CHEMICAL", 401, 409], ["propofol", "CHEMICAL", 411, 419], ["patient", "ORGANISM", 111, 118], ["patient", "ORGANISM", 183, 190], ["patients", "ORGANISM", 357, 365], ["fentanyl", "SIMPLE_CHEMICAL", 401, 409], ["propofol", "SIMPLE_CHEMICAL", 411, 419], ["patient", "SPECIES", 111, 118], ["patient", "SPECIES", 183, 190], ["patients", "SPECIES", 357, 365], ["COVID", "TEST", 331, 336], ["medications", "TREATMENT", 380, 391], ["fentanyl", "TREATMENT", 401, 409], ["propofol", "TREATMENT", 411, 419], ["pressor drugs", "TREATMENT", 425, 438], ["titration (dose adjustment", "TREATMENT", 453, 479], ["side effects", "PROBLEM", 576, 588]]], ["Drugs requiring titration are typically administered intravenously (IV).", [["Drugs", "TREATMENT", 0, 5], ["titration", "TREATMENT", 16, 25]]], ["Under normal circumstances, drug titration requires frontline nurses to enter and exit the patient's room multiple times within the span of an hour, to adjust dosage on the patient's IV bag, as needed.", [["patient", "ORGANISM", 91, 98], ["patient", "ORGANISM", 173, 180], ["patient", "SPECIES", 91, 98], ["patient", "SPECIES", 173, 180], ["drug titration", "TREATMENT", 28, 42], ["the patient's IV bag", "TREATMENT", 169, 189], ["normal", "OBSERVATION", 6, 12]]], ["However, amidst acute PPE shortages during the COVID-19 pandemic, the higher the frequency of entering and exiting patient rooms, the greater the risk of exposure to the virus for nurses (healthcare workers), which, in turn, increases their risk of spreading the virus to other coworkers, patients, and their families.", [["patient", "ORGANISM", 115, 122], ["patients", "ORGANISM", 289, 297], ["patient", "SPECIES", 115, 122], ["patients", "SPECIES", 289, 297], ["amidst acute PPE shortages", "PROBLEM", 9, 35], ["the COVID", "TEST", 43, 52], ["acute", "OBSERVATION_MODIFIER", 16, 21], ["PPE", "OBSERVATION_MODIFIER", 22, 25]]], ["Therefore, to mitigate their own risk of exposure amidst PPE shortages, ICU nurses are faced with having to identify innovative ways to titrate IV medications as often as needed, while limiting the frequency with which they enter and exit patient rooms.", [["patient", "ORGANISM", 239, 246], ["patient", "SPECIES", 239, 246], ["IV medications", "TREATMENT", 144, 158]]], ["In this scenario, one potential solution could be to bring all patient IV bag-stands outside the patient rooms into the ICU hallway, to enable drug titration without entering patient rooms.", [["patient", "ORGANISM", 63, 70], ["patient", "ORGANISM", 97, 104], ["patient", "ORGANISM", 175, 182], ["patient", "SPECIES", 63, 70], ["patient", "SPECIES", 97, 104], ["patient", "SPECIES", 175, 182], ["all patient IV bag", "TREATMENT", 59, 77], ["drug titration", "TREATMENT", 143, 157]]], ["However, the flip side to this dynamic trade-off, is that it poses an increased risk to patient safety by making it difficult to concurrently verify two unique identifiers prior to medication changes, one for the medication and one for the patient.", [["patient", "ORGANISM", 88, 95], ["patient", "ORGANISM", 240, 247], ["patient", "SPECIES", 88, 95], ["patient", "SPECIES", 240, 247], ["medication changes", "TREATMENT", 181, 199], ["the medication", "TREATMENT", 209, 223], ["increased", "OBSERVATION_MODIFIER", 70, 79]]], ["Under normal circumstances, both medication and patient would be verified (scanned) every time dosage is changed, to ensure that the correct medication reaches the correct patient, in accordance with international patient safety protocols for prevention of medication errors [49] .", [["patient", "ORGANISM", 48, 55], ["patient", "ORGANISM", 172, 179], ["patient", "ORGANISM", 214, 221], ["patient", "SPECIES", 48, 55], ["patient", "SPECIES", 172, 179], ["patient", "SPECIES", 214, 221], ["both medication", "TREATMENT", 28, 43], ["the correct medication", "TREATMENT", 129, 151], ["international patient safety protocols", "TREATMENT", 200, 238], ["medication errors", "PROBLEM", 257, 274], ["normal", "OBSERVATION", 6, 12]]], ["However, bringing the IV bag-stand outside the patient room makes it difficult for the patient to be concurrently verified.", [["patient", "ORGANISM", 47, 54], ["patient", "ORGANISM", 87, 94], ["patient", "SPECIES", 47, 54], ["patient", "SPECIES", 87, 94], ["the IV bag", "TREATMENT", 18, 28]]], ["Additionally, since the IV bag-stands for all COVID-19 patients are placed next to each other in a common hallway, there is greater scope for confusion as to which IV bag-stand belongs to which patient, and hence, a higher risk of medication error by way of wrong medication to the wrong patient.", [["confusion", "DISEASE", 142, 151], ["patients", "ORGANISM", 55, 63], ["patient", "ORGANISM", 194, 201], ["patient", "ORGANISM", 288, 295], ["patients", "SPECIES", 55, 63], ["patient", "SPECIES", 194, 201], ["patient", "SPECIES", 288, 295], ["the IV bag", "TREATMENT", 20, 30], ["all COVID", "TREATMENT", 42, 51], ["confusion", "PROBLEM", 142, 151], ["IV bag", "TREATMENT", 164, 170], ["medication error", "PROBLEM", 231, 247], ["wrong medication", "TREATMENT", 258, 274]]], ["To mitigate this patient safety risk prior to drug titration, an individual ICU nurse may call upon a nurse colleague in the ICU to double-check that the IV bag-stand being titrated, corresponds to the correct patient (which in turn, is an example of resilience on the frontlines that enables safe care to be provided in the ICU, despite obstacles during COVID-19).Application of Organizational Resilience Framework to the Hospital ICU ContextHowever, this novel workaround developed by some ICU nurses would need to become standard protocol at the unit level to ensure safety of all patients receiving titrated medication on the ICU.", [["patient", "ORGANISM", 17, 24], ["patient", "ORGANISM", 210, 217], ["patients", "ORGANISM", 584, 592], ["patient", "SPECIES", 17, 24], ["patient", "SPECIES", 210, 217], ["patients", "SPECIES", 584, 592], ["drug titration", "TREATMENT", 46, 60], ["the IV bag", "TREATMENT", 150, 160], ["safe care", "TREATMENT", 293, 302], ["COVID", "TEST", 355, 360], ["standard protocol", "TREATMENT", 524, 541], ["titrated medication", "TREATMENT", 603, 622]]], ["However, under rapidly evolving pressures created by COVID-19, a number of barriers to communication could arise due to trust issues.", [["COVID-19", "CHEMICAL", 53, 61], ["COVID", "TEST", 53, 58], ["trust issues", "PROBLEM", 120, 132], ["pressures", "OBSERVATION_MODIFIER", 32, 41]]], ["For example, regular ICU nurses who originally devised the workarounds may not trust float-pool (non-ICU) nurses new to the ICU to properly implement practice changes due to inadequate training.", [["practice changes", "TREATMENT", 150, 166], ["inadequate training", "TREATMENT", 174, 193]]], ["This lack of trust, in turn, may serve as a barrier to involving float-pool nurses in workarounds that have been designed to ensure patient safety amidst rapid process changes.", [["patient", "ORGANISM", 132, 139], ["patient", "SPECIES", 132, 139]]], ["Such a situation in turn, has the potential to increase variation in drug titration practices in the ICU, thereby increasing the opportunity for error and patient harm.Application of Organizational Resilience Framework to the Hospital ICU ContextSimilarly, communication between regular ICU nurses and managers could suffer due to lack of visibility of managers on the frontlines of ICU care.", [["patient", "ORGANISM", 155, 162], ["patient", "SPECIES", 155, 162], ["drug titration practices", "TREATMENT", 69, 93], ["ICU care", "TREATMENT", 383, 391]]], ["In the absence of any efforts from managers and senior hospital leaders to be present on the frontlines to understand the challenges, ICU nurses may feel betrayed by lack of emotional support from the leadership, for the unprecedented risks, pressures, and moral distress experienced on the frontlines during COVID-19.", [["emotional support", "TREATMENT", 174, 191], ["pressures", "TEST", 242, 251], ["moral distress", "PROBLEM", 257, 271], ["COVID", "TEST", 309, 314]]], ["This lack of trust, in turn, has potential to considerably hinder communication related to patient safety between ICU nurses and managers.", [["patient", "ORGANISM", 91, 98], ["patient", "SPECIES", 91, 98]]], ["In the absence of systems for learning from individual error recovery (problem-solving) at the organizational level, resilience remains reactive (brittle) and restricted to the frontlines, with no way of advancing to team and organizational levels.", [["organizational levels", "TEST", 226, 247], ["reactive", "OBSERVATION_MODIFIER", 136, 144]]], ["This prevents the safety-benefits of novel workarounds (developed by some ICU nurses) from being applied to all patients on the unit.", [["patients", "ORGANISM", 112, 120], ["patients", "SPECIES", 112, 120]]], ["When resilience remains restricted to the individual level, it has potential to engender practice variations on the frontlines, thereby increasing the likelihood of unsafe practices and preventable errors.Application of Organizational Resilience Framework to the Hospital ICU ContextAnother example of a workaround implemented by ICU nurses to ensure patient safety during COVID-19, may be the use of written handoff sheets (to supplement verbal handoffs) during the end-of-shift clinical handover process.", [["patient", "ORGANISM", 351, 358], ["patient", "SPECIES", 351, 358], ["preventable errors", "PROBLEM", 186, 204]]], ["Owing to large volumes of high-severity patients and time constraints in the handoff process during COVID-19, regular ICU nurses may have worked to develop a template for written handoffs to supplement verbal handoffs during the shift handover process.", [["patients", "ORGANISM", 40, 48], ["patients", "SPECIES", 40, 48], ["verbal handoffs", "TREATMENT", 202, 217], ["large", "OBSERVATION_MODIFIER", 9, 14], ["volumes", "OBSERVATION_MODIFIER", 15, 22], ["high-severity", "OBSERVATION_MODIFIER", 26, 39]]], ["The written handoff sheets, in turn, may be crucial for incoming nurses to gain a quick overview of patients' medical histories (that are used to calculate patient risk scores).", [["patients", "ORGANISM", 100, 108], ["patient", "ORGANISM", 156, 163], ["patients", "SPECIES", 100, 108], ["patient", "SPECIES", 156, 163]]], ["The risk scores, in turn, could be vital in helping nurses determine the priorities for patient care in the unit (e.g., in responding to changes in patient conditions resulting from medication changes), which, in turn, may be crucial for patient safety.", [["patient", "ORGANISM", 88, 95], ["patient", "ORGANISM", 148, 155], ["patient", "ORGANISM", 238, 245], ["patient", "SPECIES", 88, 95], ["patient", "SPECIES", 148, 155], ["patient", "SPECIES", 238, 245], ["The risk scores", "PROBLEM", 0, 15], ["medication changes", "TREATMENT", 182, 200]]], ["However, owing to interpersonal trust issues (discussed earlier), the regular ICU nurses who devised these novel workarounds (written handoff templates), may refrain from sharing them with their peers (e.g., float-pool nurses) and their managers, thereby propagating a pattern of reactive (brittle) resilience on the frontlines that has no way of advancing to team and organizational levels.", [["reactive (brittle) resilience", "PROBLEM", 280, 309], ["organizational levels", "TEST", 369, 390], ["reactive", "OBSERVATION_MODIFIER", 280, 288]]], ["The latter in turn, has potential to increase the potential for practice variation, errors, and preventable deaths in the ICU.Application of Organizational Resilience Framework to the Hospital ICU ContextAs discussed earlier, being forced to witness unsafe practices, preventable errors, and large volumes of deaths on the frontlines, has potential to create chronic emotional and interpersonal stress, leading to exhaustion and cynicism, the classic symptoms of nurse burnout [4] [5] [6] .", [["deaths", "DISEASE", 108, 114], ["deaths", "DISEASE", 309, 315], ["chronic emotional and interpersonal stress", "DISEASE", 359, 401], ["practice variation", "PROBLEM", 64, 82], ["preventable errors", "PROBLEM", 268, 286], ["chronic emotional and interpersonal stress", "PROBLEM", 359, 401], ["exhaustion", "PROBLEM", 414, 424], ["cynicism", "PROBLEM", 429, 437], ["the classic symptoms", "PROBLEM", 439, 459], ["large", "OBSERVATION_MODIFIER", 292, 297], ["chronic", "OBSERVATION_MODIFIER", 359, 366]]], ["Burnout resulting from chronic emotional distress in turn, has potential to result in high staff turnover and low retention not only during COVID-19, but beyond the pandemic period [2] [3] [4] [12] [13] [14] [15] .", [["Burnout", "DISEASE", 0, 7], ["chronic emotional distress", "DISEASE", 23, 49], ["[2] [3] [4] [12] [13] [14] [15]", "CHEMICAL", 181, 212], ["[2] [3] [4] [12] [13] [14] [15]", "SIMPLE_CHEMICAL", 181, 212], ["Burnout", "PROBLEM", 0, 7], ["chronic emotional distress", "PROBLEM", 23, 49], ["high staff turnover", "PROBLEM", 86, 105], ["low retention", "PROBLEM", 110, 123], ["COVID", "TEST", 140, 145], ["chronic", "OBSERVATION_MODIFIER", 23, 30], ["emotional distress", "OBSERVATION", 31, 49]]], ["For example, burnout may prompt healthcare workers to contemplate moving to a different HCO (e.g., ICU in a different hospital) or to a different setting of care (e.g., from the ICU to outpatient clinic practice) or to pursue an alternate career altogether, which in turn, could endanger society's ability to sustain an adequate healthcare workforce to fulfill HCO operations in the short run, and to meet to public health needs in the longer run, should a similar pandemic recur in the future.Application of Organizational Resilience Framework to the Hospital ICU ContextIn summary, a stoic approach to healthcare worker support during the pandemic has the potential to severely restrict organizational resilience needed to recover from setbacks in patient care, by eroding trust and mitigating communication from healthcare workers to managers regarding safety concerns.", [["burnout", "DISEASE", 13, 20], ["patient", "ORGANISM", 750, 757], ["patient", "SPECIES", 750, 757], ["HCO operations", "TREATMENT", 361, 375]]], ["The latter, in turn, has the potential to adversely impact patient safety, staff retention, and HCO operations, during and beyond the pandemic period.Discussion: Recommendations for HCO LeadershipThe above framework application suggests that in order to preserve organizational resilience during the COVID-19 pandemic, HCO leaders need to adopt a holistic consideration of worker psychological safety-one that recognizes the complex impact of emotional distress experienced by healthcare workers during the pandemic.", [["emotional distress", "DISEASE", 443, 461], ["patient", "ORGANISM", 59, 66], ["patient", "SPECIES", 59, 66], ["staff retention", "TREATMENT", 75, 90], ["HCO operations", "TREATMENT", 96, 110], ["The above framework application", "TREATMENT", 196, 227], ["the COVID", "TEST", 296, 305], ["emotional distress", "PROBLEM", 443, 461]]], ["Meaningful support for emotional distress during the pandemic, can enable healthcare workers to trust that their organization is putting its people first, which, in turn, can enable them to feel psychologically safe and empowered to speak up about safety concerns and workarounds implemented on the frontlines [12, 13, 33] .", [["emotional distress", "DISEASE", 23, 41], ["people", "ORGANISM", 141, 147], ["people", "SPECIES", 141, 147], ["Meaningful support", "TREATMENT", 0, 18], ["emotional distress", "PROBLEM", 23, 41]]], ["Since communication between healthcare workers and managers in regard to workarounds, is crucial for resilience to advance from individual to organizational levels, the first recommendation for HCO leaders would be to create a work environment characterized by trust, psychological safety, and empowerment, to enable healthcare workers to freely communicate safety concerns with their managers.Discussion: Recommendations for HCO LeadershipConcurrently, since learning from individual error recovery is crucial for advancing from reactive (brittle) resilience at the frontlines to proactive (full) resilience at the organizational level, the second recommendation for HCO leaders would be to develop communication structures that enable the organization to learn from individual error recovery (problem-solving) strategies.", [["organizational levels", "TEST", 142, 163], ["HCO leaders", "TREATMENT", 194, 205], ["advancing from reactive (brittle) resilience", "PROBLEM", 515, 559], ["HCO leaders", "TREATMENT", 668, 679], ["communication structures", "PROBLEM", 700, 724], ["solving) strategies", "TREATMENT", 803, 822], ["reactive", "OBSERVATION_MODIFIER", 530, 538]]], ["Advancing from reactive to proactive resilience at an organizational level in turn, can help to eliminate practice variation and enable all patients to benefit from the tradeoffs and workarounds implemented on the frontlines, to keep patients safe despite obstacles.", [["patients", "ORGANISM", 140, 148], ["patients", "ORGANISM", 234, 242], ["patients", "SPECIES", 140, 148], ["patients", "SPECIES", 234, 242], ["proactive resilience", "TREATMENT", 27, 47], ["the tradeoffs", "TREATMENT", 165, 178], ["the frontlines", "TREATMENT", 210, 224], ["reactive", "OBSERVATION_MODIFIER", 15, 23]]], ["Both sets of recommendations for HCO leaders are discussed below.Recommendation 1: Create an Environment of Trust, Psychological Safety, and Empowerment to Enable Individual Workers to Communicate Patient Safety Concerns to ManagersFrom the earlier discussion, we can infer that a key strategy for building trust during the pandemic, would be for leaders to listen to the specific concerns of healthcare workers, understand the sources of emotional distress, assure healthcare workers that their concerns have been heard, and provide targeted support to mitigate concerns to the greatest extent possible [12, 13, 35, 36] .", [["emotional distress", "DISEASE", 439, 457], ["Patient", "SPECIES", 197, 204], ["HCO leaders", "TREATMENT", 33, 44], ["emotional distress", "PROBLEM", 439, 457]]], ["For example, to address specific concerns about access to PPE, spreading infection to family, and lack of access to rapid testing, HCO leaders must provide adequate PPE, rapid access to occupational health with testing, and resources to avoid spreading the infection at home, if necessary.", [["infection", "DISEASE", 73, 82], ["infection", "DISEASE", 257, 266], ["PPE", "PROBLEM", 58, 61], ["spreading infection", "PROBLEM", 63, 82], ["rapid testing", "TEST", 116, 129], ["HCO leaders", "TREATMENT", 131, 142], ["testing", "TEST", 211, 218], ["the infection", "PROBLEM", 253, 266], ["infection", "OBSERVATION", 73, 82], ["infection", "OBSERVATION", 257, 266]]], ["Similarly, to address specific concerns about not being able to provide competent care to an unfamiliar patient base, HCO leaders must provide access to training to build a critical knowledge base while striving to promote teamwork, solidarity, and communication.", [["patient", "ORGANISM", 104, 111], ["patient", "SPECIES", 104, 111], ["competent care", "TREATMENT", 72, 86]]], ["They must acknowledge unprecedented challenges faced by healthcare workers and encourage individuals to ask for help and rely on each other for support, rather than going it alone [12, 22] .Recommendation 1: Create an Environment of Trust, Psychological Safety, and Empowerment to Enable Individual Workers to Communicate Patient Safety Concerns to ManagersIn addition to providing targeted support for concerns, leaders need to be visible on the frontlines during the pandemic, more than ever.", [["Patient", "SPECIES", 322, 329], ["support", "TREATMENT", 144, 151], ["targeted support", "TREATMENT", 382, 398]]], ["Leaders (e.g., nursing managers, department chairs, and hospital leaders) must make an effort to visit units caring for COVID-19 patients regularly, to provide reassurance [6, 12, 21, 22] .", [["patients", "ORGANISM", 129, 137], ["patients", "SPECIES", 129, 137]]], ["They are also expected to provide acknowledgment for the moral distress experienced by healthcare workers and direct them to available resources for emotional support (e.g., employee assistance program).", [["the moral distress", "PROBLEM", 53, 71], ["emotional support", "TREATMENT", 149, 166]]], ["The focus-group sessions conducted by Stanford Medicine found that an overarching request of healthcare workers is be honored with simple and genuine expressions of gratitude for their willingness to put themselves in harm's way for patients [12] .Recommendation 1: Create an Environment of Trust, Psychological Safety, and Empowerment to Enable Individual Workers to Communicate Patient Safety Concerns to ManagersWhen employees trust that their organization prioritizes their well-being, they feel psychologically safe and empowered to speak up about safety concerns, which enables patient safety to improve in everyday clinical practice [33] .", [["patients", "ORGANISM", 233, 241], ["patient", "ORGANISM", 584, 591], ["patients", "SPECIES", 233, 241], ["Patient", "SPECIES", 380, 387], ["patient", "SPECIES", 584, 591]]], ["Empowered workers are also resilient in implementing solutions to ensure patient safety, despite obstacles, and sharing those innovations with peers and managers, to enable learning and change [43, 45] .", [["patient", "ORGANISM", 73, 80], ["patient", "SPECIES", 73, 80]]], ["In other words, they are pre-requisites for preserving organizational resilience, patient safety, and staff retention, during and beyond the pandemic.Recommendation 2: Develop Communication Structures to Enable the Organization to Learn from the Problem-Solving Strategies and Communications of Individual Healthcare WorkersAn environment that enables workers to communicate about safety concerns and workarounds needs to be combined with communication structures that enable the organization to learn from the individual-level communications and error recovery (problem-solving) strategies.", [["patient", "ORGANISM", 82, 89], ["patient", "SPECIES", 82, 89], ["communication structures", "PROBLEM", 439, 463]]], ["This in turn, requires innovative communication structures that engage all levels of the organization, from frontline workers to senior leadership in communication related to patient safety, on an ongoing basis.", [["patient", "ORGANISM", 175, 182], ["patient", "SPECIES", 175, 182], ["innovative communication structures", "TREATMENT", 23, 58]]], ["An example of such a communication structure would be 'tiered team huddles' [50, 51] .", [["a communication structure", "PROBLEM", 19, 44]]], ["Tiered huddles enable open sharing of issues from the frontlines, with middle and senior leadership levels of the organization.", [["middle", "ANATOMY_MODIFIER", 71, 77]]], ["As such, they have the potential to improve communication across boundaries to enable organizational learning, resilience, patient safety, and lasting improvement (change).", [["patient", "ORGANISM", 123, 130], ["patient", "SPECIES", 123, 130]]], ["A formal organizational performance improvement committee structure that utilizes 'boundary spanners' (as described above) also has the potential to achieve similar results [52, 53] .Recommendation 2: Develop Communication Structures to Enable the Organization to Learn from the Problem-Solving Strategies and Communications of Individual Healthcare WorkersImportantly, the use of boundary spanners in tiered huddles enables workers to adopt a learning mindset rather than a performance mindset.", [["A formal organizational performance", "TEST", 0, 35], ["boundary spanners", "TREATMENT", 381, 398]]], ["A learning culture, cultivated through innovative communication structures (like those described above), can enable workers to offer ideas for practice changes (e.g., bringing IV-bags to the hallway for drug titration versus the established practice of entering each patient's room to perform titration) and to communicate those ideas to leadership to enable organizational learning [52] [53] [54] [55] .", [["patient", "ORGANISM", 267, 274], ["patient", "SPECIES", 267, 274], ["A learning culture", "TEST", 0, 18], ["practice changes", "TREATMENT", 143, 159], ["IV-bags", "TREATMENT", 176, 183], ["drug titration", "TREATMENT", 203, 217]]], ["Ideas for new practices in turn, could range from new roles (e.g., non-ICU nurse serving in ICU), new sites of care (e.g., use of makeshift ICUs), to new technologies (e.g., use of telehealth, social media, or digital patient navigation), which, when implemented consistently at the organizational level, could help to ensure patient safety and lasting improvement, even under challenging conditions [56] .Recommendation 2: Develop Communication Structures to Enable the Organization to Learn from the Problem-Solving Strategies and Communications of Individual Healthcare WorkersIt would be relevant to note, that the concept of Relational Coordination (RC) in the organization science literature serves to integrate both sets of recommendations (discussed above) into a cohesive whole.", [["patient", "ORGANISM", 218, 225], ["patient", "ORGANISM", 326, 333], ["patient", "SPECIES", 218, 225], ["patient", "SPECIES", 326, 333], ["social media", "TREATMENT", 193, 205], ["Relational Coordination (RC)", "TREATMENT", 630, 658]]], ["In other words, RC serves to integrate both sets of recommendations for HCO leaders discussed in this paper, i.e., (1) creating an environment of mutual trust to enable problem-solving communication to flow freely from individual healthcare workers to managers; and (2) developing a communication structure that enables the organization to learn from individual problem-solving strategies, to allow resilience to progress from reactive to proactive stages.ConclusionsThis paper applies the organizational resilience framework to discuss how a stoic approach to healthcare worker support during the COVID-19 pandemic has the potential to restrict organizational resilience, and adversely impact patient safety and staff retention during and beyond the pandemic period.", [["patient", "ORGANISM", 694, 701], ["patient", "SPECIES", 694, 701], ["HCO leaders", "TREATMENT", 72, 83], ["a communication structure", "PROBLEM", 281, 306], ["solving strategies", "TREATMENT", 370, 388], ["reactive", "OBSERVATION_MODIFIER", 427, 435]]], ["To overcome these challenges, HCO leaders need to adopt a holistic consideration of worker psychological safety-one that recognizes the broader impact of emotional distress created by COVID-19.", [["emotional distress", "DISEASE", 154, 172], ["COVID-19", "CHEMICAL", 184, 192], ["HCO leaders", "TREATMENT", 30, 41], ["emotional distress", "PROBLEM", 154, 172]]], ["Meaningful support for emotional distress during the pandemic, enables healthcare workers to trust that their organization has their backs, which in turn, enables them to feel psychologically safe and empowered to communicate safety concerns and problem-solving strategies to managers, thereby enabling resilience to advance from individual to organizational levels.", [["emotional distress", "DISEASE", 23, 41], ["backs", "ORGANISM_SUBDIVISION", 133, 138], ["Meaningful support", "TREATMENT", 0, 18], ["emotional distress", "PROBLEM", 23, 41], ["organizational levels", "TEST", 344, 365]]], ["Concurrently, since learning from individual error recovery is crucial for advancing from reactive to proactive resilience at the organizational level, HCOs need to develop communication structures that enable the organization to learn from individual problem-solving strategies to prevent problem recurrence, reduce practice variation, increase patient safety, and ensure lasting improvement (change).", [["patient", "ORGANISM", 346, 353], ["patient", "SPECIES", 346, 353], ["proactive resilience", "TREATMENT", 102, 122], ["communication structures", "PROBLEM", 173, 197], ["solving strategies", "TREATMENT", 260, 278], ["problem recurrence", "PROBLEM", 290, 308]]], ["Correspondingly, this paper puts forth two sets of recommendations for HCO leaders to preserve resilience, patient safety, and staff retention during and beyond the COVID-19 pandemic:Conclusions1.ConclusionsCreate an environment of trust, psychological safety, and empowerment to enable individual workers to communicate patient safety concerns to managers.2.Develop communication structures to enable the organization to learn from the problem-solving strategies and communications of individual healthcare workers.2.As discussed in this paper, concurrent implementation of both sets of recommendations can enable HCO leaders to preserve organizational resilience, patient safety, and staff retention, to ensure sustainable HCO operations during and beyond the COVID-19 pandemic.2.Author Contributions: This paper has two authors, both of whom have contributed substantially to the work reported, in the following manner: \"conceptualization, P.R.; investigation, P.R. and J.L.W.; writing-original draft preparation, P.R.; writing-review and editing, P.R. All authors have read and agreed to the published version of the manuscript.", [["patient", "ORGANISM", 107, 114], ["patient", "ORGANISM", 321, 328], ["patient", "ORGANISM", 666, 673], ["patient", "SPECIES", 107, 114], ["patient", "SPECIES", 321, 328], ["patient", "SPECIES", 666, 673], ["HCO leaders", "TREATMENT", 71, 82], ["communication structures", "PROBLEM", 367, 391], ["solving strategies", "TREATMENT", 445, 463], ["sustainable HCO operations", "TREATMENT", 713, 739], ["the COVID", "TEST", 758, 767], ["pandemic", "PROBLEM", 771, 779]]]], "6efcaa639a97ba506cf341230c166208d1312a11": [["Introduction the P domain which forms trimeric surface protrusions.", [["surface", "ANATOMY", 47, 54], ["P domain", "DNA", 17, 25], ["the P domain", "TEST", 13, 25], ["trimeric surface protrusions", "PROBLEM", 38, 66], ["trimeric", "OBSERVATION_MODIFIER", 38, 46], ["surface protrusions", "OBSERVATION", 47, 66]]], ["The Orsay CP is structurally distinct from alphanodaviruses (e.g. Flock House virus) [24] [25] [26] [27] , but has a structural fold closely resembling that of the betanodavirus [28] .", [["Flock House virus", "ORGANISM", 66, 83], ["Flock House virus", "SPECIES", 66, 83], ["The Orsay CP", "PROBLEM", 0, 12], ["structurally distinct from alphanodaviruses", "PROBLEM", 16, 59], ["a structural fold closely", "PROBLEM", 115, 140]]]], "PMC7120522": [["The Sf9 Cell Expression System ::: Principles of GPCR Analysis in the Sf9 Cell Expression SystemPharmacological characterization of GPCRs is commonly performed in transfected mammalian cells or in cells that endogenously express the receptor of interest (Kenakin 1996).", [["Cell", "ANATOMY", 8, 12], ["Cell", "ANATOMY", 74, 78], ["cells", "ANATOMY", 185, 190], ["cells", "ANATOMY", 197, 202], ["Sf9 Cell", "CELL", 4, 12], ["Sf9 Cell", "CELL", 70, 78], ["mammalian cells", "CELL", 175, 190], ["cells", "CELL", 197, 202], ["GPCRs", "PROTEIN", 132, 137], ["transfected mammalian cells", "CELL_LINE", 163, 190], ["Sf9", "SPECIES", 70, 73], ["GPCR Analysis", "TEST", 49, 62], ["SystemPharmacological characterization", "TEST", 90, 128], ["GPCRs", "TEST", 132, 137], ["Sf9 Cell", "OBSERVATION", 4, 12], ["mammalian cells", "OBSERVATION", 175, 190]]], ["There are, however, several problems of mammalian cell systems.", [["cell", "ANATOMY", 50, 54], ["mammalian cell", "CELL", 40, 54], ["mammalian cell systems", "PROBLEM", 40, 62], ["mammalian cell systems", "OBSERVATION", 40, 62]]], ["First, mammalian cells normally express various additional GPCRs, which may result in GPCR heteromerization or signaling crosstalk (Breitwieser 2004; Prezeau et al. 2010; Gomes et al. 2016).", [["cells", "ANATOMY", 17, 22], ["mammalian cells", "CELL", 7, 22], ["GPCR", "GENE_OR_GENE_PRODUCT", 86, 90], ["mammalian cells", "CELL_TYPE", 7, 22], ["GPCRs", "PROTEIN", 59, 64], ["GPCR heteromerization", "PROBLEM", 86, 107], ["mammalian cells", "OBSERVATION", 7, 22]]], ["For example, signaling crosstalk between GPCRs has been described for the G\u03b1i-coupled GABABR and the G\u03b1q-coupled mGlu1AR (Rives et al. 2009).", [["GPCRs", "GENE_OR_GENE_PRODUCT", 41, 46], ["GABABR", "GENE_OR_GENE_PRODUCT", 86, 92], ["G\u03b1q-", "GENE_OR_GENE_PRODUCT", 101, 105], ["mGlu1AR", "GENE_OR_GENE_PRODUCT", 113, 120], ["GPCRs", "PROTEIN", 41, 46], ["G\u03b1i-coupled GABABR", "PROTEIN", 74, 92], ["G\u03b1q-coupled mGlu1AR", "PROTEIN", 101, 120], ["signaling crosstalk between GPCRs", "PROBLEM", 13, 46]]], ["Another example is ACKR1 (atypical chemokine receptor 1), which has been shown to functionally antagonize CCR5 by forming ACKR1/CCR5 heterodimers (Chakera et al. 2008).", [["ACKR1", "GENE_OR_GENE_PRODUCT", 19, 24], ["atypical chemokine receptor 1", "GENE_OR_GENE_PRODUCT", 26, 55], ["CCR5", "GENE_OR_GENE_PRODUCT", 106, 110], ["ACKR1", "GENE_OR_GENE_PRODUCT", 122, 127], ["CCR5", "GENE_OR_GENE_PRODUCT", 128, 132], ["ACKR1", "PROTEIN", 19, 24], ["atypical chemokine receptor 1", "PROTEIN", 26, 55], ["CCR5", "PROTEIN", 106, 110], ["ACKR1", "PROTEIN", 122, 127], ["CCR5 heterodimers", "PROTEIN", 128, 145], ["CCR5", "TEST", 106, 110], ["ACKR1/CCR5 heterodimers", "TREATMENT", 122, 145]]], ["Second, the presence of other constitutively active receptors may interfere with the analysis of agonist-independent activity of the receptor of interest.", [["constitutively active receptors", "PROTEIN", 30, 61], ["the analysis", "TEST", 81, 93]]], ["For example, the inverse FPR1 agonist cyclosporin H failed to inhibit basal G\u03b1i protein activity in HL-60 cells, indicating that these cells additionally express other constitutively active receptors different from FPR1 (Wenzel-Seifert and Seifert 1993; Seifert and Wenzel-Seifert 2003).", [["HL-60 cells", "ANATOMY", 100, 111], ["cells", "ANATOMY", 135, 140], ["cyclosporin H", "CHEMICAL", 38, 51], ["cyclosporin H", "CHEMICAL", 38, 51], ["FPR1", "GENE_OR_GENE_PRODUCT", 25, 29], ["cyclosporin H", "SIMPLE_CHEMICAL", 38, 51], ["G\u03b1i", "GENE_OR_GENE_PRODUCT", 76, 79], ["HL-60 cells", "CELL", 100, 111], ["cells", "CELL", 135, 140], ["FPR1", "GENE_OR_GENE_PRODUCT", 215, 219], ["FPR1", "PROTEIN", 25, 29], ["G\u03b1i protein", "PROTEIN", 76, 87], ["HL-60 cells", "CELL_LINE", 100, 111], ["constitutively active receptors", "PROTEIN", 168, 199], ["the inverse FPR1 agonist cyclosporin H", "TREATMENT", 13, 51], ["basal G\u03b1i protein activity", "TEST", 70, 96], ["HL", "TEST", 100, 102], ["these cells", "PROBLEM", 129, 140], ["FPR1", "TEST", 215, 219], ["Wenzel", "TEST", 221, 227], ["Seifert", "TEST", 240, 247], ["Seifert", "TEST", 254, 261], ["Wenzel", "TEST", 266, 272]]], ["Third, promiscuous G protein coupling of GPCRs in the presence of several G protein subtypes may preclude the analysis of GPCR-G protein selectivity (Woehler and Ponimaskin 2009).", [["G protein", "GENE_OR_GENE_PRODUCT", 19, 28], ["G protein", "GENE_OR_GENE_PRODUCT", 74, 83], ["GPCR-G", "GENE_OR_GENE_PRODUCT", 122, 128], ["G protein", "PROTEIN", 19, 28], ["G protein subtypes", "PROTEIN", 74, 92], ["GPCR", "PROTEIN", 122, 126], ["G protein", "PROTEIN", 127, 136], ["promiscuous G protein coupling of GPCRs", "PROBLEM", 7, 46], ["several G protein subtypes", "PROBLEM", 66, 92], ["the analysis", "TEST", 106, 118], ["GPCR", "TEST", 122, 126], ["protein selectivity", "TEST", 129, 148]]], ["Finally, some GPCRs are only expressed at low levels in mammalian cells, rendering it difficult to obtain a sufficiently high signal-to-noise ratio in functional and ligand binding assays.The Sf9 Cell Expression System ::: Principles of GPCR Analysis in the Sf9 Cell Expression SystemAs discussed in a comprehensive review article (Schneider and Seifert 2010c), the problems listed above are effectively addressed by using the Sf9 cell expression system.", [["cells", "ANATOMY", 66, 71], ["Cell", "ANATOMY", 196, 200], ["Cell", "ANATOMY", 262, 266], ["cell", "ANATOMY", 431, 435], ["mammalian cells", "CELL", 56, 71], ["Sf9 Cell", "CELL", 192, 200], ["Cell", "CELL", 262, 266], ["Sf9 cell", "CELL", 427, 435], ["GPCRs", "PROTEIN", 14, 19], ["mammalian cells", "CELL_TYPE", 56, 71], ["some GPCRs", "PROBLEM", 9, 19], ["low levels in mammalian cells", "PROBLEM", 42, 71], ["GPCR Analysis", "TEST", 237, 250], ["the Sf9 cell expression system", "TREATMENT", 423, 453], ["low levels", "OBSERVATION_MODIFIER", 42, 52], ["mammalian cells", "OBSERVATION", 56, 71], ["Sf9 Cell", "OBSERVATION", 192, 200], ["Sf9 cell", "OBSERVATION", 427, 435]]], ["Sf9 cells are derived from the Sf21 cell line, which had been originally isolated from the pupal ovarian tissue of the American fall army worm (Spodoptera frugiperda).", [["Sf9 cells", "ANATOMY", 0, 9], ["Sf21 cell line", "ANATOMY", 31, 45], ["pupal ovarian tissue", "ANATOMY", 91, 111], ["Spodoptera frugiperda", "DISEASE", 144, 165], ["Sf9 cells", "CELL", 0, 9], ["Sf21 cell line", "CELL", 31, 45], ["pupal ovarian tissue", "TISSUE", 91, 111], ["army worm", "ORGANISM", 133, 142], ["Spodoptera frugiperda", "ORGANISM", 144, 165], ["Sf9 cells", "CELL_LINE", 0, 9], ["Sf21 cell line", "CELL_LINE", 31, 45], ["Spodoptera frugiperda", "SPECIES", 144, 165], ["Sf9", "SPECIES", 0, 3], ["American fall army worm", "SPECIES", 119, 142], ["Spodoptera frugiperda", "SPECIES", 144, 165], ["Sf9 cells", "PROBLEM", 0, 9], ["the Sf21 cell line", "TREATMENT", 27, 45], ["Sf21 cell line", "OBSERVATION", 31, 45], ["pupal ovarian tissue", "OBSERVATION", 91, 111]]], ["The protein of interest is expressed by infecting Sf9 cells with baculoviruses encoding the corresponding gene.", [["Sf9 cells", "ANATOMY", 50, 59], ["Sf9 cells", "CELL", 50, 59], ["Sf9 cells", "CELL_LINE", 50, 59], ["Sf9", "SPECIES", 50, 53], ["baculoviruses", "TREATMENT", 65, 78], ["infecting Sf9 cells", "OBSERVATION", 40, 59]]], ["Although Sf9 cells express G\u03b1i-, G\u03b1q-, and G\u03b1s-like proteins, insect cell G\u03b1i is not activated by mammalian GPCRs.", [["Sf9 cells", "ANATOMY", 9, 18], ["cell", "ANATOMY", 69, 73], ["Sf9 cells", "CELL", 9, 18], ["G\u03b1i-", "GENE_OR_GENE_PRODUCT", 27, 31], ["G\u03b1q", "GENE_OR_GENE_PRODUCT", 33, 36], ["G\u03b1s", "GENE_OR_GENE_PRODUCT", 43, 46], ["insect cell", "CELL", 62, 73], ["G\u03b1i", "GENE_OR_GENE_PRODUCT", 74, 77], ["Sf9 cells", "CELL_LINE", 9, 18], ["G\u03b1i-", "PROTEIN", 27, 31], ["G\u03b1q", "PROTEIN", 33, 36], ["G\u03b1s", "PROTEIN", 43, 46], ["G\u03b1i", "PROTEIN", 74, 77], ["mammalian GPCRs", "PROTEIN", 98, 113], ["Sf9", "SPECIES", 9, 12], ["Sf9 cells", "TEST", 9, 18], ["G\u03b1i-", "TEST", 27, 31], ["G\u03b1q", "TEST", 33, 36], ["G\u03b1s", "TEST", 43, 46], ["insect cell G\u03b1i", "TEST", 62, 77], ["insect cell", "OBSERVATION", 62, 73]]], ["This renders Sf9 cells a functionally \u201cG\u03b1i-free\u201d system and permits the analysis of G\u03b1i-coupled receptors without the necessity of pertussis toxin (PTX)-mediated GPCR/G\u03b1i uncoupling.", [["Sf9 cells", "ANATOMY", 13, 22], ["PTX", "CHEMICAL", 148, 151], ["PTX", "CHEMICAL", 148, 151], ["Sf9 cells", "CELL", 13, 22], ["G\u03b1i-coupled receptors", "GENE_OR_GENE_PRODUCT", 84, 105], ["pertussis toxin", "SIMPLE_CHEMICAL", 131, 146], ["PTX", "SIMPLE_CHEMICAL", 148, 151], ["GPCR", "GENE_OR_GENE_PRODUCT", 162, 166], ["G\u03b1i", "GENE_OR_GENE_PRODUCT", 167, 170], ["Sf9 cells", "CELL_LINE", 13, 22], ["G\u03b1i-coupled receptors", "PROTEIN", 84, 105], ["GPCR", "PROTEIN", 162, 166], ["G\u03b1i", "PROTEIN", 167, 170], ["the analysis", "TEST", 68, 80], ["G\u03b1i-coupled receptors", "PROBLEM", 84, 105], ["pertussis toxin", "PROBLEM", 131, 146], ["PTX", "PROBLEM", 148, 151], ["mediated GPCR", "PROBLEM", 153, 166], ["G\u03b1i uncoupling", "PROBLEM", 167, 181]]], ["Also, PTX would not be active in Sf9 cells, because it does not enter the cells (Wenzel-Seifert et al. 1998).", [["Sf9 cells", "ANATOMY", 33, 42], ["cells", "ANATOMY", 74, 79], ["PTX", "CHEMICAL", 6, 9], ["PTX", "CHEMICAL", 6, 9], ["PTX", "SIMPLE_CHEMICAL", 6, 9], ["Sf9 cells", "CELL", 33, 42], ["cells", "CELL", 74, 79], ["Sf9 cells", "CELL_LINE", 33, 42], ["Sf9", "SPECIES", 33, 36], ["PTX", "PROBLEM", 6, 9], ["PTX", "OBSERVATION", 6, 9], ["would not be", "UNCERTAINTY", 10, 22], ["active", "OBSERVATION_MODIFIER", 23, 29]]], ["By contrast, uncoupling of G\u03b1i-coupled GPCRs by PTX in mammalian cells is problematic.", [["mammalian cells", "ANATOMY", 55, 70], ["PTX", "CHEMICAL", 48, 51], ["PTX", "CHEMICAL", 48, 51], ["G\u03b1i-coupled GPCRs", "GENE_OR_GENE_PRODUCT", 27, 44], ["PTX", "SIMPLE_CHEMICAL", 48, 51], ["mammalian cells", "CELL", 55, 70], ["G\u03b1i-coupled GPCRs", "PROTEIN", 27, 44], ["mammalian cells", "CELL_TYPE", 55, 70], ["G\u03b1i-coupled GPCRs", "PROBLEM", 27, 44], ["PTX in mammalian cells", "PROBLEM", 48, 70], ["PTX", "OBSERVATION", 48, 51], ["mammalian cells", "OBSERVATION", 55, 70]]], ["Despite entering mammalian cells, PTX is not capable of completely inactivating all G\u03b1i proteins (Wenzel-Seifert and Seifert 1990).The Sf9 Cell Expression System ::: Principles of GPCR Analysis in the Sf9 Cell Expression SystemMoreover, Sf9 cells do not express constitutively active GPCRs and therefore provide a low-background environment for the analysis of agonist-independent receptor activity.", [["cells", "ANATOMY", 27, 32], ["Cell", "ANATOMY", 139, 143], ["Cell", "ANATOMY", 205, 209], ["Sf9 cells", "ANATOMY", 237, 246], ["PTX", "CHEMICAL", 34, 37], ["PTX", "CHEMICAL", 34, 37], ["mammalian cells", "CELL", 17, 32], ["PTX", "SIMPLE_CHEMICAL", 34, 37], ["G\u03b1i", "GENE_OR_GENE_PRODUCT", 84, 87], ["Sf9 Cell", "CELL", 135, 143], ["Cell", "CELL", 205, 209], ["Sf9 cells", "CELL", 237, 246], ["mammalian cells", "CELL_TYPE", 17, 32], ["G\u03b1i proteins", "PROTEIN", 84, 96], ["Sf9 cells", "CELL_LINE", 237, 246], ["constitutively active GPCRs", "PROTEIN", 262, 289], ["entering mammalian cells", "TREATMENT", 8, 32], ["PTX", "PROBLEM", 34, 37], ["Wenzel", "TEST", 98, 104], ["GPCR Analysis", "TEST", 180, 193], ["Sf9 cells", "TEST", 237, 246], ["a low-background environment", "TREATMENT", 312, 340], ["the analysis", "TEST", 345, 357], ["mammalian cells", "OBSERVATION", 17, 32], ["Sf9 Cell", "OBSERVATION", 135, 143]]], ["Furthermore, the highly efficient baculovirus promoters lead to very high expression levels of GPCRs in Sf9 cells.", [["Sf9 cells", "ANATOMY", 104, 113], ["baculovirus", "ORGANISM", 34, 45], ["GPCRs", "GENE_OR_GENE_PRODUCT", 95, 100], ["Sf9 cells", "CELL", 104, 113], ["baculovirus promoters", "DNA", 34, 55], ["GPCRs", "PROTEIN", 95, 100], ["Sf9 cells", "CELL_LINE", 104, 113], ["baculovirus", "SPECIES", 34, 45], ["Sf9", "SPECIES", 104, 107], ["the highly efficient baculovirus promoters", "PROBLEM", 13, 55], ["very high expression levels of GPCRs in Sf9 cells", "PROBLEM", 64, 113], ["Sf9 cells", "OBSERVATION", 104, 113]]], ["This results in high signal-to-noise ratios in binding assays and allows the purification of receptor protein, e.g. for crystallization purposes.", [["receptor protein", "PROTEIN", 93, 109], ["high signal-to-noise ratios in binding assays", "PROBLEM", 16, 61], ["receptor protein", "TREATMENT", 93, 109], ["crystallization purposes", "TEST", 120, 144]]], ["Finally, as explained below, Sf9 cell membranes expressing large amounts of GPCRs and G proteins can be used to study G protein activation in steady-state GTPase assays and experiments with [35S]GTP\u03b3S ([35S]-labeled guanosine 5\u2032-O-[\u03b3-thio]triphosphate).The Sf9 Cell Expression System ::: Principles of GPCR Analysis in the Sf9 Cell Expression SystemFor the preparation of baculoviruses encoding the gene of interest, several straightforward methods are established.", [["cell membranes", "ANATOMY", 33, 47], ["Cell", "ANATOMY", 261, 265], ["Cell", "ANATOMY", 327, 331], ["guanosine 5\u2032-O-[\u03b3-thio]triphosphate", "CHEMICAL", 216, 251], ["[35S]GTP\u03b3S", "CHEMICAL", 190, 200], ["[35S]-labeled guanosine 5\u2032-O-[\u03b3-thio]triphosphate", "CHEMICAL", 202, 251], ["Sf9 cell", "CELL", 29, 37], ["membranes", "CELLULAR_COMPONENT", 38, 47], ["G proteins", "GENE_OR_GENE_PRODUCT", 86, 96], ["G protein", "GENE_OR_GENE_PRODUCT", 118, 127], ["[35S]GTP\u03b3S", "SIMPLE_CHEMICAL", 190, 200], ["[35S]-labeled guanosine 5\u2032-O-[\u03b3-thio]triphosphate", "SIMPLE_CHEMICAL", 202, 251], ["Sf9 Cell", "CELL", 257, 265], ["Sf9 Cell", "CELL", 323, 331], ["baculoviruses", "ORGANISM", 372, 385], ["GPCRs", "PROTEIN", 76, 81], ["G proteins", "PROTEIN", 86, 96], ["G protein", "PROTEIN", 118, 127], ["GTPase", "PROTEIN", 155, 161], ["Sf9 cell membranes", "PROBLEM", 29, 47], ["large amounts of GPCRs and G proteins", "PROBLEM", 59, 96], ["study G protein activation", "TEST", 112, 138], ["GTPase assays", "TEST", 155, 168], ["GTP", "TEST", 195, 198], ["guanosine", "TREATMENT", 216, 225], ["thio]triphosphate", "TREATMENT", 234, 251], ["GPCR Analysis", "TEST", 302, 315], ["the Sf9 Cell Expression", "TREATMENT", 319, 342], ["the preparation of baculoviruses", "TREATMENT", 353, 385], ["several straightforward methods", "TREATMENT", 417, 448], ["Sf9 Cell", "OBSERVATION", 257, 265], ["Sf9 Cell", "OBSERVATION", 323, 331]]], ["The Sf9 cell studies discussed in this chapter were performed by using the BaculoGold\u2122 kit from Invitrogen.", [["Sf9 cell", "ANATOMY", 4, 12], ["Sf9 cell", "CELL", 4, 12], ["Invitrogen", "GENE_OR_GENE_PRODUCT", 96, 106], ["The Sf9 cell studies", "TEST", 0, 20], ["Sf9 cell", "OBSERVATION", 4, 12]]], ["As explained in Fig. 1, the gene of interest (in this example hH4R) is cloned into a pVL1392 baculovirus transfer vector, which is transfected into Sf9 cells together with the missing part of the baculovirus genome (BaculoGold\u2122 DNA).", [["Sf9 cells", "ANATOMY", 148, 157], ["hH4R", "GENE_OR_GENE_PRODUCT", 62, 66], ["pVL1392", "GENE_OR_GENE_PRODUCT", 85, 92], ["Sf9 cells", "CELL", 148, 157], ["baculovirus", "ORGANISM", 196, 207], ["DNA", "CELLULAR_COMPONENT", 228, 231], ["hH4R", "DNA", 62, 66], ["pVL1392 baculovirus transfer vector", "DNA", 85, 120], ["Sf9 cells", "CELL_LINE", 148, 157], ["baculovirus genome", "DNA", 196, 214], ["BaculoGold\u2122 DNA", "DNA", 216, 231], ["pVL1392 baculovirus", "SPECIES", 85, 104], ["Sf9", "SPECIES", 148, 151], ["baculovirus", "SPECIES", 196, 207], ["a pVL1392 baculovirus transfer vector", "TREATMENT", 83, 120], ["the baculovirus genome", "TREATMENT", 192, 214]]]], "PMC5161441": [["IntroductionZika virus (ZIKV) is an emerging flavivirus that has been largely neglected for > 60 years after its discovery due to its restricted geographical distribution and its presumed low clinical significance (Chan et al., 2016a).", [["flavivirus", "DISEASE", 45, 55], ["IntroductionZika virus", "ORGANISM", 0, 22], ["ZIKV", "GENE_OR_GENE_PRODUCT", 24, 28], ["IntroductionZika virus", "SPECIES", 0, 22], ["ZIKV", "SPECIES", 24, 28], ["IntroductionZika virus (ZIKV", "PROBLEM", 0, 28], ["an emerging flavivirus", "PROBLEM", 33, 55], ["flavivirus", "OBSERVATION", 45, 55], ["presumed", "UNCERTAINTY", 179, 187], ["low", "OBSERVATION_MODIFIER", 188, 191]]], ["Since 2007, large-scale outbreaks of ZIKV infection have occurred in the Pacific islands, Latin America, and most recently, USA and Southeast Asia (Duffy et al., 2009, Musso and Gubler, 2016, Zhu et al., 2016).", [["ZIKV infection", "DISEASE", 37, 51], ["ZIKV", "ORGANISM", 37, 41], ["ZIKV", "SPECIES", 37, 41], ["ZIKV infection", "PROBLEM", 37, 51], ["large", "OBSERVATION_MODIFIER", 12, 17], ["-scale", "OBSERVATION_MODIFIER", 17, 23], ["ZIKV infection", "OBSERVATION", 37, 51], ["Pacific", "OBSERVATION_MODIFIER", 73, 80], ["islands", "OBSERVATION_MODIFIER", 81, 88]]], ["As of 27 October 2016, > 70 countries/territories have reported continuing mosquito-borne transmission of ZIKV (World Health Organization.", [["ZIKV", "DISEASE", 106, 110], ["ZIKV", "SPECIES", 106, 110], ["ZIKV", "PROBLEM", 106, 110]]], ["In addition to mosquito-borne transmission, sexual and transplacental transmissions of ZIKV have also been reported (Chan et al., 2016a, Musso et al., 2015a, Foy et al., 2011, Calvet et al., 2016).", [["ZIKV", "GENE_OR_GENE_PRODUCT", 87, 91], ["ZIKV", "SPECIES", 87, 91]]], ["These non-vector-borne transmission routes render the control of the continuing epidemic more complicated.IntroductionZIKV was not considered as an important human pathogen in the past as most infected adult patients were asymptomatic or developed a self-limiting acute febrile illness which resolved within 1\u20132 weeks (Chan et al., 2016a, Duffy et al., 2009).", [["febrile illness", "DISEASE", 270, 285], ["human", "ORGANISM", 158, 163], ["patients", "ORGANISM", 208, 216], ["human", "SPECIES", 158, 163], ["patients", "SPECIES", 208, 216], ["human", "SPECIES", 158, 163], ["These non-vector-borne transmission routes", "TREATMENT", 0, 42], ["IntroductionZIKV", "TREATMENT", 106, 122], ["a self-limiting acute febrile illness", "PROBLEM", 248, 285], ["acute", "OBSERVATION_MODIFIER", 264, 269], ["febrile", "OBSERVATION", 270, 277]]], ["However, it has been recently recognized that infected mothers may transmit the virus transplacentally to developing fetuses, leading to congenital malformations, including microcephaly, cerebral malformations, ophthalmological and hearing defects, and arthrogryposis (Chan et al., 2016a, Mlakar et al., 2016, de Paula et al., 2016, Leal et al., 2016).", [["fetuses", "ANATOMY", 117, 124], ["cerebral", "ANATOMY", 187, 195], ["congenital malformations", "DISEASE", 137, 161], ["microcephaly", "DISEASE", 173, 185], ["cerebral malformations", "DISEASE", 187, 209], ["ophthalmological and hearing defects", "DISEASE", 211, 247], ["arthrogryposis", "DISEASE", 253, 267], ["mothers", "ORGANISM", 55, 62], ["fetuses", "ORGAN", 117, 124], ["cerebral", "ORGAN", 187, 195], ["the virus", "PROBLEM", 76, 85], ["developing fetuses", "PROBLEM", 106, 124], ["congenital malformations", "PROBLEM", 137, 161], ["microcephaly", "PROBLEM", 173, 185], ["cerebral malformations", "PROBLEM", 187, 209], ["ophthalmological and hearing defects", "PROBLEM", 211, 247], ["arthrogryposis", "PROBLEM", 253, 267], ["infected", "OBSERVATION", 46, 54], ["congenital", "OBSERVATION_MODIFIER", 137, 147], ["malformations", "OBSERVATION", 148, 161], ["microcephaly", "OBSERVATION", 173, 185], ["cerebral", "ANATOMY", 187, 195], ["malformations", "OBSERVATION", 196, 209], ["hearing defects", "OBSERVATION", 232, 247], ["arthrogryposis", "OBSERVATION", 253, 267]]], ["Some infected adults may also develop severe neurological complications, such as Guillain-Barr\u00e9 syndrome, meningoencephalitis, and myelitis (Cao-Lormeau et al., 2016, Carteaux et al., 2016, Mecharles et al., 2016).", [["neurological", "ANATOMY", 45, 57], ["neurological complications", "DISEASE", 45, 71], ["Guillain-Barr\u00e9 syndrome", "DISEASE", 81, 104], ["meningoencephalitis", "DISEASE", 106, 125], ["myelitis", "DISEASE", 131, 139], ["adults", "ORGANISM", 14, 20], ["Some infected adults", "PROBLEM", 0, 20], ["severe neurological complications", "PROBLEM", 38, 71], ["Guillain-Barr\u00e9 syndrome", "PROBLEM", 81, 104], ["meningoencephalitis", "PROBLEM", 106, 125], ["myelitis", "PROBLEM", 131, 139], ["infected", "OBSERVATION", 5, 13], ["severe", "OBSERVATION_MODIFIER", 38, 44], ["neurological", "OBSERVATION_MODIFIER", 45, 57], ["complications", "OBSERVATION", 58, 71], ["Barr\u00e9 syndrome", "OBSERVATION", 90, 104], ["meningoencephalitis", "OBSERVATION", 106, 125], ["myelitis", "OBSERVATION", 131, 139]]], ["Moreover, ZIKV-related fatalities have been increasingly recognized.", [["ZIKV", "CHEMICAL", 10, 14], ["fatalities", "DISEASE", 23, 33], ["ZIKV", "PROBLEM", 10, 14], ["ZIKV", "OBSERVATION", 10, 14]]], ["Most of the patients with fatal infection had underlying medical conditions and some were markedly immunosuppressed, including a patient with systemic lupus erythematosus and rheumatoid arthritis who was on corticosteroid therapy and died of disseminated infection with detectable ZIKV RNA in blood, brain, spleen, liver, kidney, lung, and heart obtained at postmortem examination (Pan American Health Organization/World Health Oganization (PAHO/WHO), 2015; Sarmiento-Ospina et al., 2016, Arzuza-Ortega et al., 2016).IntroductionA number of animal models have been developed for studying the pathogenesis and evaluating countermeasures for ZIKV infection.", [["blood", "ANATOMY", 293, 298], ["brain", "ANATOMY", 300, 305], ["spleen", "ANATOMY", 307, 313], ["liver", "ANATOMY", 315, 320], ["kidney", "ANATOMY", 322, 328], ["lung", "ANATOMY", 330, 334], ["heart", "ANATOMY", 340, 345], ["infection", "DISEASE", 32, 41], ["systemic lupus erythematosus", "DISEASE", 142, 170], ["rheumatoid arthritis", "DISEASE", 175, 195], ["infection", "DISEASE", 255, 264], ["infection", "DISEASE", 645, 654], ["patients", "ORGANISM", 12, 20], ["patient", "ORGANISM", 129, 136], ["blood", "ORGANISM_SUBSTANCE", 293, 298], ["brain", "ORGAN", 300, 305], ["spleen", "ORGAN", 307, 313], ["liver", "ORGAN", 315, 320], ["kidney", "ORGAN", 322, 328], ["lung", "ORGAN", 330, 334], ["heart", "ORGAN", 340, 345], ["ZIKV", "ORGANISM", 640, 644], ["ZIKV RNA", "RNA", 281, 289], ["patients", "SPECIES", 12, 20], ["patient", "SPECIES", 129, 136], ["ZIKV", "SPECIES", 281, 285], ["ZIKV", "SPECIES", 640, 644], ["fatal infection", "PROBLEM", 26, 41], ["underlying medical conditions", "PROBLEM", 46, 75], ["markedly immunosuppressed", "PROBLEM", 90, 115], ["systemic lupus erythematosus", "PROBLEM", 142, 170], ["rheumatoid arthritis", "PROBLEM", 175, 195], ["corticosteroid therapy", "TREATMENT", 207, 229], ["disseminated infection", "PROBLEM", 242, 264], ["detectable ZIKV RNA in blood, brain, spleen, liver, kidney, lung, and heart", "PROBLEM", 270, 345], ["postmortem examination", "TEST", 358, 380], ["the pathogenesis", "PROBLEM", 588, 604], ["countermeasures", "TREATMENT", 620, 635], ["ZIKV infection", "PROBLEM", 640, 654], ["fatal", "OBSERVATION_MODIFIER", 26, 31], ["infection", "OBSERVATION", 32, 41], ["markedly", "OBSERVATION_MODIFIER", 90, 98], ["immunosuppressed", "OBSERVATION", 99, 115], ["systemic", "OBSERVATION_MODIFIER", 142, 150], ["lupus erythematosus", "OBSERVATION", 151, 170], ["rheumatoid arthritis", "OBSERVATION", 175, 195], ["disseminated", "OBSERVATION_MODIFIER", 242, 254], ["infection", "OBSERVATION", 255, 264], ["ZIKV RNA", "OBSERVATION", 281, 289], ["blood", "ANATOMY", 293, 298], ["brain", "ANATOMY", 300, 305], ["spleen", "ANATOMY", 307, 313], ["liver", "ANATOMY", 315, 320], ["kidney", "ANATOMY", 322, 328], ["lung", "ANATOMY", 330, 334], ["heart", "ANATOMY", 340, 345]]], ["Rhesus macaques with subcutaneous ZIKV inoculation develop mild clinical signs that resemble the self-limiting illness in most infected immunocompetent adults (Dudley et al., 2016).", [["subcutaneous", "ANATOMY", 21, 33], ["self-limiting illness", "DISEASE", 97, 118], ["Rhesus macaques", "ORGANISM", 0, 15], ["adults", "ORGANISM", 152, 158], ["Rhesus macaques", "SPECIES", 0, 15], ["Rhesus macaques", "SPECIES", 0, 15], ["ZIKV", "SPECIES", 34, 38], ["subcutaneous ZIKV inoculation", "PROBLEM", 21, 50], ["mild clinical signs", "PROBLEM", 59, 78], ["the self-limiting illness", "PROBLEM", 93, 118], ["subcutaneous", "ANATOMY", 21, 33], ["ZIKV", "OBSERVATION", 34, 38], ["mild", "OBSERVATION_MODIFIER", 59, 63]]], ["This non-human primate model provides a robust platform for the evaluation of vaccines and host immune response (Abbink et al., 2016).", [["the evaluation", "TEST", 60, 74], ["vaccines", "TREATMENT", 78, 86]]], ["However, the mild clinical disease in these primates is suboptimal for antiviral treatment evaluation.", [["primates", "ORGANISM", 44, 52], ["the mild clinical disease in these primates", "PROBLEM", 9, 52], ["antiviral treatment evaluation", "TEST", 71, 101], ["mild", "OBSERVATION_MODIFIER", 13, 17], ["clinical", "OBSERVATION_MODIFIER", 18, 26], ["disease", "OBSERVATION", 27, 34]]], ["Moreover, expertise and facilities for working with non-human primates are not available in most research laboratories.", [["non-human", "ORGANISM", 52, 61], ["primates", "ORGANISM", 62, 70]]], ["Wild-type adult BALB/c mice are not susceptible to intraperitoneal ZIKV inoculation (Dick, 1952).", [["intraperitoneal", "ANATOMY", 51, 66], ["ZIKV", "CHEMICAL", 67, 71], ["Wild-type adult BALB/c mice", "ORGANISM", 0, 27], ["intraperitoneal", "IMMATERIAL_ANATOMICAL_ENTITY", 51, 66], ["ZIKV", "ORGANISM", 67, 71], ["mice", "SPECIES", 23, 27], ["mice", "SPECIES", 23, 27], ["ZIKV", "SPECIES", 67, 71], ["intraperitoneal ZIKV inoculation", "PROBLEM", 51, 83]]], ["Suckling and young mice with intracerebral ZIKV inoculation develop disease that is localized to the central nervous system (Dick, 1952, Way et al., 1976, Weinbren and Williams, 1958, Bell et al., 1971).", [["intracerebral", "ANATOMY", 29, 42], ["central nervous system", "ANATOMY", 101, 123], ["ZIKV", "CHEMICAL", 43, 47], ["mice", "ORGANISM", 19, 23], ["intracerebral ZIKV", "ORGANISM", 29, 47], ["central nervous system", "ANATOMICAL_SYSTEM", 101, 123], ["mice", "SPECIES", 19, 23], ["mice", "SPECIES", 19, 23], ["ZIKV", "SPECIES", 43, 47], ["intracerebral ZIKV inoculation develop disease", "PROBLEM", 29, 75], ["central", "ANATOMY_MODIFIER", 101, 108], ["nervous system", "ANATOMY", 109, 123]]], ["Pregnant mice and fetal mice with partially intact type I interferon signaling response (fetuses of female mice deficienct in type I interferon signaling response crossed to wild-type male mice) were used to study pathogenesis in pregnancy and maternal-fetal transmission, but these models are technically more demanding (Miner et al., 2016, Cugola et al., 2016).", [["fetal", "ANATOMY", 18, 23], ["fetuses", "ANATOMY", 89, 96], ["fetal", "ANATOMY", 253, 258], ["mice", "ORGANISM", 9, 13], ["fetal mice", "ORGANISM", 18, 28], ["type I interferon", "GENE_OR_GENE_PRODUCT", 51, 68], ["fetuses", "ORGANISM", 89, 96], ["mice", "ORGANISM", 107, 111], ["type I interferon", "GENE_OR_GENE_PRODUCT", 126, 143], ["mice", "ORGANISM", 189, 193], ["fetal", "DEVELOPING_ANATOMICAL_STRUCTURE", 253, 258], ["interferon", "PROTEIN", 58, 68], ["interferon", "PROTEIN", 133, 143], ["mice", "SPECIES", 9, 13], ["mice", "SPECIES", 24, 28], ["mice", "SPECIES", 107, 111], ["mice", "SPECIES", 189, 193], ["mice", "SPECIES", 9, 13], ["mice", "SPECIES", 24, 28], ["mice", "SPECIES", 107, 111], ["mice", "SPECIES", 189, 193], ["partially intact type I interferon signaling response", "PROBLEM", 34, 87], ["female mice deficienct", "PROBLEM", 100, 122], ["type I interferon signaling response", "TREATMENT", 126, 162], ["pregnancy", "PROBLEM", 230, 239], ["maternal-fetal transmission", "PROBLEM", 244, 271]]], ["Type I/II interferon-signaling-/receptor-deficient mice with intraperitoneal or subcutaneous ZIKV inoculation develop fatal, disseminated infection (Lazear et al., 2016, Dowall et al., 2016, Aliota et al., 2016, Rossi et al., 2016).", [["intraperitoneal", "ANATOMY", 61, 76], ["subcutaneous", "ANATOMY", 80, 92], ["ZIKV", "CHEMICAL", 93, 97], ["infection", "DISEASE", 138, 147], ["Type I/II interferon-signaling-/receptor", "GENE_OR_GENE_PRODUCT", 0, 40], ["mice", "ORGANISM", 51, 55], ["intraperitoneal", "IMMATERIAL_ANATOMICAL_ENTITY", 61, 76], ["Type I/II interferon-signaling-/receptor", "PROTEIN", 0, 40], ["mice", "SPECIES", 51, 55], ["mice", "SPECIES", 51, 55], ["ZIKV", "SPECIES", 93, 97], ["Type I/II interferon", "PROBLEM", 0, 20], ["intraperitoneal or subcutaneous ZIKV inoculation", "PROBLEM", 61, 109], ["disseminated infection", "PROBLEM", 125, 147], ["intraperitoneal", "ANATOMY", 61, 76], ["subcutaneous", "ANATOMY", 80, 92], ["ZIKV", "OBSERVATION", 93, 97], ["fatal", "OBSERVATION_MODIFIER", 118, 123], ["disseminated", "OBSERVATION_MODIFIER", 125, 137], ["infection", "OBSERVATION", 138, 147]]], ["These models are useful for the evaluation of countermeasures for ZIKV infection as the protective effects of antivirals drugs and vaccines are more easily observed in treated mice.", [["infection", "DISEASE", 71, 80], ["ZIKV", "ORGANISM", 66, 70], ["mice", "ORGANISM", 176, 180], ["mice", "SPECIES", 176, 180], ["ZIKV", "SPECIES", 66, 70], ["mice", "SPECIES", 176, 180], ["the evaluation", "TEST", 28, 42], ["countermeasures", "TREATMENT", 46, 61], ["ZIKV infection", "PROBLEM", 66, 80], ["antivirals drugs", "TREATMENT", 110, 126], ["vaccines", "TREATMENT", 131, 139]]], ["However, such models have complete/near-complete deficiency in interferon response and do not resemble the real clinical situation in immunosuppressed humans.", [["humans", "ORGANISM", 151, 157], ["interferon", "PROTEIN", 63, 73], ["humans", "SPECIES", 151, 157], ["humans", "SPECIES", 151, 157], ["complete deficiency in interferon response", "PROBLEM", 40, 82], ["deficiency", "OBSERVATION", 49, 59], ["interferon response", "OBSERVATION", 63, 82]]], ["Moreover, these mice are suboptimal for the study of host immune response and may be too expensive for laboratories in resource-limited areas.IntroductionBecause of these limitations and knowledge gaps, we developed and characterized a more readily available mouse model which resembles immunosuppressed hosts with disseminated infection.", [["infection", "DISEASE", 328, 337], ["mice", "ORGANISM", 16, 20], ["mouse", "ORGANISM", 259, 264], ["mice", "SPECIES", 16, 20], ["mouse", "SPECIES", 259, 264], ["mice", "SPECIES", 16, 20], ["mouse", "SPECIES", 259, 264], ["the study", "TEST", 40, 49], ["disseminated infection", "PROBLEM", 315, 337], ["disseminated", "OBSERVATION_MODIFIER", 315, 327], ["infection", "OBSERVATION", 328, 337]]], ["We showed that these mice developed inflammation in multiple organs, including the testes, which may have important implications on ZIKV's long-term outcome and effects on fertility.", [["organs", "ANATOMY", 61, 67], ["testes", "ANATOMY", 83, 89], ["inflammation", "DISEASE", 36, 48], ["mice", "ORGANISM", 21, 25], ["organs", "ORGAN", 61, 67], ["testes", "ORGAN", 83, 89], ["ZIKV", "CANCER", 132, 136], ["mice", "SPECIES", 21, 25], ["mice", "SPECIES", 21, 25], ["ZIKV", "SPECIES", 132, 136], ["inflammation in multiple organs", "PROBLEM", 36, 67], ["inflammation", "OBSERVATION", 36, 48], ["multiple", "OBSERVATION_MODIFIER", 52, 60], ["organs", "ANATOMY", 61, 67], ["testes", "ANATOMY", 83, 89]]], ["We also utilized this novel animal model to show that early treatment with clinically approved recombinant type I interferons improved the clinical outcome of these mice.Virus Strain and Titration ::: MethodsA clinical isolate of ZIKV (Puerto Rico strain PRVABC59) was kindly provided by Brandy Russell and Barbara Johnson, Centers for Disease Control and Prevention, USA.", [["ZIKV", "CHEMICAL", 230, 234], ["type I interferons", "GENE_OR_GENE_PRODUCT", 107, 125], ["mice", "ORGANISM", 165, 169], ["Virus", "ORGANISM", 170, 175], ["ZIKV", "ORGANISM", 230, 234], ["recombinant type I interferons", "PROTEIN", 95, 125], ["mice", "SPECIES", 165, 169], ["mice", "SPECIES", 165, 169], ["ZIKV", "SPECIES", 230, 234], ["this novel animal model", "TREATMENT", 17, 40], ["Virus Strain", "TREATMENT", 170, 182], ["MethodsA", "TREATMENT", 201, 209], ["ZIKV (Puerto Rico strain PRVABC59", "TREATMENT", 230, 263], ["Disease Control", "TREATMENT", 336, 351]]], ["The virus was amplified by three additional passages in Vero cells (ATCC) in minimum essential medium (MEM) supplemented with 1% fetal calf serum and 100 units/ml penicillin plus 100 \u03bcg/ml streptomycin to make working stocks of the virus.", [["Vero cells", "ANATOMY", 56, 66], ["ATCC", "ANATOMY", 68, 72], ["fetal calf serum", "ANATOMY", 129, 145], ["penicillin", "CHEMICAL", 163, 173], ["streptomycin", "CHEMICAL", 189, 201], ["penicillin", "CHEMICAL", 163, 173], ["streptomycin", "CHEMICAL", 189, 201], ["Vero cells", "CELL", 56, 66], ["ATCC", "CELL", 68, 72], ["fetal calf", "ORGANISM_SUBSTANCE", 129, 139], ["serum", "ORGANISM_SUBSTANCE", 140, 145], ["penicillin", "SIMPLE_CHEMICAL", 163, 173], ["streptomycin", "SIMPLE_CHEMICAL", 189, 201], ["Vero cells", "CELL_LINE", 56, 66], ["ATCC", "CELL_LINE", 68, 72], ["calf", "SPECIES", 135, 139], ["The virus", "PROBLEM", 0, 9], ["Vero cells (ATCC) in minimum essential medium (MEM)", "TREATMENT", 56, 107], ["1% fetal calf serum", "TREATMENT", 126, 145], ["penicillin", "TREATMENT", 163, 173], ["streptomycin", "TREATMENT", 189, 201], ["the virus", "PROBLEM", 228, 237], ["virus", "OBSERVATION", 4, 9], ["Vero cells", "OBSERVATION", 56, 66]]], ["For virus titration, aliquots of ZIKV were applied on confluent Vero cells in 96-well plates for 50% tissue culture infectious dose (TCID50) assay as we previously described with slight modifications (Zhou et al., 2014).", [["Vero cells", "ANATOMY", 64, 74], ["tissue", "ANATOMY", 101, 107], ["ZIKV", "SIMPLE_CHEMICAL", 33, 37], ["Vero cells", "CELL", 64, 74], ["tissue", "TISSUE", 101, 107], ["confluent Vero cells", "CELL_LINE", 54, 74], ["ZIKV", "SPECIES", 33, 37], ["virus titration", "TREATMENT", 4, 19], ["ZIKV", "TREATMENT", 33, 37], ["confluent Vero cells", "TEST", 54, 74]]], ["Briefly, serial 10-fold dilutions of ZIKV were inoculated in a Vero cell monolayer in quadruplicate and cultured in penicillin/streptomycin-supplemented MEM.", [["Vero cell monolayer", "ANATOMY", 63, 82], ["ZIKV", "CHEMICAL", 37, 41], ["penicillin", "CHEMICAL", 116, 126], ["streptomycin", "CHEMICAL", 127, 139], ["penicillin", "CHEMICAL", 116, 126], ["streptomycin", "CHEMICAL", 127, 139], ["ZIKV", "ORGANISM", 37, 41], ["Vero cell monolayer", "CELL", 63, 82], ["penicillin", "SIMPLE_CHEMICAL", 116, 126], ["streptomycin", "SIMPLE_CHEMICAL", 127, 139], ["Vero cell monolayer", "CELL_LINE", 63, 82], ["ZIKV", "SPECIES", 37, 41], ["serial 10-fold dilutions", "TREATMENT", 9, 33], ["ZIKV", "PROBLEM", 37, 41], ["a Vero cell monolayer", "TREATMENT", 61, 82], ["penicillin", "TREATMENT", 116, 126], ["streptomycin", "TREATMENT", 127, 139], ["Vero cell monolayer", "OBSERVATION", 63, 82]]], ["The plates were observed for cytopathic effect for 5 days.", [["The plates", "TREATMENT", 0, 10], ["cytopathic effect", "PROBLEM", 29, 46]]], ["Viral titer was calculated with the Reed and M\u00fcnch endpoint method.", [["Viral", "ORGANISM", 0, 5], ["Viral titer", "TEST", 0, 11]]], ["One TCID50 was interpreted as the amount of virus that causes cytopathic effect in 50% of inoculated wells.Animal Model and Viral Challenge ::: MethodsApproval was obtained from the Committee on the Use of Live Animals in Teaching and Research of The University of Hong Kong.", [["virus", "PROBLEM", 44, 49], ["cytopathic effect", "PROBLEM", 62, 79], ["virus", "OBSERVATION", 44, 49], ["cytopathic", "OBSERVATION_MODIFIER", 62, 72], ["effect", "OBSERVATION_MODIFIER", 73, 79], ["Viral Challenge", "OBSERVATION", 124, 139]]], ["Male and female BALB/c mice, 6\u20138 weeks old, were obtained from the Laboratory Animal Unit of The University of Hong Kong.", [["female BALB/c mice", "ORGANISM", 9, 27], ["mice", "SPECIES", 23, 27], ["mice", "SPECIES", 23, 27]]], ["The mice were kept in biosafety level-2 housing and given access to standard pellet feed and water ad libitum.", [["mice", "ORGANISM", 4, 8], ["mice", "SPECIES", 4, 8], ["mice", "SPECIES", 4, 8], ["standard pellet feed", "TREATMENT", 68, 88]]], ["Virus inoculation experiments were performed in a biosafety level-2 animal facility according to the standard operating procedures approved by the Committee on the Use of Live Animals in Teaching and Research of The University of Hong Kong as we described previously (Zhang et al., 2014).", [["Virus", "ORGANISM", 0, 5], ["Virus inoculation experiments", "TEST", 0, 29]]], ["The mice were randomly divided into 11 groups and given different regimens of virus inoculation, dexamethasone, and recombinant interferon treatment (Table 1).", [["dexamethasone", "CHEMICAL", 97, 110], ["dexamethasone", "CHEMICAL", 97, 110], ["mice", "ORGANISM", 4, 8], ["dexamethasone", "SIMPLE_CHEMICAL", 97, 110], ["interferon", "PROTEIN", 128, 138], ["mice", "SPECIES", 4, 8], ["mice", "SPECIES", 4, 8], ["The mice", "TREATMENT", 0, 8], ["virus inoculation", "TREATMENT", 78, 95], ["dexamethasone", "TREATMENT", 97, 110], ["recombinant interferon treatment", "TREATMENT", 116, 148]]], ["Phosphate-buffered saline (PBS) was used to dilute the virus stocks to the desired concentration, and inocula were back-titrated to verify the dose given.", [["Phosphate", "CHEMICAL", 0, 9], ["Phosphate", "CHEMICAL", 0, 9], ["Phosphate-buffered saline", "SIMPLE_CHEMICAL", 0, 25], ["PBS", "SIMPLE_CHEMICAL", 27, 30], ["Phosphate-buffered saline (PBS)", "TREATMENT", 0, 31], ["the virus stocks", "TREATMENT", 51, 67], ["inocula", "TREATMENT", 102, 109]]], ["On the day of virus inoculation, a dose of the virus equivalent to 6 \u00d7 106 TCID50 (3.24 \u00d7 106 plaque forming units) in 200 \u03bcl of PBS was inoculated via the intraperitoneal route into mice under ketamine (100 mg/kg) and xylazine (10 mg/kg) anesthesia.", [["plaque", "ANATOMY", 94, 100], ["intraperitoneal", "ANATOMY", 156, 171], ["ketamine", "CHEMICAL", 194, 202], ["xylazine", "CHEMICAL", 219, 227], ["ketamine", "CHEMICAL", 194, 202], ["xylazine", "CHEMICAL", 219, 227], ["intraperitoneal", "IMMATERIAL_ANATOMICAL_ENTITY", 156, 171], ["mice", "ORGANISM", 183, 187], ["ketamine", "SIMPLE_CHEMICAL", 194, 202], ["xylazine", "SIMPLE_CHEMICAL", 219, 227], ["mice", "SPECIES", 183, 187], ["mice", "SPECIES", 183, 187], ["virus inoculation", "TREATMENT", 14, 31], ["the virus", "TREATMENT", 43, 52], ["PBS", "TREATMENT", 129, 132], ["ketamine", "TREATMENT", 194, 202], ["xylazine", "TREATMENT", 219, 227], ["anesthesia", "TREATMENT", 239, 249]]], ["Mice in the negative-control groups (groups 5 to 8) were injected with the same volume of PBS.", [["Mice", "ORGANISM", 0, 4], ["Mice", "SPECIES", 0, 4], ["the same volume of PBS", "TREATMENT", 71, 93]]], ["Mice were monitored three times each day for clinical signs of disease and a numerical score was assigned at each observation as previously described (Dowall et al., 2016, Graham et al., 2015).", [["Mice", "ORGANISM", 0, 4], ["Mice", "SPECIES", 0, 4], ["disease", "PROBLEM", 63, 70], ["a numerical score", "TEST", 75, 92], ["disease", "OBSERVATION", 63, 70]]], ["Their body weight and survival were monitored for 14 days post-inoculation (dpi) or until euthanasia.", [["body", "ANATOMY", 6, 10], ["body", "ORGANISM_SUBDIVISION", 6, 10], ["Their body weight", "TEST", 0, 17], ["survival", "TREATMENT", 22, 30], ["euthanasia", "PROBLEM", 90, 100]]], ["Three mice in each group (except groups 7 and 8 which included mock-infected control mice without dexamethasone immunosuppression and group 9 which included ZIKV-inoculated, dexamethasone-immunosuppressed mice without dexamethasone withdrawal) were sacrificed at 5 dpi for virological, histological, and immunohistochemistry analyses.", [["dexamethasone", "CHEMICAL", 98, 111], ["ZIKV", "CHEMICAL", 157, 161], ["dexamethasone", "CHEMICAL", 174, 187], ["dexamethasone", "CHEMICAL", 218, 231], ["dexamethasone", "CHEMICAL", 98, 111], ["dexamethasone", "CHEMICAL", 174, 187], ["dexamethasone", "CHEMICAL", 218, 231], ["mice", "ORGANISM", 6, 10], ["mice", "ORGANISM", 85, 89], ["dexamethasone", "SIMPLE_CHEMICAL", 98, 111], ["ZIKV", "ORGANISM", 157, 161], ["dexamethasone", "SIMPLE_CHEMICAL", 174, 187], ["mice", "ORGANISM", 205, 209], ["dexamethasone", "SIMPLE_CHEMICAL", 218, 231], ["mice", "SPECIES", 6, 10], ["mice", "SPECIES", 85, 89], ["mice", "SPECIES", 205, 209], ["mice", "SPECIES", 6, 10], ["mice", "SPECIES", 85, 89], ["mice", "SPECIES", 205, 209], ["dexamethasone immunosuppression", "TREATMENT", 98, 129], ["ZIKV", "PROBLEM", 157, 161], ["dexamethasone", "TREATMENT", 174, 187], ["dexamethasone withdrawal", "PROBLEM", 218, 242], ["virological", "TEST", 273, 284], ["immunohistochemistry analyses", "TEST", 304, 333]]], ["The remaining mice were sacrificed at 14 dpi or euthanized when there was a 20% weight loss or 10% weight loss with \u2265 1 clinical sign (Dowall et al., 2016).", [["weight loss", "DISEASE", 80, 91], ["weight loss", "DISEASE", 99, 110], ["mice", "ORGANISM", 14, 18], ["mice", "SPECIES", 14, 18], ["mice", "SPECIES", 14, 18], ["a 20% weight loss", "PROBLEM", 74, 91], ["10% weight loss", "PROBLEM", 95, 110]]], ["Samples of brain, testis/epididymis (male), prostate (male), ovary/uterus (female), kidney, urinary bladder, spleen, liver, pancreas, intestine, heart, lung, and salivary gland were collected at necropsy.", [["Samples", "ANATOMY", 0, 7], ["brain", "ANATOMY", 11, 16], ["testis", "ANATOMY", 18, 24], ["epididymis", "ANATOMY", 25, 35], ["prostate", "ANATOMY", 44, 52], ["ovary", "ANATOMY", 61, 66], ["uterus", "ANATOMY", 67, 73], ["kidney", "ANATOMY", 84, 90], ["urinary bladder", "ANATOMY", 92, 107], ["spleen", "ANATOMY", 109, 115], ["liver", "ANATOMY", 117, 122], ["pancreas", "ANATOMY", 124, 132], ["intestine", "ANATOMY", 134, 143], ["heart", "ANATOMY", 145, 150], ["lung", "ANATOMY", 152, 156], ["salivary gland", "ANATOMY", 162, 176], ["brain", "ORGAN", 11, 16], ["testis", "ORGAN", 18, 24], ["epididymis", "ORGAN", 25, 35], ["prostate", "CANCER", 44, 52], ["ovary", "ORGAN", 61, 66], ["uterus", "ORGAN", 67, 73], ["kidney", "ORGAN", 84, 90], ["urinary bladder", "MULTI-TISSUE_STRUCTURE", 92, 107], ["spleen", "ORGAN", 109, 115], ["liver", "ORGAN", 117, 122], ["pancreas", "ORGAN", 124, 132], ["intestine", "ORGAN", 134, 143], ["heart", "ORGAN", 145, 150], ["lung", "ORGAN", 152, 156], ["salivary gland", "ORGAN", 162, 176], ["Samples of brain, testis/epididymis (male), prostate (male), ovary/uterus (female), kidney, urinary bladder, spleen, liver, pancreas, intestine, heart, lung, and salivary gland", "PROBLEM", 0, 176], ["brain", "ANATOMY", 11, 16], ["testis", "ANATOMY", 18, 24], ["epididymis", "ANATOMY", 25, 35], ["prostate", "ANATOMY", 44, 52], ["ovary", "ANATOMY", 61, 66], ["uterus", "ANATOMY", 67, 73], ["kidney", "ANATOMY", 84, 90], ["urinary bladder", "ANATOMY", 92, 107], ["spleen", "ANATOMY", 109, 115], ["liver", "ANATOMY", 117, 122], ["pancreas", "ANATOMY", 124, 132], ["intestine", "ANATOMY", 134, 143], ["heart", "ANATOMY", 145, 150], ["lung", "ANATOMY", 152, 156], ["salivary gland", "ANATOMY", 162, 176]]], ["The specimens were separated into two parts, one immediately fixed in 10% PBS-buffered formalin, the other immediately frozen at \u2212 80 \u00b0C until further experiments.", [["specimens", "ANATOMY", 4, 13], ["formalin", "CHEMICAL", 87, 95], ["specimens", "CELL", 4, 13], ["formalin", "SIMPLE_CHEMICAL", 87, 95], ["The specimens", "TEST", 0, 13]]], ["Blood samples were also collected for RNA extraction and real-time PCR analysis.Histopathology and Immunohistochemistry ::: MethodsParaffin-embedded tissues were cut into 4\u20136 \u03bcm sections, mounted on slides, and stained with hematoxylin and eosin (H&E) for light microscopy examination as we previously described (Zheng et al., 2008).", [["Blood samples", "ANATOMY", 0, 13], ["tissues", "ANATOMY", 149, 156], ["4\u20136 \u03bcm sections", "ANATOMY", 171, 186], ["hematoxylin", "CHEMICAL", 224, 235], ["eosin", "CHEMICAL", 240, 245], ["Blood samples", "ORGANISM_SUBSTANCE", 0, 13], ["tissues", "TISSUE", 149, 156], ["hematoxylin", "SIMPLE_CHEMICAL", 224, 235], ["eosin", "SIMPLE_CHEMICAL", 240, 245], ["Blood samples", "TEST", 0, 13], ["RNA extraction", "TEST", 38, 52], ["real-time PCR analysis", "TEST", 57, 79], ["Histopathology", "TEST", 80, 94], ["Immunohistochemistry", "TEST", 99, 119], ["MethodsParaffin-embedded tissues", "TREATMENT", 124, 156], ["slides", "TEST", 199, 205], ["hematoxylin", "TEST", 224, 235], ["light microscopy examination", "TEST", 256, 284]]], ["For immunohistochemical staining of ZIKV-NS1 antigen, mouse antiserum against ZIKV-NS1 protein prepared as we previously described was used as primary antibody (Chan et al., 2016b).", [["ZIKV-NS1 antigen", "GENE_OR_GENE_PRODUCT", 36, 52], ["mouse", "ORGANISM", 54, 59], ["antiserum", "ORGANISM_SUBSTANCE", 60, 69], ["ZIKV-NS1", "ORGANISM", 78, 86], ["ZIKV", "PROTEIN", 36, 40], ["NS1 antigen", "PROTEIN", 41, 52], ["ZIKV", "PROTEIN", 78, 82], ["NS1 protein", "PROTEIN", 83, 94], ["primary antibody", "PROTEIN", 143, 159], ["mouse", "SPECIES", 54, 59], ["ZIKV", "SPECIES", 36, 40], ["mouse", "SPECIES", 54, 59], ["ZIKV", "SPECIES", 78, 82], ["immunohistochemical staining", "TEST", 4, 32], ["ZIKV", "TEST", 36, 40], ["NS1 antigen", "TEST", 41, 52], ["mouse antiserum", "TREATMENT", 54, 69], ["ZIKV", "PROBLEM", 78, 82], ["NS1 protein", "PROBLEM", 83, 94]]], ["De-paraffinized and rehydrated tissue sections were treated with Antigen Unmasking Solution according to manufacturer's instructions (Vector Laboratories Inc., Burlingame, CA, USA) and then stained with Mouse on Mouse Polymer IHC kit (Abcam, Cambridge, United Kingdom).", [["tissue sections", "ANATOMY", 31, 46], ["tissue sections", "CANCER", 31, 46], ["Mouse", "ORGANISM", 203, 208], ["Mouse", "ORGANISM", 212, 217], ["Mouse", "SPECIES", 203, 208], ["Mouse", "SPECIES", 212, 217], ["Mouse", "SPECIES", 212, 217], ["rehydrated tissue sections", "TREATMENT", 20, 46], ["Antigen Unmasking Solution", "TREATMENT", 65, 91]]], ["The primary antibody mouse anti-ZIKV-NS1 antiserum (1:1000 dilution with 1% BSA/PBS) was incubated at 4 \u00b0C overnight.", [["mouse", "ORGANISM", 21, 26], ["NS1", "ORGANISM", 37, 40], ["antiserum", "ORGANISM_SUBSTANCE", 41, 50], ["BSA", "SIMPLE_CHEMICAL", 76, 79], ["anti-ZIKV", "PROTEIN", 27, 36], ["NS1", "PROTEIN", 37, 40], ["mouse", "SPECIES", 21, 26], ["mouse", "SPECIES", 21, 26], ["anti-ZIKV", "SPECIES", 27, 36], ["The primary antibody mouse anti-ZIKV", "TREATMENT", 0, 36], ["NS1 antiserum", "TREATMENT", 37, 50], ["1% BSA/PBS", "TREATMENT", 73, 83]]], ["This was followed by Mouse on Mouse HRP polymer kit (Abcam) with horseradish peroxidase-conjugated secondary antibody for 15 min.", [["Mouse", "ORGANISM", 21, 26], ["Mouse", "ORGANISM", 30, 35], ["HRP", "GENE_OR_GENE_PRODUCT", 36, 39], ["Abcam", "GENE_OR_GENE_PRODUCT", 53, 58], ["horseradish peroxidase", "SIMPLE_CHEMICAL", 65, 87], ["Mouse HRP polymer kit", "PROTEIN", 30, 51], ["Abcam", "PROTEIN", 53, 58], ["horseradish peroxidase", "PROTEIN", 65, 87], ["conjugated secondary antibody", "PROTEIN", 88, 117], ["Mouse", "SPECIES", 21, 26], ["Mouse", "SPECIES", 30, 35], ["horseradish", "SPECIES", 65, 76], ["Mouse", "SPECIES", 30, 35], ["Mouse HRP polymer kit (Abcam)", "TREATMENT", 30, 59], ["horseradish peroxidase", "TREATMENT", 65, 87]]], ["Color development was performed using 3,3\u2032-diaminobenzidine (DAB) (Vector Laboratories, Burlingame, CA, USA).", [["3,3\u2032-diaminobenzidine", "CHEMICAL", 38, 59], ["DAB", "CHEMICAL", 61, 64], ["3,3\u2032-diaminobenzidine", "CHEMICAL", 38, 59], ["DAB", "CHEMICAL", 61, 64], ["3,3\u2032-diaminobenzidine", "SIMPLE_CHEMICAL", 38, 59], ["DAB", "SIMPLE_CHEMICAL", 61, 64]]], ["For immunohistochemical staining of CD45 and CD8, the sections were incubated at 4 \u00b0C for overnight with primary antibody (rabbit anti-mouse CD45, or rat anti-mouse CD8\u03b1 (Abcam) after antigen unmasking and blocking.", [["sections", "ANATOMY", 54, 62], ["CD45", "GENE_OR_GENE_PRODUCT", 36, 40], ["CD8", "GENE_OR_GENE_PRODUCT", 45, 48], ["rabbit", "ORGANISM", 123, 129], ["CD45", "GENE_OR_GENE_PRODUCT", 141, 145], ["rat", "ORGANISM", 150, 153], ["anti-mouse CD8\u03b1", "GENE_OR_GENE_PRODUCT", 154, 169], ["Abcam", "GENE_OR_GENE_PRODUCT", 171, 176], ["CD45", "PROTEIN", 36, 40], ["CD8", "PROTEIN", 45, 48], ["primary antibody", "PROTEIN", 105, 121], ["rabbit anti-mouse CD45", "PROTEIN", 123, 145], ["rat anti-mouse CD8\u03b1", "PROTEIN", 150, 169], ["Abcam", "PROTEIN", 171, 176], ["rabbit", "SPECIES", 123, 129], ["rat", "SPECIES", 150, 153], ["anti-mouse", "SPECIES", 154, 164], ["rabbit", "SPECIES", 123, 129], ["rat", "SPECIES", 150, 153], ["immunohistochemical staining", "TEST", 4, 32], ["CD45", "TEST", 36, 40], ["CD8", "TEST", 45, 48], ["the sections", "TEST", 50, 62], ["primary antibody", "TEST", 105, 121], ["rabbit anti-mouse CD45", "TEST", 123, 145], ["rat anti-mouse CD8", "TEST", 150, 168], ["Abcam", "TEST", 171, 176]]], ["This was then followed by incubation with biotin-conjugated goat anti-rabbit IgG or goat anti-rat IgG (Calbiochem, Darmstadt, Germany) for 30 min at room temperature.", [["biotin", "CHEMICAL", 42, 48], ["biotin", "CHEMICAL", 42, 48], ["biotin", "SIMPLE_CHEMICAL", 42, 48], ["goat", "ORGANISM", 60, 64], ["goat", "ORGANISM", 84, 88], ["biotin-conjugated goat anti-rabbit IgG", "PROTEIN", 42, 80], ["goat anti-rat IgG", "PROTEIN", 84, 101], ["goat", "SPECIES", 60, 64], ["anti-rabbit", "SPECIES", 65, 76], ["goat", "SPECIES", 84, 88], ["goat", "SPECIES", 60, 64], ["anti-rabbit", "SPECIES", 65, 76], ["goat", "SPECIES", 84, 88], ["biotin", "TREATMENT", 42, 48], ["conjugated goat anti-rabbit IgG", "TREATMENT", 49, 80], ["goat anti-rat IgG", "TREATMENT", 84, 101]]], ["Streptavidin/peroxidase complex reagent (Vector Laboratories) was then added and incubated at room temperature for 30 min.", [["Streptavidin", "GENE_OR_GENE_PRODUCT", 0, 12], ["peroxidase", "GENE_OR_GENE_PRODUCT", 13, 23], ["Streptavidin/peroxidase complex reagent", "TREATMENT", 0, 39]]], ["Color development was done with DAB (Vector Laboratories).", [["DAB", "SIMPLE_CHEMICAL", 32, 35], ["DAB (Vector Laboratories", "TEST", 32, 56]]], ["All tissue sections were examined microscopically by two pathologists in an operator-blinded manner.", [["tissue sections", "ANATOMY", 4, 19], ["tissue sections", "CANCER", 4, 19], ["All tissue sections", "TEST", 0, 19]]], ["Images were captured with Nikon80i imaging system equipped with Spot-advance computer software.Viral Load Studies ::: MethodsTotal nucleic acid (TNA) was extracted from the blood and necropsied tissues using EZ1 Virus Mini Kit v2.0 and QIAsymphony DSP Virus/Pathogen Mini Kit (QIAGEN, Hilden, Germany), respectively, as we previously described (Zheng et al., 2008, Chan et al., 2016b, Chan et al., 2015a).", [["blood", "ANATOMY", 173, 178], ["tissues", "ANATOMY", 194, 201], ["nucleic acid", "CHEMICAL", 131, 143], ["Total nucleic acid", "SIMPLE_CHEMICAL", 125, 143], ["blood", "ORGANISM_SUBSTANCE", 173, 178], ["tissues", "TISSUE", 194, 201], ["Images", "TEST", 0, 6], ["Nikon80i imaging system", "TEST", 26, 49], ["Methods", "TREATMENT", 118, 125], ["Total nucleic acid (TNA", "TEST", 125, 148], ["the blood", "TEST", 169, 178], ["EZ1 Virus", "TEST", 208, 217], ["Kit v", "TEST", 223, 228], ["QIAsymphony DSP Virus", "PROBLEM", 236, 257], ["nucleic acid", "OBSERVATION", 131, 143], ["blood", "ANATOMY", 173, 178], ["necropsied tissues", "ANATOMY", 183, 201]]], ["ZIKV envelope gene was measured by using QuantiNova Probe RT-PCR Kit (QIAGEN) in LightCycler 96 Real-Time PCR System (Roche Diagnostics, Basel, Switzerland).", [["ZIKV", "GENE_OR_GENE_PRODUCT", 0, 4], ["ZIKV envelope gene", "DNA", 0, 18], ["ZIKV", "SPECIES", 0, 4], ["ZIKV envelope gene", "TREATMENT", 0, 18], ["LightCycler", "TEST", 81, 92]]], ["5 \u03bcl of purified TNA was amplified in a 20 \u03bcl-reaction containing 10 \u03bcl of 2 \u00d7 QuantiNova Probe RT-PCR Master Mix, 0.2 \u03bcl QN Probe RT-mix, 0.8 \u03bcM forward primer, 0.8 \u03bcM reverse primer, and 200 nM probe.", [["TNA", "GENE_OR_GENE_PRODUCT", 17, 20], ["purified TNA", "PROTEIN", 8, 20], ["purified TNA", "TREATMENT", 8, 20]]], ["Forward primer (5\u2032-CGYTGCCCAACACAAGG-3\u2032), reverse primer (5\u2032-CCACYAAYGTTCTTTTGCABACA-3\u2032), and probe (5\u2032-HEX-AGCCTACCTTGAYAAGCARTCAGACACTC-IABkFQ-3\u2032) targeting the ZIKV envelope gene as we previously described were used (Chan et al., 2016b).", [["ZIKV envelope", "GENE_OR_GENE_PRODUCT", 163, 176], ["Forward primer", "DNA", 0, 14], ["reverse primer", "DNA", 42, 56], ["5\u2032-HEX-AGCCTACCTTGAYAAGCARTCAGACACTC", "DNA", 101, 137], ["IABkFQ", "DNA", 138, 144], ["ZIKV envelope gene", "DNA", 163, 181], ["Forward primer", "TEST", 0, 14], ["5\u2032-CGYTGCCCAACACAAGG", "TEST", 16, 36], ["5\u2032-CCACYAAYGTTCTTTTGCABACA", "TEST", 58, 84], ["5\u2032-HEX-AGCCTACCTTGAYAAGCARTCAGACACTC", "TEST", 101, 137], ["the ZIKV envelope gene", "TREATMENT", 159, 181], ["ZIKV", "OBSERVATION", 163, 167]]], ["Internal control \u03b2-actin gene was measured by using QuantiNova SYBR Green RT-PCR Kit (QIAGEN) in LightCycler 96 Real-Time PCR System.", [["\u03b2-actin", "GENE_OR_GENE_PRODUCT", 17, 24], ["\u03b2-actin gene", "DNA", 17, 29], ["Internal control \u03b2-actin gene", "TREATMENT", 0, 29], ["LightCycler", "TEST", 97, 108]]], ["5 \u03bcl of purified TNA was amplified in a 20 \u03bcl-reaction containing 10 \u03bcl of 2 \u00d7 QuantiNova SYBR Green RT-PCR Master Mix, 0.2 \u03bcl QN SYBR Green RT-mix, 0.5 \u03bcM forward primer (5\u2032-ACGGCCAGGTCATCACTATTG-3\u2032) and 0.5 \u03bcM reverse primer (5\u2032-CAAGAAGGAAGGCTGGAAAAG-3\u2032) for the \u03b2-actin gene.", [["TNA", "GENE_OR_GENE_PRODUCT", 17, 20], ["\u03b2-actin", "GENE_OR_GENE_PRODUCT", 265, 272], ["purified TNA", "PROTEIN", 8, 20], ["\u03b2-actin gene", "DNA", 265, 277], ["purified TNA", "TREATMENT", 8, 20], ["ACGGCCAGGTCATCACTATTG", "TEST", 175, 196], ["\u2032-CAAGAAGGAAGGCTGGAAAAG", "TEST", 229, 252], ["the \u03b2-actin gene", "TREATMENT", 261, 277]]], ["A series of 10-fold dilutions equivalent to 1 \u00d7 102 to 1 \u00d7 106 copies/reaction mixture were prepared to generate standard curves and run in parallel with the test samples.Statistical Analysis ::: MethodsAll data were analyzed with GraphPad Prism software (GraphPad Software, Inc).", [["10-fold dilutions", "TREATMENT", 12, 29], ["copies/reaction mixture", "TREATMENT", 63, 86], ["the test samples", "TEST", 154, 170]]], ["Kaplan-Meier survival curves were analyzed by the log rank test, and weight losses were compared using two-way ANOVA.", [["Meier survival curves", "TEST", 7, 28], ["the log rank test", "TEST", 46, 63], ["weight losses", "PROBLEM", 69, 82]]], ["Student's t-test was used to determine significant differences in virus titers, and Tukey\u2013Kramer post hoc tests were used to discern differences among individual treatment groups as previously reported (Aliota et al., 2016, Rossi et al., 2016).", [["Student's t-test", "TEST", 0, 16], ["significant differences in virus titers", "PROBLEM", 39, 78], ["hoc tests", "TEST", 102, 111]]], ["P-values < 0.05 were considered statistically significant.Dexamethasone-immunosuppressed Mice Developed Disseminated ZIKV Infection ::: ResultsTo establish a novel mouse model for ZIKV infection, we compared the clinical, histological, and virological findings of male (group 1) and female (group 2) mice with dexamethasone immunosuppression and ZIKV infection with those of the appropriate controls (groups 3 to 8) (Table 1).", [["Dexamethasone", "CHEMICAL", 58, 71], ["Disseminated ZIKV Infection", "DISEASE", 104, 131], ["ZIKV infection", "DISEASE", 180, 194], ["dexamethasone", "CHEMICAL", 310, 323], ["ZIKV infection", "DISEASE", 346, 360], ["Dexamethasone", "CHEMICAL", 58, 71], ["dexamethasone", "CHEMICAL", 310, 323], ["Dexamethasone", "SIMPLE_CHEMICAL", 58, 71], ["Mice", "ORGANISM", 89, 93], ["mouse", "ORGANISM", 164, 169], ["ZIKV", "ORGANISM", 180, 184], ["mice", "ORGANISM", 300, 304], ["dexamethasone", "SIMPLE_CHEMICAL", 310, 323], ["Mice", "SPECIES", 89, 93], ["mouse", "SPECIES", 164, 169], ["mice", "SPECIES", 300, 304], ["ZIKV", "SPECIES", 117, 121], ["mouse", "SPECIES", 164, 169], ["ZIKV", "SPECIES", 180, 184], ["mice", "SPECIES", 300, 304], ["ZIKV", "SPECIES", 346, 350], ["P-values", "TEST", 0, 8], ["Dexamethasone", "TREATMENT", 58, 71], ["Disseminated ZIKV Infection", "PROBLEM", 104, 131], ["a novel mouse model", "TREATMENT", 156, 175], ["ZIKV infection", "PROBLEM", 180, 194], ["dexamethasone immunosuppression", "TREATMENT", 310, 341], ["ZIKV infection", "PROBLEM", 346, 360], ["Disseminated", "OBSERVATION_MODIFIER", 104, 116], ["ZIKV Infection", "OBSERVATION", 117, 131], ["ZIKV infection", "OBSERVATION", 346, 360]]], ["In terms of the clinical parameters, the dexamethasone-immunosuppressed mice developed mild (~ 5%) weight loss (Fig. 1A) and no mortality at 5 dpi (Fig. 1B and C).", [["dexamethasone", "CHEMICAL", 41, 54], ["weight loss", "DISEASE", 99, 110], ["dexamethasone", "CHEMICAL", 41, 54], ["dexamethasone", "SIMPLE_CHEMICAL", 41, 54], ["mice", "ORGANISM", 72, 76], ["mice", "SPECIES", 72, 76], ["mice", "SPECIES", 72, 76], ["the dexamethasone", "TREATMENT", 37, 54], ["weight loss", "PROBLEM", 99, 110], ["mild", "OBSERVATION_MODIFIER", 87, 91]]], ["The weight loss of the dexamethasone-immunosuppressed mice with ZIKV inoculation (groups 1 and 2) was consistently more significant than those of their comparators, including the ZIKV-inoculated male mice without dexamethasone immunosuppression (groups 3 and 4) and mock-infected mice without dexamethasone immunosuppression (groups 7 and 8) starting at 1 dpi (P < 0.05).", [["weight loss", "DISEASE", 4, 15], ["dexamethasone", "CHEMICAL", 23, 36], ["ZIKV", "CHEMICAL", 64, 68], ["dexamethasone", "CHEMICAL", 213, 226], ["dexamethasone", "CHEMICAL", 293, 306], ["dexamethasone", "CHEMICAL", 23, 36], ["dexamethasone", "CHEMICAL", 213, 226], ["dexamethasone", "CHEMICAL", 293, 306], ["dexamethasone", "SIMPLE_CHEMICAL", 23, 36], ["mice", "ORGANISM", 54, 58], ["ZIKV", "ORGANISM", 179, 183], ["mice", "ORGANISM", 200, 204], ["dexamethasone", "SIMPLE_CHEMICAL", 213, 226], ["mice", "ORGANISM", 280, 284], ["dexamethasone", "SIMPLE_CHEMICAL", 293, 306], ["mice", "SPECIES", 54, 58], ["mice", "SPECIES", 200, 204], ["mice", "SPECIES", 280, 284], ["mice", "SPECIES", 54, 58], ["ZIKV", "SPECIES", 64, 68], ["mice", "SPECIES", 200, 204], ["mice", "SPECIES", 280, 284], ["The weight loss", "PROBLEM", 0, 15], ["the dexamethasone", "TREATMENT", 19, 36], ["ZIKV inoculation", "TREATMENT", 64, 80], ["dexamethasone immunosuppression", "TREATMENT", 213, 244], ["dexamethasone immunosuppression", "TREATMENT", 293, 324], ["weight loss", "OBSERVATION_MODIFIER", 4, 15]]], ["Minimal histological changes and inflammatory infiltrates were seen in the tissues of the male and female mice with dexamethasone immunosuppression and ZIKV inoculation (groups 1 and 2).", [["tissues", "ANATOMY", 75, 82], ["dexamethasone", "CHEMICAL", 116, 129], ["ZIKV", "CHEMICAL", 152, 156], ["dexamethasone", "CHEMICAL", 116, 129], ["tissues", "TISSUE", 75, 82], ["mice", "ORGANISM", 106, 110], ["dexamethasone", "SIMPLE_CHEMICAL", 116, 129], ["mice", "SPECIES", 106, 110], ["mice", "SPECIES", 106, 110], ["ZIKV", "SPECIES", 152, 156], ["Minimal histological changes", "PROBLEM", 0, 28], ["inflammatory infiltrates", "PROBLEM", 33, 57], ["dexamethasone immunosuppression", "TREATMENT", 116, 147], ["ZIKV inoculation", "TREATMENT", 152, 168], ["histological", "OBSERVATION", 8, 20], ["inflammatory", "OBSERVATION_MODIFIER", 33, 45], ["infiltrates", "OBSERVATION", 46, 57], ["tissues", "ANATOMY", 75, 82], ["dexamethasone immunosuppression", "OBSERVATION", 116, 147]]], ["On the other hand, ZIKV-NS1 protein expression was detected by immunohistochemical staining in most tissues of these mice, but not in dexamethasone-immunosuppressed mice with mock infection, suggesting that the viral protein expression was specific and not related to dexamethasone effects (Fig. 2).", [["tissues", "ANATOMY", 100, 107], ["dexamethasone", "CHEMICAL", 134, 147], ["mock infection", "DISEASE", 175, 189], ["dexamethasone", "CHEMICAL", 268, 281], ["dexamethasone", "CHEMICAL", 134, 147], ["dexamethasone", "CHEMICAL", 268, 281], ["ZIKV", "GENE_OR_GENE_PRODUCT", 19, 23], ["NS1", "GENE_OR_GENE_PRODUCT", 24, 27], ["tissues", "TISSUE", 100, 107], ["mice", "ORGANISM", 117, 121], ["dexamethasone", "SIMPLE_CHEMICAL", 134, 147], ["mice", "ORGANISM", 165, 169], ["dexamethasone", "SIMPLE_CHEMICAL", 268, 281], ["ZIKV", "PROTEIN", 19, 23], ["NS1", "PROTEIN", 24, 27], ["viral protein", "PROTEIN", 211, 224], ["mice", "SPECIES", 117, 121], ["mice", "SPECIES", 165, 169], ["ZIKV", "SPECIES", 19, 23], ["mice", "SPECIES", 117, 121], ["mice", "SPECIES", 165, 169], ["ZIKV", "TEST", 19, 23], ["NS1 protein expression", "PROBLEM", 24, 46], ["immunohistochemical staining", "TEST", 63, 91], ["dexamethasone", "TREATMENT", 134, 147], ["mock infection", "PROBLEM", 175, 189], ["the viral protein expression", "PROBLEM", 207, 235], ["dexamethasone effects", "TREATMENT", 268, 289], ["most tissues", "OBSERVATION_MODIFIER", 95, 107], ["infection", "OBSERVATION", 180, 189]]], ["The dexamethasone-immunosuppressed mice with ZIKV inoculation (groups 1 and 2) also had high mean viral loads in blood and most tissues at 5 dpi, especially in the testis/epididymis, ovary/uterus, prostate, spleen, and pancreas (Figs 3A and B and S1A and B).", [["blood", "ANATOMY", 113, 118], ["tissues", "ANATOMY", 128, 135], ["testis", "ANATOMY", 164, 170], ["epididymis", "ANATOMY", 171, 181], ["ovary", "ANATOMY", 183, 188], ["uterus", "ANATOMY", 189, 195], ["prostate", "ANATOMY", 197, 205], ["spleen", "ANATOMY", 207, 213], ["pancreas", "ANATOMY", 219, 227], ["dexamethasone", "CHEMICAL", 4, 17], ["ZIKV", "CHEMICAL", 45, 49], ["dexamethasone", "CHEMICAL", 4, 17], ["dexamethasone", "SIMPLE_CHEMICAL", 4, 17], ["mice", "ORGANISM", 35, 39], ["blood", "ORGANISM_SUBSTANCE", 113, 118], ["tissues", "TISSUE", 128, 135], ["testis", "ORGAN", 164, 170], ["epididymis", "ORGAN", 171, 181], ["ovary", "ORGAN", 183, 188], ["uterus", "ORGAN", 189, 195], ["prostate", "ORGAN", 197, 205], ["spleen", "ORGAN", 207, 213], ["pancreas", "ORGAN", 219, 227], ["B", "GENE_OR_GENE_PRODUCT", 241, 242], ["S1A", "GENE_OR_GENE_PRODUCT", 247, 250], ["B", "GENE_OR_GENE_PRODUCT", 255, 256], ["mice", "SPECIES", 35, 39], ["mice", "SPECIES", 35, 39], ["ZIKV", "SPECIES", 45, 49], ["The dexamethasone", "TREATMENT", 0, 17], ["ZIKV inoculation (groups", "TREATMENT", 45, 69], ["high mean viral loads in blood and most tissues", "PROBLEM", 88, 135], ["ovary/uterus, prostate, spleen, and pancreas", "PROBLEM", 183, 227], ["viral loads", "OBSERVATION", 98, 109], ["most tissues", "ANATOMY", 123, 135], ["testis", "ANATOMY", 164, 170], ["epididymis", "ANATOMY", 171, 181], ["ovary", "ANATOMY", 183, 188], ["uterus", "ANATOMY", 189, 195], ["prostate", "ANATOMY", 197, 205], ["spleen", "ANATOMY", 207, 213], ["pancreas", "ANATOMY", 219, 227]]], ["These findings at 5 dpi were suggestive of disseminated but non-lethal ZIKV infection involving different organs with minimal inflammatory response due to dexamethasone immunosuppression.Clinical Deterioration with Multi-organ Inflammatory Cell Infiltrates Occurred in the Mice after Dexamethasone Withdrawal ::: ResultsTo investigate the possible effects of immune reconstitution in the dexamethasone-immunosuppressed mice, dexamethasone was stopped after 9 dpi.", [["organs", "ANATOMY", 106, 112], ["Cell", "ANATOMY", 240, 244], ["ZIKV infection", "DISEASE", 71, 85], ["dexamethasone", "CHEMICAL", 155, 168], ["dexamethasone", "CHEMICAL", 388, 401], ["dexamethasone", "CHEMICAL", 425, 438], ["dexamethasone", "CHEMICAL", 155, 168], ["Dexamethasone", "CHEMICAL", 284, 297], ["dexamethasone", "CHEMICAL", 388, 401], ["dexamethasone", "CHEMICAL", 425, 438], ["ZIKV", "CANCER", 71, 75], ["organs", "ORGAN", 106, 112], ["dexamethasone", "SIMPLE_CHEMICAL", 155, 168], ["Mice", "ORGANISM", 273, 277], ["Dexamethasone", "SIMPLE_CHEMICAL", 284, 297], ["dexamethasone", "SIMPLE_CHEMICAL", 388, 401], ["mice", "ORGANISM", 419, 423], ["dexamethasone", "SIMPLE_CHEMICAL", 425, 438], ["Mice", "SPECIES", 273, 277], ["mice", "SPECIES", 419, 423], ["ZIKV", "SPECIES", 71, 75], ["mice", "SPECIES", 419, 423], ["non-lethal ZIKV infection", "PROBLEM", 60, 85], ["minimal inflammatory response", "PROBLEM", 118, 147], ["dexamethasone immunosuppression", "TREATMENT", 155, 186], ["Clinical Deterioration", "PROBLEM", 187, 209], ["Multi-organ Inflammatory Cell Infiltrates", "PROBLEM", 215, 256], ["immune reconstitution", "TREATMENT", 359, 380], ["the dexamethasone", "TREATMENT", 384, 401], ["immunosuppressed mice", "TREATMENT", 402, 423], ["dexamethasone", "TREATMENT", 425, 438], ["suggestive of", "UNCERTAINTY", 29, 42], ["disseminated", "OBSERVATION_MODIFIER", 43, 55], ["non-lethal", "OBSERVATION_MODIFIER", 60, 70], ["ZIKV", "OBSERVATION", 71, 75], ["minimal", "OBSERVATION_MODIFIER", 118, 125], ["inflammatory response", "OBSERVATION", 126, 147], ["dexamethasone immunosuppression", "OBSERVATION", 155, 186], ["Multi-organ", "ANATOMY", 215, 226], ["Inflammatory Cell Infiltrates", "OBSERVATION", 227, 256], ["immune reconstitution", "OBSERVATION", 359, 380]]], ["This led to prominent weight loss and increased symptoms in the dexamethasone-immunosuppressed mice (groups 1 and 2).", [["weight loss", "DISEASE", 22, 33], ["dexamethasone", "CHEMICAL", 64, 77], ["dexamethasone", "CHEMICAL", 64, 77], ["dexamethasone", "SIMPLE_CHEMICAL", 64, 77], ["mice", "ORGANISM", 95, 99], ["mice", "SPECIES", 95, 99], ["mice", "SPECIES", 95, 99], ["prominent weight loss", "PROBLEM", 12, 33], ["increased symptoms", "PROBLEM", 38, 56], ["the dexamethasone", "TREATMENT", 60, 77], ["immunosuppressed mice (groups", "TREATMENT", 78, 107], ["prominent", "OBSERVATION_MODIFIER", 12, 21], ["weight loss", "OBSERVATION", 22, 33], ["increased", "OBSERVATION_MODIFIER", 38, 47], ["symptoms", "OBSERVATION", 48, 56]]], ["The most prominent body weight loss was observed in the male mice with dexamethasone immunosuppression and ZIKV inoculation (group 1), with all 6 mice having weight loss of \u2265 10% at 12 dpi (Fig. 1A).", [["body", "ANATOMY", 19, 23], ["weight loss", "DISEASE", 24, 35], ["dexamethasone", "CHEMICAL", 71, 84], ["ZIKV", "CHEMICAL", 107, 111], ["weight loss", "DISEASE", 158, 169], ["dexamethasone", "CHEMICAL", 71, 84], ["body", "ORGANISM_SUBDIVISION", 19, 23], ["mice", "ORGANISM", 61, 65], ["dexamethasone", "SIMPLE_CHEMICAL", 71, 84], ["mice", "ORGANISM", 146, 150], ["mice", "SPECIES", 61, 65], ["mice", "SPECIES", 146, 150], ["mice", "SPECIES", 61, 65], ["ZIKV", "SPECIES", 107, 111], ["mice", "SPECIES", 146, 150], ["The most prominent body weight loss", "PROBLEM", 0, 35], ["dexamethasone immunosuppression", "TREATMENT", 71, 102], ["ZIKV inoculation", "PROBLEM", 107, 123], ["weight loss", "PROBLEM", 158, 169], ["most", "OBSERVATION_MODIFIER", 4, 8], ["prominent", "OBSERVATION_MODIFIER", 9, 18], ["body", "OBSERVATION_MODIFIER", 19, 23], ["weight loss", "OBSERVATION", 24, 35]]], ["All of the female mice with dexamethasone immunosuppression and ZIKV inoculation (group 2) also had progressive weight loss and 4/6 (66.7%) of them had \u2265 10% weight loss at 14 dpi.", [["dexamethasone", "CHEMICAL", 28, 41], ["ZIKV", "CHEMICAL", 64, 68], ["weight loss", "DISEASE", 112, 123], ["weight loss", "DISEASE", 158, 169], ["dexamethasone", "CHEMICAL", 28, 41], ["mice", "ORGANISM", 18, 22], ["dexamethasone", "SIMPLE_CHEMICAL", 28, 41], ["mice", "SPECIES", 18, 22], ["mice", "SPECIES", 18, 22], ["ZIKV", "SPECIES", 64, 68], ["dexamethasone immunosuppression", "TREATMENT", 28, 59], ["ZIKV inoculation", "PROBLEM", 64, 80], ["progressive weight loss", "PROBLEM", 100, 123], ["weight loss", "PROBLEM", 158, 169], ["progressive", "OBSERVATION_MODIFIER", 100, 111], ["weight loss", "OBSERVATION", 112, 123]]], ["In contrast, none of the mice with dexamethasone immunosuppression from 3 days before to 13 days post-infection (group 9) developed abrupt weight loss between 10 dpi and 14 dpi (Fig. 1A).", [["dexamethasone", "CHEMICAL", 35, 48], ["weight loss", "DISEASE", 139, 150], ["dexamethasone", "CHEMICAL", 35, 48], ["mice", "ORGANISM", 25, 29], ["dexamethasone", "SIMPLE_CHEMICAL", 35, 48], ["mice", "SPECIES", 25, 29], ["mice", "SPECIES", 25, 29], ["dexamethasone immunosuppression", "TREATMENT", 35, 66], ["abrupt weight loss", "PROBLEM", 132, 150]]], ["The weight loss of mice in groups 1 and 2 became consistently more than those of their comparators in the other control groups (groups 3 to 8), including those in the dexamethasone-immunosuppressed mice with mock infection (groups 5 and 6) since 10 dpi (P < 0.05).", [["weight loss", "DISEASE", 4, 15], ["dexamethasone", "CHEMICAL", 167, 180], ["mock infection", "DISEASE", 208, 222], ["dexamethasone", "CHEMICAL", 167, 180], ["mice", "ORGANISM", 19, 23], ["dexamethasone", "SIMPLE_CHEMICAL", 167, 180], ["mice", "ORGANISM", 198, 202], ["mice", "SPECIES", 19, 23], ["mice", "SPECIES", 198, 202], ["mice", "SPECIES", 19, 23], ["mice", "SPECIES", 198, 202], ["The weight loss of mice in groups", "PROBLEM", 0, 33], ["the dexamethasone", "TREATMENT", 163, 180], ["mock infection", "PROBLEM", 208, 222], ["weight", "OBSERVATION_MODIFIER", 4, 10], ["loss", "OBSERVATION_MODIFIER", 11, 15], ["infection", "OBSERVATION", 213, 222]]], ["Together, these findings suggested that the combination of immune reconstitution after dexamethasone withdrawal and disseminated virus infection were responsible for the abrupt clinical deterioration.", [["dexamethasone", "CHEMICAL", 87, 100], ["disseminated virus infection", "DISEASE", 116, 144], ["dexamethasone", "CHEMICAL", 87, 100], ["dexamethasone", "SIMPLE_CHEMICAL", 87, 100], ["immune reconstitution", "TREATMENT", 59, 80], ["dexamethasone withdrawal", "PROBLEM", 87, 111], ["disseminated virus infection", "PROBLEM", 116, 144], ["the abrupt clinical deterioration", "PROBLEM", 166, 199], ["immune reconstitution", "OBSERVATION", 59, 80], ["disseminated", "OBSERVATION_MODIFIER", 116, 128], ["virus infection", "OBSERVATION", 129, 144], ["abrupt", "OBSERVATION_MODIFIER", 170, 176]]], ["All of the mice in groups 1 and 2 developed rapid breathing, lethargy, and/or ruffled fur since 11 dpi (group 1) or 12 dpi (group 2), shortly after dexamethasone was stopped(Fig. 1B).", [["lethargy", "DISEASE", 61, 69], ["dexamethasone", "CHEMICAL", 148, 161], ["dexamethasone", "CHEMICAL", 148, 161], ["mice", "ORGANISM", 11, 15], ["dexamethasone", "SIMPLE_CHEMICAL", 148, 161], ["mice", "SPECIES", 11, 15], ["mice", "SPECIES", 11, 15], ["rapid breathing", "PROBLEM", 44, 59], ["lethargy", "PROBLEM", 61, 69], ["ruffled fur", "PROBLEM", 78, 89], ["dexamethasone", "TREATMENT", 148, 161], ["rapid", "OBSERVATION_MODIFIER", 44, 49], ["breathing", "OBSERVATION", 50, 59]]], ["The reasons for the earlier onset of weight loss and symptoms in the male mice were not fully understood, but might be related to the higher cumulative dose of dexamethasone because of their higher baseline body weights and/or possible effects of androgen on virus replication (Tian et al., 2012).", [["body", "ANATOMY", 207, 211], ["weight loss", "DISEASE", 37, 48], ["dexamethasone", "CHEMICAL", 160, 173], ["dexamethasone", "CHEMICAL", 160, 173], ["androgen", "CHEMICAL", 247, 255], ["mice", "ORGANISM", 74, 78], ["dexamethasone", "SIMPLE_CHEMICAL", 160, 173], ["body", "ORGANISM_SUBDIVISION", 207, 211], ["androgen", "SIMPLE_CHEMICAL", 247, 255], ["mice", "SPECIES", 74, 78], ["mice", "SPECIES", 74, 78], ["weight loss", "PROBLEM", 37, 48], ["symptoms", "PROBLEM", 53, 61], ["dexamethasone", "TREATMENT", 160, 173], ["their higher baseline body weights", "PROBLEM", 185, 219], ["androgen on virus replication", "TREATMENT", 247, 276]]], ["Based on the predefined criteria, all 6 (100%) male and 4/6 (66.7%) female mice were euthanized at 12 dpi and 14 dpi, respectively (Fig. 1C).", [["mice", "ORGANISM", 75, 79], ["mice", "SPECIES", 75, 79], ["mice", "SPECIES", 75, 79]]], ["Comparatively, all the mice in the other control groups (groups 3 to 9) had either gained weight or had < 5% weight loss with spontaneous recovery at 14 dpi (Fig. 1A), remained asymptomatic (Fig. 1B), and survived through the study period (Fig. 1C).Clinical Deterioration with Multi-organ Inflammatory Cell Infiltrates Occurred in the Mice after Dexamethasone Withdrawal ::: ResultsAt euthanasia (12\u201314 dpi), H&E staining of the necropsied tissues of these mice showed prominent acute inflammatory reactions with predominantly lymphocytic infiltrates.", [["Cell", "ANATOMY", 302, 306], ["tissues", "ANATOMY", 440, 447], ["lymphocytic infiltrates", "ANATOMY", 527, 550], ["weight loss", "DISEASE", 109, 120], ["Dexamethasone", "CHEMICAL", 346, 359], ["mice", "ORGANISM", 23, 27], ["Mice", "ORGANISM", 335, 339], ["Dexamethasone", "SIMPLE_CHEMICAL", 346, 359], ["tissues", "TISSUE", 440, 447], ["mice", "ORGANISM", 457, 461], ["lymphocytic infiltrates", "PATHOLOGICAL_FORMATION", 527, 550], ["mice", "SPECIES", 23, 27], ["Mice", "SPECIES", 335, 339], ["mice", "SPECIES", 457, 461], ["mice", "SPECIES", 23, 27], ["mice", "SPECIES", 457, 461], ["5% weight loss", "PROBLEM", 106, 120], ["asymptomatic", "PROBLEM", 177, 189], ["Clinical Deterioration", "PROBLEM", 249, 271], ["Multi-organ Inflammatory Cell Infiltrates", "PROBLEM", 277, 318], ["Dexamethasone Withdrawal", "PROBLEM", 346, 370], ["H&E staining", "TEST", 409, 421], ["prominent acute inflammatory reactions", "PROBLEM", 469, 507], ["predominantly lymphocytic infiltrates", "PROBLEM", 513, 550], ["Multi-organ", "ANATOMY", 277, 288], ["Inflammatory Cell Infiltrates", "OBSERVATION", 289, 318], ["prominent", "OBSERVATION_MODIFIER", 469, 478], ["acute", "OBSERVATION_MODIFIER", 479, 484], ["inflammatory", "OBSERVATION", 485, 497], ["predominantly", "OBSERVATION_MODIFIER", 513, 526], ["lymphocytic infiltrates", "OBSERVATION", 527, 550]]], ["The most prominent inflammatory changes were seen in the brain (cortical parenchymal and perivascular lymphocytic infiltrates) (Fig. 4A to C), kidney (acute tubulitis and interstitial inflammation) (Fig. 4D to F), and testis (necrotic and hemorrhagic seminiferous tubules with marked lymphocytic infiltration in the perimeter of the tubules and the interstitium) (Fig. 5A to D).", [["brain", "ANATOMY", 57, 62], ["cortical parenchymal", "ANATOMY", 64, 84], ["perivascular lymphocytic infiltrates", "ANATOMY", 89, 125], ["kidney", "ANATOMY", 143, 149], ["tubulitis", "ANATOMY", 157, 166], ["interstitial", "ANATOMY", 171, 183], ["testis", "ANATOMY", 218, 224], ["necrotic", "ANATOMY", 226, 234], ["seminiferous tubules", "ANATOMY", 251, 271], ["lymphocytic", "ANATOMY", 284, 295], ["tubules", "ANATOMY", 333, 340], ["interstitium", "ANATOMY", 349, 361], ["interstitial inflammation", "DISEASE", 171, 196], ["necrotic", "DISEASE", 226, 234], ["hemorrhagic", "DISEASE", 239, 250], ["brain", "ORGAN", 57, 62], ["cortical parenchymal", "MULTI-TISSUE_STRUCTURE", 64, 84], ["perivascular lymphocytic infiltrates", "TISSUE", 89, 125], ["kidney", "ORGAN", 143, 149], ["testis", "ORGAN", 218, 224], ["seminiferous tubules", "TISSUE", 251, 271], ["tubules", "TISSUE", 333, 340], ["interstitium", "TISSUE", 349, 361], ["The most prominent inflammatory changes", "PROBLEM", 0, 39], ["cortical parenchymal and perivascular lymphocytic infiltrates", "PROBLEM", 64, 125], ["kidney (acute tubulitis", "PROBLEM", 143, 166], ["interstitial inflammation", "PROBLEM", 171, 196], ["testis (necrotic and hemorrhagic seminiferous tubules", "PROBLEM", 218, 271], ["marked lymphocytic infiltration", "PROBLEM", 277, 308], ["most", "OBSERVATION_MODIFIER", 4, 8], ["prominent", "OBSERVATION_MODIFIER", 9, 18], ["inflammatory", "OBSERVATION", 19, 31], ["brain", "ANATOMY", 57, 62], ["cortical", "ANATOMY_MODIFIER", 64, 72], ["parenchymal", "ANATOMY_MODIFIER", 73, 84], ["perivascular", "ANATOMY_MODIFIER", 89, 101], ["lymphocytic infiltrates", "OBSERVATION", 102, 125], ["kidney", "ANATOMY", 143, 149], ["acute", "OBSERVATION_MODIFIER", 151, 156], ["tubulitis", "OBSERVATION", 157, 166], ["interstitial", "ANATOMY_MODIFIER", 171, 183], ["inflammation", "OBSERVATION", 184, 196], ["testis", "ANATOMY", 218, 224], ["necrotic", "OBSERVATION_MODIFIER", 226, 234], ["hemorrhagic", "OBSERVATION_MODIFIER", 239, 250], ["seminiferous tubules", "OBSERVATION", 251, 271], ["marked", "OBSERVATION_MODIFIER", 277, 283], ["lymphocytic infiltration", "OBSERVATION", 284, 308], ["tubules", "ANATOMY_MODIFIER", 333, 340], ["interstitium", "ANATOMY_MODIFIER", 349, 361]]], ["ZIKV-NS1 protein expression was still visible, but to a lesser degree, in the immunohistochemical staining of the testis/epididymis, ovary/uterus, kidney, spleen, small intestine, pancreas, and salivary gland of the dexamethasone-immunosuppressed mice with ZIKV inoculation at 12\u201314 dpi compared with 5 dpi.", [["testis", "ANATOMY", 114, 120], ["epididymis", "ANATOMY", 121, 131], ["ovary", "ANATOMY", 133, 138], ["uterus", "ANATOMY", 139, 145], ["kidney", "ANATOMY", 147, 153], ["spleen", "ANATOMY", 155, 161], ["small intestine", "ANATOMY", 163, 178], ["pancreas", "ANATOMY", 180, 188], ["salivary gland", "ANATOMY", 194, 208], ["dexamethasone", "CHEMICAL", 216, 229], ["ZIKV", "CHEMICAL", 257, 261], ["dexamethasone", "CHEMICAL", 216, 229], ["ZIKV", "GENE_OR_GENE_PRODUCT", 0, 4], ["NS1", "GENE_OR_GENE_PRODUCT", 5, 8], ["testis", "ORGAN", 114, 120], ["epididymis", "ORGAN", 121, 131], ["ovary", "ORGAN", 133, 138], ["uterus", "ORGAN", 139, 145], ["kidney", "ORGAN", 147, 153], ["spleen", "ORGAN", 155, 161], ["small intestine", "ORGAN", 163, 178], ["pancreas", "ORGAN", 180, 188], ["salivary gland", "ORGAN", 194, 208], ["dexamethasone", "SIMPLE_CHEMICAL", 216, 229], ["mice", "ORGANISM", 247, 251], ["ZIKV", "PROTEIN", 0, 4], ["NS1", "PROTEIN", 5, 8], ["mice", "SPECIES", 247, 251], ["ZIKV", "SPECIES", 0, 4], ["mice", "SPECIES", 247, 251], ["ZIKV", "SPECIES", 257, 261], ["ZIKV", "TEST", 0, 4], ["NS1 protein expression", "TEST", 5, 27], ["the immunohistochemical staining", "TEST", 74, 106], ["ovary/uterus, kidney, spleen, small intestine, pancreas", "PROBLEM", 133, 188], ["the dexamethasone", "TREATMENT", 212, 229], ["immunosuppressed mice", "TREATMENT", 230, 251], ["ZIKV inoculation", "TREATMENT", 257, 273], ["lesser degree", "OBSERVATION_MODIFIER", 56, 69], ["immunohistochemical staining", "OBSERVATION", 78, 106], ["testis", "ANATOMY", 114, 120], ["epididymis", "ANATOMY", 121, 131], ["ovary", "ANATOMY", 133, 138], ["uterus", "ANATOMY", 139, 145], ["kidney", "ANATOMY", 147, 153], ["spleen", "ANATOMY", 155, 161], ["small intestine", "ANATOMY", 163, 178], ["pancreas", "ANATOMY", 180, 188], ["salivary gland", "ANATOMY", 194, 208]]], ["In contrast, no inflammatory reaction and viral protein expression were seen in any organ of the control mice with ZIKV inoculation alone (groups 3 and 4) or dexamethasone immunosuppression alone (groups 5 and 6) (Fig. 5C and D).", [["organ", "ANATOMY", 84, 89], ["ZIKV", "CHEMICAL", 115, 119], ["dexamethasone", "CHEMICAL", 158, 171], ["dexamethasone", "CHEMICAL", 158, 171], ["organ", "ORGAN", 84, 89], ["mice", "ORGANISM", 105, 109], ["dexamethasone", "SIMPLE_CHEMICAL", 158, 171], ["viral protein", "PROTEIN", 42, 55], ["mice", "SPECIES", 105, 109], ["mice", "SPECIES", 105, 109], ["ZIKV", "SPECIES", 115, 119], ["inflammatory reaction", "PROBLEM", 16, 37], ["viral protein expression", "PROBLEM", 42, 66], ["ZIKV inoculation", "TREATMENT", 115, 131], ["dexamethasone immunosuppression", "TREATMENT", 158, 189], ["no", "UNCERTAINTY", 13, 15], ["inflammatory", "OBSERVATION_MODIFIER", 16, 28], ["reaction", "OBSERVATION", 29, 37], ["viral protein expression", "OBSERVATION", 42, 66]]], ["These findings confirmed that mice with ZIKV inoculation but no dexamethasone immunosuppression were not susceptible to infection as previously reported, and that the histological changes in the model mice (groups 1 and 2) were unrelated to dexamethasone-induced effects such as drug-induced testicular toxicity (Lazear et al., 2016, Dowall et al., 2016, Aliota et al., 2016, Rossi et al., 2016, Khorsandi et al., 2013).", [["testicular", "ANATOMY", 292, 302], ["ZIKV", "CHEMICAL", 40, 44], ["dexamethasone", "CHEMICAL", 64, 77], ["infection", "DISEASE", 120, 129], ["dexamethasone", "CHEMICAL", 241, 254], ["testicular toxicity", "DISEASE", 292, 311], ["dexamethasone", "CHEMICAL", 64, 77], ["dexamethasone", "CHEMICAL", 241, 254], ["mice", "ORGANISM", 30, 34], ["dexamethasone", "SIMPLE_CHEMICAL", 64, 77], ["mice", "ORGANISM", 201, 205], ["dexamethasone", "SIMPLE_CHEMICAL", 241, 254], ["testicular", "ORGAN", 292, 302], ["mice", "SPECIES", 30, 34], ["mice", "SPECIES", 201, 205], ["mice", "SPECIES", 30, 34], ["ZIKV", "SPECIES", 40, 44], ["mice", "SPECIES", 201, 205], ["ZIKV inoculation", "PROBLEM", 40, 56], ["dexamethasone immunosuppression", "TREATMENT", 64, 95], ["infection", "PROBLEM", 120, 129], ["the histological changes", "PROBLEM", 163, 187], ["dexamethasone", "TREATMENT", 241, 254], ["drug-induced testicular toxicity", "PROBLEM", 279, 311], ["infection", "OBSERVATION", 120, 129], ["testicular", "ANATOMY", 292, 302]]], ["The absence of inflammatory infiltrates in ZIKV-inoculated, dexamethasone-immunosuppressed mice without dexamethasone withdrawal (group 9) supported the role of the host immune response in eliciting the clinical and histological changes in the ZIKV-inoculated mice with dexamethasone withdrawal (groups 1 and 2).Clinical Deterioration with Multi-organ Inflammatory Cell Infiltrates Occurred in the Mice after Dexamethasone Withdrawal ::: ResultsTo further confirm the presence of inflammatory infiltrates and characterize the cell types involved in the host immune response, we stained the necropsied testis of the dexamethasone-immunosuppressed mice with ZIKV inoculation and those of the dexamethasone-immunosuppressed mock-infected control mice with CD45 (pan-leukocyte) and CD8 (cytotoxic T lymphocyte) antibodies.", [["Cell", "ANATOMY", 365, 369], ["cell", "ANATOMY", 526, 530], ["testis", "ANATOMY", 601, 607], ["pan-leukocyte", "ANATOMY", 759, 772], ["CD8 (cytotoxic T lymphocyte", "ANATOMY", 778, 805], ["dexamethasone", "CHEMICAL", 60, 73], ["dexamethasone", "CHEMICAL", 104, 117], ["dexamethasone", "CHEMICAL", 270, 283], ["dexamethasone", "CHEMICAL", 615, 628], ["ZIKV", "CHEMICAL", 656, 660], ["dexamethasone", "CHEMICAL", 690, 703], ["dexamethasone", "CHEMICAL", 60, 73], ["dexamethasone", "CHEMICAL", 104, 117], ["dexamethasone", "CHEMICAL", 270, 283], ["Dexamethasone", "CHEMICAL", 409, 422], ["dexamethasone", "CHEMICAL", 615, 628], ["dexamethasone", "CHEMICAL", 690, 703], ["dexamethasone", "SIMPLE_CHEMICAL", 60, 73], ["mice", "ORGANISM", 91, 95], ["dexamethasone", "SIMPLE_CHEMICAL", 104, 117], ["ZIKV", "ORGANISM", 244, 248], ["mice", "ORGANISM", 260, 264], ["dexamethasone", "SIMPLE_CHEMICAL", 270, 283], ["Mice", "ORGANISM", 398, 402], ["Dexamethasone", "SIMPLE_CHEMICAL", 409, 422], ["cell", "CELL", 526, 530], ["testis", "ORGAN", 601, 607], ["dexamethasone", "SIMPLE_CHEMICAL", 615, 628], ["mice", "ORGANISM", 646, 650], ["ZIKV", "ORGANISM", 656, 660], ["dexamethasone", "SIMPLE_CHEMICAL", 690, 703], ["mice", "ORGANISM", 743, 747], ["CD45", "GENE_OR_GENE_PRODUCT", 753, 757], ["pan-leukocyte", "CELL", 759, 772], ["CD8", "GENE_OR_GENE_PRODUCT", 778, 781], ["cytotoxic T lymphocyte) antibodies", "GENE_OR_GENE_PRODUCT", 783, 817], ["CD45", "PROTEIN", 753, 757], ["pan-leukocyte) and CD8 (cytotoxic T lymphocyte) antibodies", "PROTEIN", 759, 817], ["mice", "SPECIES", 91, 95], ["mice", "SPECIES", 260, 264], ["Mice", "SPECIES", 398, 402], ["mice", "SPECIES", 646, 650], ["mice", "SPECIES", 743, 747], ["ZIKV", "SPECIES", 43, 47], ["mice", "SPECIES", 91, 95], ["mice", "SPECIES", 260, 264], ["mice", "SPECIES", 646, 650], ["ZIKV", "SPECIES", 656, 660], ["mice", "SPECIES", 743, 747], ["inflammatory infiltrates", "PROBLEM", 15, 39], ["ZIKV", "PROBLEM", 43, 47], ["dexamethasone", "TREATMENT", 60, 73], ["dexamethasone withdrawal", "PROBLEM", 104, 128], ["dexamethasone withdrawal", "TREATMENT", 270, 294], ["Clinical Deterioration", "PROBLEM", 312, 334], ["Multi-organ Inflammatory Cell Infiltrates", "PROBLEM", 340, 381], ["inflammatory infiltrates", "PROBLEM", 480, 504], ["the dexamethasone", "TREATMENT", 611, 628], ["immunosuppressed mice", "TREATMENT", 629, 650], ["ZIKV inoculation", "TREATMENT", 656, 672], ["the dexamethasone", "TREATMENT", 686, 703], ["immunosuppressed mock", "TREATMENT", 704, 725], ["CD45 (pan-leukocyte", "TEST", 753, 772], ["CD8", "TEST", 778, 781], ["cytotoxic T lymphocyte) antibodies", "PROBLEM", 783, 817], ["absence of", "UNCERTAINTY", 4, 14], ["inflammatory", "OBSERVATION_MODIFIER", 15, 27], ["infiltrates", "OBSERVATION", 28, 39], ["Multi-organ", "ANATOMY", 340, 351], ["Inflammatory Cell Infiltrates", "OBSERVATION", 352, 381], ["inflammatory", "OBSERVATION_MODIFIER", 480, 492], ["infiltrates", "OBSERVATION", 493, 504], ["cell types", "OBSERVATION", 526, 536]]], ["Corroborative to the histological findings, only the testis of the dexamethasone-immunosuppressed mice with ZIKV inoculation, but not those of the control mice, stained positive for CD45 (Fig. 5E and F) and CD8 antibodies (Fig. 5G and H).", [["testis", "ANATOMY", 53, 59], ["dexamethasone", "CHEMICAL", 67, 80], ["dexamethasone", "CHEMICAL", 67, 80], ["testis", "ORGAN", 53, 59], ["dexamethasone", "SIMPLE_CHEMICAL", 67, 80], ["mice", "ORGANISM", 98, 102], ["mice", "ORGANISM", 155, 159], ["CD45", "GENE_OR_GENE_PRODUCT", 182, 186], ["Fig. 5E", "GENE_OR_GENE_PRODUCT", 188, 195], ["F", "GENE_OR_GENE_PRODUCT", 200, 201], ["CD8 antibodies", "GENE_OR_GENE_PRODUCT", 207, 221], ["CD45", "PROTEIN", 182, 186], ["Fig. 5E and F", "PROTEIN", 188, 201], ["CD8 antibodies", "PROTEIN", 207, 221], ["Fig. 5G and H", "PROTEIN", 223, 236], ["mice", "SPECIES", 98, 102], ["mice", "SPECIES", 155, 159], ["mice", "SPECIES", 98, 102], ["ZIKV", "SPECIES", 108, 112], ["mice", "SPECIES", 155, 159], ["the histological findings", "TEST", 17, 42], ["the dexamethasone", "TREATMENT", 63, 80], ["ZIKV inoculation", "PROBLEM", 108, 124], ["CD45", "TEST", 182, 186], ["CD8 antibodies", "TEST", 207, 221]]], ["These findings confirmed the presence of inflammatory infiltrates and especially CD8 + T lymphocytes in the testis of the ZIKV-infected mice.Clinical Deterioration with Multi-organ Inflammatory Cell Infiltrates Occurred in the Mice after Dexamethasone Withdrawal ::: ResultsThe dexamethasone-immunosuppressed mice with ZIKV inoculation (groups 1 and 2) also had significantly lower mean viral loads in blood and most tissues at euthanasia at 12\u201314 dpi as compared with those collected at 5 dpi (\u2193 1\u20134 log10copies/106 \u03b2-actin at 12\u201314 dpi) (Figs.", [["CD8 + T lymphocytes", "ANATOMY", 81, 100], ["testis", "ANATOMY", 108, 114], ["Cell", "ANATOMY", 194, 198], ["blood", "ANATOMY", 402, 407], ["tissues", "ANATOMY", 417, 424], ["dexamethasone", "CHEMICAL", 278, 291], ["ZIKV", "CHEMICAL", 319, 323], ["Dexamethasone", "CHEMICAL", 238, 251], ["dexamethasone", "CHEMICAL", 278, 291], ["CD8", "GENE_OR_GENE_PRODUCT", 81, 84], ["testis", "ORGAN", 108, 114], ["ZIKV", "GENE_OR_GENE_PRODUCT", 122, 126], ["mice", "ORGANISM", 136, 140], ["Mice", "ORGANISM", 227, 231], ["Dexamethasone", "SIMPLE_CHEMICAL", 238, 251], ["dexamethasone", "SIMPLE_CHEMICAL", 278, 291], ["mice", "ORGANISM", 309, 313], ["blood", "ORGANISM_SUBSTANCE", 402, 407], ["tissues", "TISSUE", 417, 424], ["\u03b2-actin", "GENE_OR_GENE_PRODUCT", 517, 524], ["CD8 + T lymphocytes", "CELL_TYPE", 81, 100], ["actin", "PROTEIN", 519, 524], ["mice", "SPECIES", 136, 140], ["Mice", "SPECIES", 227, 231], ["mice", "SPECIES", 309, 313], ["ZIKV", "SPECIES", 122, 126], ["mice", "SPECIES", 136, 140], ["mice", "SPECIES", 309, 313], ["ZIKV", "SPECIES", 319, 323], ["inflammatory infiltrates", "PROBLEM", 41, 65], ["T lymphocytes", "PROBLEM", 87, 100], ["Clinical Deterioration", "PROBLEM", 141, 163], ["Multi-organ Inflammatory Cell Infiltrates", "PROBLEM", 169, 210], ["The dexamethasone", "TREATMENT", 274, 291], ["ZIKV inoculation (groups", "TREATMENT", 319, 343], ["significantly lower mean viral loads in blood and most tissues at euthanasia", "PROBLEM", 362, 438], ["inflammatory", "OBSERVATION_MODIFIER", 41, 53], ["infiltrates", "OBSERVATION", 54, 65], ["T lymphocytes", "OBSERVATION", 87, 100], ["testis", "ANATOMY", 108, 114], ["ZIKV", "OBSERVATION", 122, 126], ["infected mice", "OBSERVATION", 127, 140], ["Multi-organ", "ANATOMY", 169, 180], ["Inflammatory Cell Infiltrates", "OBSERVATION", 181, 210], ["viral loads", "OBSERVATION", 387, 398], ["blood", "ANATOMY", 402, 407], ["most tissues", "OBSERVATION_MODIFIER", 412, 424]]], ["3A and B and S1A and B).", [["B", "GENE_OR_GENE_PRODUCT", 7, 8], ["S1A", "GENE_OR_GENE_PRODUCT", 13, 16], ["B", "GENE_OR_GENE_PRODUCT", 21, 22], ["B", "PROTEIN", 7, 8], ["S1A", "PROTEIN", 13, 16], ["B", "PROTEIN", 21, 22]]], ["At euthanasia (12\u201314 dpi), viral RNA was still detectable in most tissues of the male mice (up to 3 log10copies/106 \u03b2-actin), but viremia was absent.", [["tissues", "ANATOMY", 66, 73], ["viremia", "DISEASE", 130, 137], ["tissues", "TISSUE", 66, 73], ["mice", "ORGANISM", 86, 90], ["\u03b2-actin", "GENE_OR_GENE_PRODUCT", 116, 123], ["viral RNA", "RNA", 27, 36], ["mice", "SPECIES", 86, 90], ["mice", "SPECIES", 86, 90], ["viral RNA", "TEST", 27, 36], ["viremia", "PROBLEM", 130, 137], ["viral RNA", "OBSERVATION", 27, 36], ["most tissues", "OBSERVATION_MODIFIER", 61, 73], ["viremia", "OBSERVATION", 130, 137]]], ["The control mice with ZIKV inoculation but no dexamethasone immunosuppression had undetectable viral RNA in blood and most tissues, which was consistent with previous reports (Lazear et al., 2016, Dowall et al., 2016, Aliota et al., 2016, Rossi et al., 2016).", [["blood", "ANATOMY", 108, 113], ["tissues", "ANATOMY", 123, 130], ["ZIKV", "CHEMICAL", 22, 26], ["dexamethasone", "CHEMICAL", 46, 59], ["dexamethasone", "CHEMICAL", 46, 59], ["mice", "ORGANISM", 12, 16], ["dexamethasone", "SIMPLE_CHEMICAL", 46, 59], ["blood", "ORGANISM_SUBSTANCE", 108, 113], ["tissues", "TISSUE", 123, 130], ["viral RNA", "RNA", 95, 104], ["mice", "SPECIES", 12, 16], ["mice", "SPECIES", 12, 16], ["ZIKV", "SPECIES", 22, 26], ["ZIKV inoculation", "TREATMENT", 22, 38], ["dexamethasone immunosuppression", "TREATMENT", 46, 77], ["undetectable viral RNA in blood and most tissues", "PROBLEM", 82, 130], ["no", "UNCERTAINTY", 43, 45], ["viral RNA", "OBSERVATION", 95, 104], ["most tissues", "ANATOMY", 118, 130], ["consistent with", "UNCERTAINTY", 142, 157]]], ["Overall, these findings were suggestive of multi-organ inflammation upon immune reconstitution with partial viral clearance in the mice after withdrawal of dexamethasone immunosuppression.Treatment with Recombinant Type I Interferons was Associated with Better Clinical Outcome in the Mice ::: ResultsWe next evaluated the effects of recombinant type I interferon treatment in our mouse model.", [["multi-organ", "ANATOMY", 43, 54], ["inflammation", "DISEASE", 55, 67], ["dexamethasone", "CHEMICAL", 156, 169], ["type I interferon", "CHEMICAL", 346, 363], ["dexamethasone", "CHEMICAL", 156, 169], ["mice", "ORGANISM", 131, 135], ["dexamethasone", "SIMPLE_CHEMICAL", 156, 169], ["Type I Interferons", "GENE_OR_GENE_PRODUCT", 215, 233], ["Mice", "ORGANISM", 285, 289], ["type I interferon", "GENE_OR_GENE_PRODUCT", 346, 363], ["mouse", "ORGANISM", 381, 386], ["Recombinant Type I Interferons", "PROTEIN", 203, 233], ["recombinant type I interferon", "PROTEIN", 334, 363], ["mice", "SPECIES", 131, 135], ["Mice", "SPECIES", 285, 289], ["mouse", "SPECIES", 381, 386], ["mice", "SPECIES", 131, 135], ["mouse", "SPECIES", 381, 386], ["multi-organ inflammation", "PROBLEM", 43, 67], ["immune reconstitution", "TREATMENT", 73, 94], ["dexamethasone immunosuppression", "TREATMENT", 156, 187], ["Recombinant Type I Interferons", "TREATMENT", 203, 233], ["recombinant type I interferon treatment", "TREATMENT", 334, 373], ["our mouse model", "TREATMENT", 377, 392], ["suggestive of", "UNCERTAINTY", 29, 42], ["multi-organ", "ANATOMY", 43, 54], ["inflammation", "OBSERVATION", 55, 67], ["immune reconstitution", "OBSERVATION", 73, 94], ["partial", "OBSERVATION_MODIFIER", 100, 107], ["viral clearance", "OBSERVATION", 108, 123]]], ["We used male mice as they had earlier onset of weight loss and clinical symptoms requiring necropsy at 12 dpi.", [["weight loss", "DISEASE", 47, 58], ["mice", "ORGANISM", 13, 17], ["mice", "SPECIES", 13, 17], ["mice", "SPECIES", 13, 17], ["weight loss", "PROBLEM", 47, 58], ["clinical symptoms", "PROBLEM", 63, 80], ["necropsy", "TREATMENT", 91, 99]]], ["The mice were treated with pegylated interferon-\u03b12b (PegIntron\u00ae, Merck & Co., Inc., Whitehouse Station, NJ, USA) 1920 IU/dose every 96 h subcutaneously at 1 dpi, 5 dpi, and 9 dpi (group 10) or interferon-\u03b21b (Betaferon\u00ae, Bayer Schering Pharma AG, Berlin, Germany) 160,000 IU/dose every 48 h intraperitoneally at 1 dpi, 3 dpi, 5 dpi, 7 dpi, and 9 dpi (group 11).", [["subcutaneously", "ANATOMY", 137, 151], ["pegylated interferon-\u03b12b", "CHEMICAL", 27, 51], ["interferon-\u03b21b", "CHEMICAL", 193, 207], ["mice", "ORGANISM", 4, 8], ["interferon-\u03b12b", "SIMPLE_CHEMICAL", 37, 51], ["PegIntron\u00ae", "SIMPLE_CHEMICAL", 53, 63], ["interferon-\u03b21b", "SIMPLE_CHEMICAL", 193, 207], ["Betaferon\u00ae", "SIMPLE_CHEMICAL", 209, 219], ["interferon", "PROTEIN", 193, 203], ["mice", "SPECIES", 4, 8], ["mice", "SPECIES", 4, 8], ["pegylated interferon", "TREATMENT", 27, 47], ["NJ, USA)", "TREATMENT", 104, 112], ["interferon", "TREATMENT", 193, 203], ["Betaferon\u00ae, Bayer Schering Pharma AG, Berlin, Germany)", "TREATMENT", 209, 263]]], ["As shown in Fig. 6A, the mice treated with pegylated interferon-\u03b12b (group 10) or interferon-\u03b21b (group 11) had < 10% weight loss with spontaneous recovery at 14 dpi.", [["pegylated interferon-\u03b12b", "CHEMICAL", 43, 67], ["interferon-\u03b21b", "CHEMICAL", 82, 96], ["weight loss", "DISEASE", 118, 129], ["6A", "GENE_OR_GENE_PRODUCT", 17, 19], ["mice", "ORGANISM", 25, 29], ["interferon-\u03b12b", "GENE_OR_GENE_PRODUCT", 53, 67], ["interferon-\u03b21b", "GENE_OR_GENE_PRODUCT", 82, 96], ["interferon", "PROTEIN", 82, 92], ["mice", "SPECIES", 25, 29], ["mice", "SPECIES", 25, 29], ["pegylated interferon", "TREATMENT", 43, 63], ["interferon", "TREATMENT", 82, 92], ["weight loss", "PROBLEM", 118, 129], ["Fig", "OBSERVATION", 12, 15]]], ["The weight loss of the untreated group became significantly more than those of the mice treated with either interferon-\u03b12 or interferon-\u03b21b starting at 10 dpi (P < 0.05).", [["weight loss", "DISEASE", 4, 15], ["interferon-\u03b12", "CHEMICAL", 108, 121], ["interferon-\u03b21b", "CHEMICAL", 125, 139], ["mice", "ORGANISM", 83, 87], ["interferon-\u03b12", "GENE_OR_GENE_PRODUCT", 108, 121], ["interferon-\u03b21b", "GENE_OR_GENE_PRODUCT", 125, 139], ["interferon", "PROTEIN", 108, 118], ["interferon", "PROTEIN", 125, 135], ["mice", "SPECIES", 83, 87], ["mice", "SPECIES", 83, 87], ["The weight loss", "PROBLEM", 0, 15], ["interferon", "TREATMENT", 108, 118], ["interferon", "TREATMENT", 125, 135], ["weight", "OBSERVATION_MODIFIER", 4, 10], ["loss", "OBSERVATION_MODIFIER", 11, 15]]], ["All of these mice remained asymptomatic and survived through the study period (Fig. 6B and C).", [["mice", "ORGANISM", 13, 17], ["mice", "SPECIES", 13, 17], ["mice", "SPECIES", 13, 17], ["asymptomatic", "PROBLEM", 27, 39], ["the study", "TEST", 61, 70], ["asymptomatic", "OBSERVATION", 27, 39]]], ["None of their tissues showed prominent inflammatory reactions in H&E staining at 5 dpi or 14 dpi.", [["tissues", "ANATOMY", 14, 21], ["tissues", "TISSUE", 14, 21], ["prominent inflammatory reactions", "PROBLEM", 29, 61], ["H&E staining", "PROBLEM", 65, 77], ["prominent", "OBSERVATION_MODIFIER", 29, 38], ["inflammatory", "OBSERVATION_MODIFIER", 39, 51]]], ["ZIKV-NS1 protein expression was only rarely seen in the immunohistochemical staining of the testis/epididymis, kidney, spleen, small intestine, lung, and pancreas collected at 5 dpi, and testis, epididymis, kidney, and spleen at 14 dpi.", [["testis", "ANATOMY", 92, 98], ["epididymis", "ANATOMY", 99, 109], ["kidney", "ANATOMY", 111, 117], ["spleen", "ANATOMY", 119, 125], ["small intestine", "ANATOMY", 127, 142], ["lung", "ANATOMY", 144, 148], ["pancreas", "ANATOMY", 154, 162], ["testis", "ANATOMY", 187, 193], ["epididymis", "ANATOMY", 195, 205], ["kidney", "ANATOMY", 207, 213], ["spleen", "ANATOMY", 219, 225], ["ZIKV", "GENE_OR_GENE_PRODUCT", 0, 4], ["NS1", "GENE_OR_GENE_PRODUCT", 5, 8], ["testis", "ORGAN", 92, 98], ["epididymis", "ORGAN", 99, 109], ["kidney", "ORGAN", 111, 117], ["spleen", "ORGAN", 119, 125], ["small intestine", "ORGAN", 127, 142], ["lung", "ORGAN", 144, 148], ["pancreas", "ORGAN", 154, 162], ["testis", "ORGAN", 187, 193], ["epididymis", "ORGAN", 195, 205], ["kidney", "ORGAN", 207, 213], ["spleen", "ORGAN", 219, 225], ["ZIKV", "PROTEIN", 0, 4], ["NS1", "PROTEIN", 5, 8], ["ZIKV", "SPECIES", 0, 4], ["ZIKV", "TEST", 0, 4], ["NS1 protein expression", "TEST", 5, 27], ["the immunohistochemical staining", "TEST", 52, 84], ["immunohistochemical staining", "OBSERVATION", 56, 84], ["testis", "ANATOMY", 92, 98], ["epididymis", "ANATOMY", 99, 109], ["kidney", "ANATOMY", 111, 117], ["spleen", "ANATOMY", 119, 125], ["small intestine", "ANATOMY", 127, 142], ["lung", "ANATOMY", 144, 148], ["pancreas", "ANATOMY", 154, 162], ["testis", "ANATOMY", 187, 193], ["epididymis", "ANATOMY", 195, 205], ["kidney", "ANATOMY", 207, 213], ["spleen", "ANATOMY", 219, 225]]], ["They had reduced mean viral loads in blood and all the tissues (\u2193 2\u20134 log10copies/106 \u03b2-actin) as compared with those of the untreated mice at 5 dpi and 14 dpi (Fig. 7A and B).", [["blood", "ANATOMY", 37, 42], ["tissues", "ANATOMY", 55, 62], ["blood", "ORGANISM_SUBSTANCE", 37, 42], ["tissues", "TISSUE", 55, 62], ["\u03b2-actin", "GENE_OR_GENE_PRODUCT", 86, 93], ["mice", "ORGANISM", 135, 139], ["B", "GENE_OR_GENE_PRODUCT", 173, 174], ["actin", "PROTEIN", 88, 93], ["mice", "SPECIES", 135, 139], ["mice", "SPECIES", 135, 139], ["reduced mean viral loads in blood", "PROBLEM", 9, 42], ["viral loads", "OBSERVATION", 22, 33], ["tissues", "ANATOMY", 55, 62]]], ["The reductions were most significant in the tissues with high viral loads, such as the spleen, testis, pancreas, and prostate (P < 0.05).", [["tissues", "ANATOMY", 44, 51], ["spleen", "ANATOMY", 87, 93], ["testis", "ANATOMY", 95, 101], ["pancreas", "ANATOMY", 103, 111], ["prostate", "ANATOMY", 117, 125], ["tissues", "TISSUE", 44, 51], ["spleen", "ORGAN", 87, 93], ["testis", "ORGAN", 95, 101], ["pancreas", "ORGAN", 103, 111], ["prostate", "ORGAN", 117, 125], ["The reductions", "PROBLEM", 0, 14], ["high viral loads", "PROBLEM", 57, 73], ["reductions", "OBSERVATION_MODIFIER", 4, 14], ["most significant", "OBSERVATION_MODIFIER", 20, 36], ["tissues", "ANATOMY", 44, 51], ["high viral loads", "OBSERVATION", 57, 73], ["spleen", "ANATOMY", 87, 93], ["testis", "ANATOMY", 95, 101], ["pancreas", "ANATOMY", 103, 111], ["prostate", "ANATOMY", 117, 125]]], ["Overall, these findings suggested that early use of systemic recombinant type I interferons improved the clinical, histological, and virological parameters of mice with disseminated ZIKV infection.DiscussionThe full spectrum of clinical manifestations and complications of ZIKV infection remains incompletely understood as of today.", [["ZIKV infection", "DISEASE", 182, 196], ["infection", "DISEASE", 278, 287], ["type I interferons", "GENE_OR_GENE_PRODUCT", 73, 91], ["mice", "ORGANISM", 159, 163], ["ZIKV", "ORGANISM", 273, 277], ["systemic recombinant type I interferons", "PROTEIN", 52, 91], ["mice", "SPECIES", 159, 163], ["mice", "SPECIES", 159, 163], ["ZIKV", "SPECIES", 182, 186], ["ZIKV", "SPECIES", 273, 277], ["systemic recombinant type I interferons", "TREATMENT", 52, 91], ["disseminated ZIKV infection", "PROBLEM", 169, 196], ["clinical manifestations", "PROBLEM", 228, 251], ["ZIKV infection", "PROBLEM", 273, 287], ["disseminated", "OBSERVATION_MODIFIER", 169, 181], ["ZIKV infection", "OBSERVATION", 182, 196]]], ["The previous assumption that ZIKV infection is an entirely self-limiting disease without severe or long-lasting sequelae has been overturned by the increasing recognition of congenital malformations, neurological complications, immune-mediated thrombocytopenia, and even fatality in some immunosuppressed patients (Pan American Health Organization/World Health Oganization (PAHO/WHO), 2015; Sarmiento-Ospina et al., 2016, Arzuza-Ortega et al., 2016, Duijster et al., 2016).", [["neurological", "ANATOMY", 200, 212], ["ZIKV infection", "DISEASE", 29, 43], ["congenital malformations", "DISEASE", 174, 198], ["neurological complications", "DISEASE", 200, 226], ["thrombocytopenia", "DISEASE", 244, 260], ["patients", "ORGANISM", 305, 313], ["patients", "SPECIES", 305, 313], ["ZIKV", "SPECIES", 29, 33], ["ZIKV infection", "PROBLEM", 29, 43], ["self-limiting disease", "PROBLEM", 59, 80], ["congenital malformations", "PROBLEM", 174, 198], ["neurological complications", "PROBLEM", 200, 226], ["immune-mediated thrombocytopenia", "PROBLEM", 228, 260], ["ZIKV", "OBSERVATION_MODIFIER", 29, 33], ["infection", "OBSERVATION", 34, 43], ["self-limiting", "OBSERVATION_MODIFIER", 59, 72], ["disease", "OBSERVATION", 73, 80], ["without", "UNCERTAINTY", 81, 88], ["severe", "OBSERVATION_MODIFIER", 89, 95], ["congenital", "OBSERVATION_MODIFIER", 174, 184], ["malformations", "OBSERVATION", 185, 198], ["thrombocytopenia", "OBSERVATION", 244, 260]]], ["Notably, patients with severe non-pregnancy-related complications of ZIKV often deteriorated suddenly after an initially mild disease phase as the viral load began to decrease (Cao-Lormeau et al., 2016, Mecharles et al., 2016, Sarmiento-Ospina et al., 2016).", [["ZIKV", "DISEASE", 69, 73], ["patients", "ORGANISM", 9, 17], ["ZIKV", "ORGANISM", 69, 73], ["patients", "SPECIES", 9, 17], ["ZIKV", "SPECIES", 69, 73], ["severe non-pregnancy", "PROBLEM", 23, 43], ["ZIKV", "PROBLEM", 69, 73], ["an initially mild disease phase", "PROBLEM", 108, 139], ["the viral load", "TEST", 143, 157], ["severe", "OBSERVATION_MODIFIER", 23, 29], ["mild", "OBSERVATION_MODIFIER", 121, 125], ["disease", "OBSERVATION", 126, 133], ["viral load", "OBSERVATION", 147, 157]]], ["This has led us to hypothesize that, like many other flavivirus infections, including yellow fever, dengue, and West Nile virus infection, the host immune response may also play a role in these ZIKV-associated complications, especially during the viral clearance phase by the host immune system (Quaresma et al., 2013, Screaton et al., 2015, Wang et al., 2003).", [["flavivirus infections", "DISEASE", 53, 74], ["yellow fever", "DISEASE", 86, 98], ["dengue", "DISEASE", 100, 106], ["West Nile virus infection", "DISEASE", 112, 137], ["yellow fever", "ORGANISM", 86, 98], ["West Nile virus", "ORGANISM", 112, 127], ["yellow fever", "SPECIES", 86, 98], ["West Nile virus", "SPECIES", 112, 127], ["yellow fever, dengue", "SPECIES", 86, 106], ["West Nile virus", "SPECIES", 112, 127], ["ZIKV", "SPECIES", 194, 198], ["many other flavivirus infections", "PROBLEM", 42, 74], ["yellow fever", "PROBLEM", 86, 98], ["dengue", "PROBLEM", 100, 106], ["West Nile virus infection", "PROBLEM", 112, 137], ["associated complications", "PROBLEM", 199, 223], ["the viral clearance phase", "TEST", 243, 268], ["flavivirus", "OBSERVATION", 53, 63], ["complications", "OBSERVATION", 210, 223]]], ["In this study, we characterized a novel and readily available mouse model for severe ZIKV infection which attempts to provide an alternative venue for studying the host immune response of and evaluating countermeasures for ZIKV infection.", [["ZIKV infection", "DISEASE", 85, 99], ["infection", "DISEASE", 228, 237], ["mouse", "ORGANISM", 62, 67], ["ZIKV", "ORGANISM", 223, 227], ["mouse", "SPECIES", 62, 67], ["mouse", "SPECIES", 62, 67], ["ZIKV", "SPECIES", 85, 89], ["ZIKV", "SPECIES", 223, 227], ["this study", "TEST", 3, 13], ["severe ZIKV infection", "PROBLEM", 78, 99], ["countermeasures", "TREATMENT", 203, 218], ["ZIKV infection", "PROBLEM", 223, 237], ["severe", "OBSERVATION_MODIFIER", 78, 84], ["ZIKV", "OBSERVATION", 85, 89]]], ["The findings in our study have important implications on the pathogenesis, potential complications, and treatment of ZIKV infection.DiscussionThe dexamethasone-immunosuppressed mice with ZIKV inoculation in our study developed disseminated infection with viremia and multi-organ involvement, including the brain, urogenital tract, intestine, liver, spleen, pancreas, heart, lung, and salivary gland as evident by ZIKV-NS1 protein expression on immunohistochemical staining and/or detectable viral load in these tissues.", [["multi-organ", "ANATOMY", 267, 278], ["brain", "ANATOMY", 306, 311], ["urogenital tract", "ANATOMY", 313, 329], ["intestine", "ANATOMY", 331, 340], ["liver", "ANATOMY", 342, 347], ["spleen", "ANATOMY", 349, 355], ["pancreas", "ANATOMY", 357, 365], ["heart", "ANATOMY", 367, 372], ["lung", "ANATOMY", 374, 378], ["salivary gland", "ANATOMY", 384, 398], ["tissues", "ANATOMY", 511, 518], ["infection", "DISEASE", 122, 131], ["dexamethasone", "CHEMICAL", 146, 159], ["ZIKV", "CHEMICAL", 187, 191], ["infection", "DISEASE", 240, 249], ["viremia", "DISEASE", 255, 262], ["dexamethasone", "CHEMICAL", 146, 159], ["ZIKV", "ORGANISM", 117, 121], ["dexamethasone", "SIMPLE_CHEMICAL", 146, 159], ["mice", "ORGANISM", 177, 181], ["brain", "ORGAN", 306, 311], ["urogenital tract", "MULTI-TISSUE_STRUCTURE", 313, 329], ["intestine", "ORGAN", 331, 340], ["liver", "ORGAN", 342, 347], ["spleen", "ORGAN", 349, 355], ["pancreas", "ORGAN", 357, 365], ["heart", "ORGAN", 367, 372], ["lung", "ORGAN", 374, 378], ["salivary gland", "ORGAN", 384, 398], ["ZIKV", "GENE_OR_GENE_PRODUCT", 413, 417], ["NS1", "GENE_OR_GENE_PRODUCT", 418, 421], ["tissues", "TISSUE", 511, 518], ["ZIKV", "PROTEIN", 413, 417], ["NS1", "PROTEIN", 418, 421], ["mice", "SPECIES", 177, 181], ["ZIKV", "SPECIES", 117, 121], ["mice", "SPECIES", 177, 181], ["ZIKV", "SPECIES", 187, 191], ["our study", "TEST", 16, 25], ["potential complications", "PROBLEM", 75, 98], ["ZIKV infection", "PROBLEM", 117, 131], ["The dexamethasone", "TREATMENT", 142, 159], ["ZIKV inoculation", "PROBLEM", 187, 203], ["our study", "TEST", 207, 216], ["disseminated infection", "PROBLEM", 227, 249], ["viremia", "PROBLEM", 255, 262], ["multi-organ involvement", "PROBLEM", 267, 290], ["the brain, urogenital tract, intestine, liver, spleen, pancreas, heart, lung, and salivary gland", "PROBLEM", 302, 398], ["ZIKV", "TEST", 413, 417], ["immunohistochemical staining", "TEST", 444, 472], ["detectable viral load in these tissues", "PROBLEM", 480, 518], ["ZIKV infection", "OBSERVATION", 117, 131], ["disseminated", "OBSERVATION_MODIFIER", 227, 239], ["infection", "OBSERVATION", 240, 249], ["viremia", "OBSERVATION", 255, 262], ["brain", "ANATOMY", 306, 311], ["urogenital tract", "ANATOMY", 313, 329], ["intestine", "ANATOMY", 331, 340], ["liver", "ANATOMY", 342, 347], ["spleen", "ANATOMY", 349, 355], ["pancreas", "ANATOMY", 357, 365], ["heart", "ANATOMY", 367, 372], ["lung", "ANATOMY", 374, 378], ["salivary gland", "ANATOMY", 384, 398], ["viral load", "OBSERVATION", 491, 501], ["tissues", "ANATOMY", 511, 518]]], ["Immunohistochemistry staining of the testis confirmed the presence of inflammatory cell infiltrate (pan-leukocyte marker CD45 +) with predominantly CD8 + T lymphocytes.", [["testis", "ANATOMY", 37, 43], ["inflammatory cell", "ANATOMY", 70, 87], ["leukocyte", "ANATOMY", 104, 113], ["CD8 + T lymphocytes", "ANATOMY", 148, 167], ["testis", "ORGAN", 37, 43], ["inflammatory cell", "CELL", 70, 87], ["leukocyte", "CELL", 104, 113], ["CD45", "GENE_OR_GENE_PRODUCT", 121, 125], ["CD8", "GENE_OR_GENE_PRODUCT", 148, 151], ["CD45", "PROTEIN", 121, 125], ["CD8", "PROTEIN", 148, 151], ["T lymphocytes", "CELL_TYPE", 154, 167], ["Immunohistochemistry staining", "TEST", 0, 29], ["the testis", "TEST", 33, 43], ["inflammatory cell infiltrate", "PROBLEM", 70, 98], ["pan-leukocyte marker CD45", "TEST", 100, 125], ["testis", "ANATOMY", 37, 43], ["inflammatory", "OBSERVATION_MODIFIER", 70, 82], ["cell", "OBSERVATION", 83, 87], ["infiltrate", "OBSERVATION", 88, 98], ["predominantly", "OBSERVATION_MODIFIER", 134, 147], ["CD8 + T lymphocytes", "OBSERVATION", 148, 167]]], ["Clinically, the male mice developed earlier onset of disease than the female mice, with \u2265 10% weight loss and \u2265 1 clinical sign, which warranted euthanasia at 12 dpi.", [["weight loss", "DISEASE", 94, 105], ["mice", "ORGANISM", 21, 25], ["mice", "ORGANISM", 77, 81], ["mice", "SPECIES", 21, 25], ["mice", "SPECIES", 77, 81], ["mice", "SPECIES", 21, 25], ["mice", "SPECIES", 77, 81], ["disease", "PROBLEM", 53, 60], ["\u2265 10% weight loss", "PROBLEM", 88, 105], ["1 clinical sign", "PROBLEM", 112, 127], ["disease", "OBSERVATION", 53, 60]]], ["Their weight loss, clinical scores, and histological evidence of inflammatory reactions were most severe soon after dexamethasone withdrawal, when viral loads had already decreased by about 2\u20135 log10copies/106 \u03b2-actin.", [["weight loss", "DISEASE", 6, 17], ["dexamethasone", "CHEMICAL", 116, 129], ["dexamethasone", "CHEMICAL", 116, 129], ["dexamethasone", "SIMPLE_CHEMICAL", 116, 129], ["\u03b2-actin", "GENE_OR_GENE_PRODUCT", 210, 217], ["actin", "PROTEIN", 212, 217], ["Their weight loss", "PROBLEM", 0, 17], ["clinical scores", "PROBLEM", 19, 34], ["inflammatory reactions", "PROBLEM", 65, 87], ["dexamethasone withdrawal", "PROBLEM", 116, 140], ["viral loads", "PROBLEM", 147, 158], ["evidence of", "UNCERTAINTY", 53, 64], ["inflammatory", "OBSERVATION", 65, 77]]], ["Overall, these findings suggested that, like the other related flaviviruses, the host immune response might have led to marked clinical deterioration in the face of disseminated ZIKV infection at the time when immune-mediated clearance of the virus began.", [["infection", "DISEASE", 183, 192], ["ZIKV", "CANCER", 178, 182], ["ZIKV", "SPECIES", 178, 182], ["the other related flaviviruses", "PROBLEM", 45, 75], ["marked clinical deterioration", "PROBLEM", 120, 149], ["disseminated ZIKV infection", "PROBLEM", 165, 192], ["the virus", "PROBLEM", 239, 248], ["flaviviruses", "OBSERVATION", 63, 75], ["marked", "OBSERVATION_MODIFIER", 120, 126], ["disseminated", "OBSERVATION_MODIFIER", 165, 177], ["ZIKV", "OBSERVATION", 178, 182]]], ["Our findings provided an additional explanation for the pathogenesis of fatal ZIKV infection, which has been proposed to be related to uncontrolled virus dissemination in previously described mouse models utilizing types I/II interferon-signaling-/receptor-deficient mice that were unable to mount a robust host innate immune response.DiscussionOur mouse model is also useful for studying ZIKV's tissue tropism and potential complications of severe ZIKV infection.", [["tissue", "ANATOMY", 396, 402], ["ZIKV infection", "DISEASE", 78, 92], ["ZIKV infection", "DISEASE", 449, 463], ["ZIKV", "ORGANISM", 78, 82], ["mouse", "ORGANISM", 192, 197], ["types I/II interferon-signaling-/receptor", "GENE_OR_GENE_PRODUCT", 215, 256], ["mice", "ORGANISM", 267, 271], ["mouse", "ORGANISM", 349, 354], ["ZIKV", "ORGANISM", 389, 393], ["tissue", "TISSUE", 396, 402], ["ZIKV", "ORGANISM", 449, 453], ["interferon", "PROTEIN", 226, 236], ["mouse", "SPECIES", 192, 197], ["mice", "SPECIES", 267, 271], ["mouse", "SPECIES", 349, 354], ["ZIKV", "SPECIES", 78, 82], ["mouse", "SPECIES", 192, 197], ["mice", "SPECIES", 267, 271], ["mouse", "SPECIES", 349, 354], ["ZIKV", "SPECIES", 389, 393], ["ZIKV", "SPECIES", 449, 453], ["fatal ZIKV infection", "PROBLEM", 72, 92], ["uncontrolled virus dissemination", "PROBLEM", 135, 167], ["types I/II interferon", "TREATMENT", 215, 236], ["deficient mice", "PROBLEM", 257, 271], ["ZIKV's tissue tropism", "PROBLEM", 389, 410], ["severe ZIKV infection", "PROBLEM", 442, 463], ["fatal", "OBSERVATION_MODIFIER", 72, 77], ["ZIKV", "OBSERVATION", 78, 82], ["uncontrolled", "OBSERVATION_MODIFIER", 135, 147], ["virus", "OBSERVATION", 148, 153], ["severe", "OBSERVATION_MODIFIER", 442, 448], ["ZIKV", "OBSERVATION_MODIFIER", 449, 453], ["infection", "OBSERVATION", 454, 463]]], ["In addition to the reported findings of detectable virus particles and/or RNA in the brain, spinal cord, kidney, spleen, liver, testis, ovary, heart, lung, muscle, and blood of types I/II interferon-signaling-/receptor-deficient mice with ZIKV infection, our study identified intestine, pancreas, and salivary gland as other possible tissues and anatomical sites for virus infection (Dick, 1952, Lazear et al., 2016, Dowall et al., 2016, Aliota et al., 2016, Rossi et al., 2016).", [["brain", "ANATOMY", 85, 90], ["spinal cord", "ANATOMY", 92, 103], ["kidney", "ANATOMY", 105, 111], ["spleen", "ANATOMY", 113, 119], ["liver", "ANATOMY", 121, 126], ["testis", "ANATOMY", 128, 134], ["ovary", "ANATOMY", 136, 141], ["heart", "ANATOMY", 143, 148], ["lung", "ANATOMY", 150, 154], ["muscle", "ANATOMY", 156, 162], ["blood", "ANATOMY", 168, 173], ["intestine", "ANATOMY", 276, 285], ["pancreas", "ANATOMY", 287, 295], ["salivary gland", "ANATOMY", 301, 315], ["tissues", "ANATOMY", 334, 341], ["ZIKV infection", "DISEASE", 239, 253], ["infection", "DISEASE", 373, 382], ["brain", "ORGAN", 85, 90], ["spinal cord", "ORGAN", 92, 103], ["kidney", "ORGAN", 105, 111], ["spleen", "ORGAN", 113, 119], ["liver", "ORGAN", 121, 126], ["testis", "ORGAN", 128, 134], ["ovary", "ORGAN", 136, 141], ["heart", "ORGAN", 143, 148], ["lung", "ORGAN", 150, 154], ["muscle", "ORGAN", 156, 162], ["blood", "ORGANISM_SUBSTANCE", 168, 173], ["types I/II interferon-signaling-/receptor", "GENE_OR_GENE_PRODUCT", 177, 218], ["mice", "ORGANISM", 229, 233], ["ZIKV", "ORGANISM", 239, 243], ["intestine", "ORGAN", 276, 285], ["pancreas", "ORGAN", 287, 295], ["salivary gland", "ORGAN", 301, 315], ["tissues", "TISSUE", 334, 341], ["anatomical sites", "MULTI-TISSUE_STRUCTURE", 346, 362], ["interferon", "PROTEIN", 188, 198], ["mice", "SPECIES", 229, 233], ["mice", "SPECIES", 229, 233], ["ZIKV", "SPECIES", 239, 243], ["detectable virus particles", "PROBLEM", 40, 66], ["RNA in the brain, spinal cord, kidney, spleen, liver, testis, ovary, heart, lung, muscle", "PROBLEM", 74, 162], ["II interferon", "TREATMENT", 185, 198], ["ZIKV infection", "PROBLEM", 239, 253], ["our study", "TEST", 255, 264], ["intestine, pancreas, and salivary gland", "PROBLEM", 276, 315], ["virus infection", "PROBLEM", 367, 382], ["virus particles", "OBSERVATION", 51, 66], ["brain", "ANATOMY", 85, 90], ["spinal cord", "ANATOMY", 92, 103], ["kidney", "ANATOMY", 105, 111], ["spleen", "ANATOMY", 113, 119], ["liver", "ANATOMY", 121, 126], ["testis", "ANATOMY", 128, 134], ["ovary", "ANATOMY", 136, 141], ["heart", "ANATOMY", 143, 148], ["lung", "ANATOMY", 150, 154], ["muscle", "ANATOMY", 156, 162], ["ZIKV infection", "OBSERVATION", 239, 253], ["intestine", "ANATOMY", 276, 285], ["pancreas", "ANATOMY", 287, 295], ["salivary gland", "ANATOMY", 301, 315]]], ["This tissue tropism of ZIKV in our mouse model concurs with the in-vitro observation that ZIKV efficiently replicates in diverse cell types of neuronal, testicular, prostatic, renal, intestinal, hepatic, and placental origin (Chan et al., 2016b, Brault et al., 2016, Hughes et al., 2016).", [["tissue", "ANATOMY", 5, 11], ["cell", "ANATOMY", 129, 133], ["neuronal", "ANATOMY", 143, 151], ["testicular", "ANATOMY", 153, 163], ["prostatic", "ANATOMY", 165, 174], ["renal", "ANATOMY", 176, 181], ["intestinal", "ANATOMY", 183, 193], ["hepatic", "ANATOMY", 195, 202], ["placental", "ANATOMY", 208, 217], ["tissue", "TISSUE", 5, 11], ["ZIKV", "GENE_OR_GENE_PRODUCT", 23, 27], ["mouse", "ORGANISM", 35, 40], ["ZIKV", "GENE_OR_GENE_PRODUCT", 90, 94], ["cell", "CELL", 129, 133], ["neuronal", "CELL", 143, 151], ["testicular", "MULTI-TISSUE_STRUCTURE", 153, 163], ["prostatic", "MULTI-TISSUE_STRUCTURE", 165, 174], ["renal", "ORGAN", 176, 181], ["intestinal", "ORGAN", 183, 193], ["hepatic", "MULTI-TISSUE_STRUCTURE", 195, 202], ["placental", "ORGAN", 208, 217], ["mouse", "SPECIES", 35, 40], ["ZIKV", "SPECIES", 23, 27], ["mouse", "SPECIES", 35, 40], ["ZIKV", "SPECIES", 90, 94], ["ZIKV", "PROBLEM", 23, 27], ["ZIKV", "PROBLEM", 90, 94], ["neuronal, testicular, prostatic, renal, intestinal, hepatic, and placental origin", "PROBLEM", 143, 224], ["tropism", "OBSERVATION_MODIFIER", 12, 19], ["ZIKV", "OBSERVATION", 23, 27], ["diverse cell types", "OBSERVATION", 121, 139], ["testicular", "ANATOMY", 153, 163], ["prostatic", "ANATOMY", 165, 174], ["renal", "ANATOMY", 176, 181], ["intestinal", "ANATOMY", 183, 193], ["hepatic", "ANATOMY", 195, 202], ["placental", "ANATOMY", 208, 217], ["origin", "ANATOMY_MODIFIER", 218, 224]]], ["Such degree of virus dissemination and multi-organ involvement is also compatible with the clinical findings in patients with severe and/or fatal ZIKV infection, in whom viral particles and/or RNA were detected in multiple organs at post-mortem examination (Pan American Health Organization/World Health Oganization (PAHO/WHO), 2015; Sarmiento-Ospina et al., 2016, Arzuza-Ortega et al., 2016).", [["multi-organ", "ANATOMY", 39, 50], ["organs", "ANATOMY", 223, 229], ["ZIKV infection", "DISEASE", 146, 160], ["patients", "ORGANISM", 112, 120], ["organs", "ORGAN", 223, 229], ["patients", "SPECIES", 112, 120], ["ZIKV", "SPECIES", 146, 150], ["virus dissemination", "PROBLEM", 15, 34], ["multi-organ involvement", "PROBLEM", 39, 62], ["severe and/or fatal ZIKV infection", "PROBLEM", 126, 160], ["viral particles", "PROBLEM", 170, 185], ["RNA", "PROBLEM", 193, 196], ["post-mortem examination", "TEST", 233, 256], ["virus dissemination", "OBSERVATION", 15, 34], ["multi-organ involvement", "OBSERVATION", 39, 62], ["compatible with", "UNCERTAINTY", 71, 86], ["fatal", "OBSERVATION_MODIFIER", 140, 145], ["ZIKV infection", "OBSERVATION", 146, 160]]], ["While inflammatory neurological complications, such as Guillain-Barr\u00e9 syndrome, meningoencephalitis, and myelitis, have been recently reported in patients with ZIKV infection, inflammatory disorders of the other non-neuronal tissues were not well recognized (Cao-Lormeau et al., 2016, Carteaux et al., 2016, Mecharles et al., 2016).", [["neurological", "ANATOMY", 19, 31], ["non-neuronal tissues", "ANATOMY", 212, 232], ["neurological complications", "DISEASE", 19, 45], ["Guillain-Barr\u00e9 syndrome", "DISEASE", 55, 78], ["meningoencephalitis", "DISEASE", 80, 99], ["myelitis", "DISEASE", 105, 113], ["ZIKV infection", "DISEASE", 160, 174], ["Guillain-Barr\u00e9", "ORGANISM", 55, 69], ["patients", "ORGANISM", 146, 154], ["non-neuronal tissues", "TISSUE", 212, 232], ["patients", "SPECIES", 146, 154], ["ZIKV", "SPECIES", 160, 164], ["inflammatory neurological complications", "PROBLEM", 6, 45], ["Guillain-Barr\u00e9 syndrome", "PROBLEM", 55, 78], ["meningoencephalitis", "PROBLEM", 80, 99], ["myelitis", "PROBLEM", 105, 113], ["ZIKV infection", "PROBLEM", 160, 174], ["inflammatory disorders of the other non-neuronal tissues", "PROBLEM", 176, 232], ["inflammatory", "OBSERVATION_MODIFIER", 6, 18], ["complications", "OBSERVATION", 32, 45], ["Barr\u00e9 syndrome", "OBSERVATION", 64, 78], ["meningoencephalitis", "OBSERVATION", 80, 99], ["myelitis", "OBSERVATION", 105, 113], ["infection", "OBSERVATION", 165, 174], ["inflammatory", "OBSERVATION_MODIFIER", 176, 188], ["non-neuronal tissues", "ANATOMY", 212, 232]]], ["Our findings showed that inflammation could be observed in multiple organs including the testis, kidney, spleen, liver, intestine, pancreas, lung, and salivary gland outside the nervous system.DiscussionAmong these non-neuronal tissues, the inflammatory reactions were most prominent in the testis of our model mice.", [["organs", "ANATOMY", 68, 74], ["testis", "ANATOMY", 89, 95], ["kidney", "ANATOMY", 97, 103], ["spleen", "ANATOMY", 105, 111], ["liver", "ANATOMY", 113, 118], ["intestine", "ANATOMY", 120, 129], ["pancreas", "ANATOMY", 131, 139], ["lung", "ANATOMY", 141, 145], ["salivary gland", "ANATOMY", 151, 165], ["nervous system", "ANATOMY", 178, 192], ["non-neuronal tissues", "ANATOMY", 215, 235], ["testis", "ANATOMY", 291, 297], ["inflammation", "DISEASE", 25, 37], ["organs", "ORGAN", 68, 74], ["testis", "ORGAN", 89, 95], ["kidney", "ORGAN", 97, 103], ["spleen", "ORGAN", 105, 111], ["liver", "ORGAN", 113, 118], ["intestine", "ORGAN", 120, 129], ["pancreas", "ORGAN", 131, 139], ["lung", "ORGAN", 141, 145], ["salivary gland", "ORGAN", 151, 165], ["nervous system", "ANATOMICAL_SYSTEM", 178, 192], ["non-neuronal tissues", "TISSUE", 215, 235], ["testis", "ORGAN", 291, 297], ["mice", "ORGANISM", 311, 315], ["mice", "SPECIES", 311, 315], ["mice", "SPECIES", 311, 315], ["Our findings", "TEST", 0, 12], ["inflammation", "PROBLEM", 25, 37], ["multiple organs including the testis, kidney, spleen, liver, intestine, pancreas, lung, and salivary gland", "PROBLEM", 59, 165], ["the inflammatory reactions", "PROBLEM", 237, 263], ["inflammation", "OBSERVATION", 25, 37], ["testis", "ANATOMY", 89, 95], ["kidney", "ANATOMY", 97, 103], ["spleen", "ANATOMY", 105, 111], ["liver", "ANATOMY", 113, 118], ["intestine", "ANATOMY", 120, 129], ["pancreas", "ANATOMY", 131, 139], ["lung", "ANATOMY", 141, 145], ["salivary gland", "ANATOMY", 151, 165], ["nervous system", "ANATOMY", 178, 192], ["non-neuronal tissues", "ANATOMY", 215, 235], ["inflammatory", "OBSERVATION_MODIFIER", 241, 253], ["most prominent", "OBSERVATION_MODIFIER", 269, 283], ["testis", "ANATOMY", 291, 297]]], ["Some patients with ZIKV infection reported hematospermia, pelvic pain, and dysuria with detectable viral particles and/or RNA in their semen (Chan et al., 2016a, Musso et al., 2015a, Foy et al., 2011).", [["pelvic", "ANATOMY", 58, 64], ["semen", "ANATOMY", 135, 140], ["ZIKV infection", "DISEASE", 19, 33], ["hematospermia", "DISEASE", 43, 56], ["pelvic pain", "DISEASE", 58, 69], ["dysuria", "DISEASE", 75, 82], ["patients", "ORGANISM", 5, 13], ["pelvic", "ORGAN", 58, 64], ["semen", "ORGANISM_SUBSTANCE", 135, 140], ["viral particles", "RNA", 99, 114], ["patients", "SPECIES", 5, 13], ["ZIKV", "SPECIES", 19, 23], ["ZIKV infection", "PROBLEM", 19, 33], ["hematospermia", "PROBLEM", 43, 56], ["pelvic pain", "PROBLEM", 58, 69], ["dysuria", "PROBLEM", 75, 82], ["detectable viral particles", "PROBLEM", 88, 114], ["ZIKV infection", "OBSERVATION", 19, 33], ["pelvic", "ANATOMY", 58, 64], ["pain", "OBSERVATION", 65, 69], ["dysuria", "OBSERVATION", 75, 82], ["viral particles", "OBSERVATION", 99, 114]]], ["Histological evidence of orchitis has not been reported due to the difficulty in obtaining the patients' testicular tissues for histological examination.", [["testicular tissues", "ANATOMY", 105, 123], ["orchitis", "DISEASE", 25, 33], ["patients", "ORGANISM", 95, 103], ["testicular tissues", "TISSUE", 105, 123], ["patients", "SPECIES", 95, 103], ["orchitis", "PROBLEM", 25, 33], ["the difficulty in obtaining the patients' testicular tissues", "PROBLEM", 63, 123], ["histological examination", "TEST", 128, 152], ["orchitis", "OBSERVATION", 25, 33], ["testicular tissues", "ANATOMY", 105, 123]]], ["Previous mouse models for ZIKV infection utilizing types I/II interferon-signaling-/receptor-deficient mice have also showed that viral particles and RNA could be detected in the mice's testes, but histological analysis were not reported (Lazear et al., 2016).", [["testes", "ANATOMY", 186, 192], ["ZIKV infection", "DISEASE", 26, 40], ["mouse", "ORGANISM", 9, 14], ["ZIKV", "ORGANISM", 26, 30], ["types I/II interferon-signaling-/receptor", "GENE_OR_GENE_PRODUCT", 51, 92], ["mice", "ORGANISM", 103, 107], ["mice", "ORGANISM", 179, 183], ["testes", "ORGAN", 186, 192], ["interferon", "PROTEIN", 62, 72], ["viral particles", "RNA", 130, 145], ["mouse", "SPECIES", 9, 14], ["mice", "SPECIES", 103, 107], ["mice", "SPECIES", 179, 183], ["mouse", "SPECIES", 9, 14], ["ZIKV", "SPECIES", 26, 30], ["mice", "SPECIES", 103, 107], ["mice", "SPECIES", 179, 183], ["Previous mouse models", "PROBLEM", 0, 21], ["ZIKV infection", "PROBLEM", 26, 40], ["types I/II interferon", "TREATMENT", 51, 72], ["viral particles and RNA", "PROBLEM", 130, 153], ["histological analysis", "TEST", 198, 219], ["viral particles", "OBSERVATION", 130, 145], ["testes", "ANATOMY", 186, 192]]], ["The markedly necrotic and hemorrhagic seminiferous tubules observed in our mice are highly alarming as orchitis may have long-term effects on fertility.", [["necrotic", "ANATOMY", 13, 21], ["seminiferous tubules", "ANATOMY", 38, 58], ["necrotic", "DISEASE", 13, 21], ["hemorrhagic", "DISEASE", 26, 37], ["orchitis", "DISEASE", 103, 111], ["seminiferous tubules", "MULTI-TISSUE_STRUCTURE", 38, 58], ["mice", "ORGANISM", 75, 79], ["mice", "SPECIES", 75, 79], ["mice", "SPECIES", 75, 79], ["The markedly necrotic and hemorrhagic seminiferous tubules", "PROBLEM", 0, 58], ["orchitis", "PROBLEM", 103, 111], ["long-term effects on fertility", "PROBLEM", 121, 151], ["markedly", "OBSERVATION_MODIFIER", 4, 12], ["necrotic", "OBSERVATION_MODIFIER", 13, 21], ["hemorrhagic", "OBSERVATION_MODIFIER", 26, 37], ["seminiferous tubules", "OBSERVATION", 38, 58], ["orchitis", "OBSERVATION", 103, 111], ["long-term effects", "OBSERVATION_MODIFIER", 121, 138]]], ["These changes were not accountable by dexamethasone-induced testicular toxicity, as they were morphologically different from the latter, and were not present in any of the testes of the control mice with dexamethasone treatment and mock infection (Khorsandi et al., 2013).", [["testicular", "ANATOMY", 60, 70], ["testes", "ANATOMY", 172, 178], ["dexamethasone", "CHEMICAL", 38, 51], ["testicular toxicity", "DISEASE", 60, 79], ["dexamethasone", "CHEMICAL", 204, 217], ["infection", "DISEASE", 237, 246], ["dexamethasone", "CHEMICAL", 38, 51], ["dexamethasone", "CHEMICAL", 204, 217], ["dexamethasone", "SIMPLE_CHEMICAL", 38, 51], ["testicular", "ORGAN", 60, 70], ["testes", "ORGAN", 172, 178], ["mice", "ORGANISM", 194, 198], ["dexamethasone", "SIMPLE_CHEMICAL", 204, 217], ["mice", "SPECIES", 194, 198], ["mice", "SPECIES", 194, 198], ["dexamethasone", "TREATMENT", 38, 51], ["testicular toxicity", "PROBLEM", 60, 79], ["dexamethasone treatment", "TREATMENT", 204, 227], ["mock infection", "PROBLEM", 232, 246], ["testicular", "ANATOMY", 60, 70], ["toxicity", "OBSERVATION", 71, 79]]], ["During revision of this work, similar findings were reported in the testes of C57BL/6 mice treated with anti-Ifna1 blocking monoclonal antibody and inoculated with ZIKV (Govero et al., 2016).", [["testes", "ANATOMY", 68, 74], ["testes", "ORGAN", 68, 74], ["C57BL/6 mice", "ORGANISM", 78, 90], ["anti-Ifna1", "GENE_OR_GENE_PRODUCT", 104, 114], ["anti-Ifna1 blocking monoclonal antibody", "PROTEIN", 104, 143], ["mice", "SPECIES", 86, 90], ["mice", "SPECIES", 86, 90], ["ZIKV", "SPECIES", 164, 168], ["C57BL/6 mice", "TREATMENT", 78, 90], ["anti-Ifna1 blocking monoclonal antibody", "TREATMENT", 104, 143], ["ZIKV", "PROBLEM", 164, 168], ["testes", "ANATOMY", 68, 74]]], ["Clinical studies to confirm the presence of orchitis and to assess the fertility of convalescent male patients should be conducted to ascertain the long-term consequences of ZIKV infection regarding reproductive and hormonal derangements.", [["orchitis", "DISEASE", 44, 52], ["infection", "DISEASE", 179, 188], ["patients", "ORGANISM", 102, 110], ["ZIKV", "ORGANISM", 174, 178], ["patients", "SPECIES", 102, 110], ["ZIKV", "SPECIES", 174, 178], ["Clinical studies", "TEST", 0, 16], ["orchitis", "PROBLEM", 44, 52], ["ZIKV infection", "PROBLEM", 174, 188], ["reproductive and hormonal derangements", "PROBLEM", 199, 237], ["orchitis", "OBSERVATION", 44, 52], ["long-term", "OBSERVATION_MODIFIER", 148, 157], ["infection", "OBSERVATION", 179, 188], ["hormonal derangements", "OBSERVATION", 216, 237]]], ["Inflammation of other organs, such as acute tubulitis, interstitial nephritis, sialadenitis, hepatitis, enteritis, and acute pancreatitis have been reported in patients with ZIKV or other flavivirus infections (Chan et al., 2016a, Sarmiento-Ospina et al., 2016, Arzuza-Ortega et al., 2016, Duijster et al., 2016, Bonaldo et al., 2016, Gourinat et al., 2015, Musso et al., 2015b, Mercado et al., 2016, Bhagat et al., 2012, Torres et al., 2000, Macnamara, 1954, Chatterjee et al., 2014).", [["organs", "ANATOMY", 22, 28], ["interstitial", "ANATOMY", 55, 67], ["Inflammation", "DISEASE", 0, 12], ["acute tubulitis", "DISEASE", 38, 53], ["interstitial nephritis", "DISEASE", 55, 77], ["sialadenitis", "DISEASE", 79, 91], ["hepatitis", "DISEASE", 93, 102], ["enteritis", "DISEASE", 104, 113], ["pancreatitis", "DISEASE", 125, 137], ["flavivirus infections", "DISEASE", 188, 209], ["organs", "ORGAN", 22, 28], ["patients", "ORGANISM", 160, 168], ["patients", "SPECIES", 160, 168], ["ZIKV", "SPECIES", 174, 178], ["Inflammation of other organs", "PROBLEM", 0, 28], ["acute tubulitis", "PROBLEM", 38, 53], ["interstitial nephritis", "PROBLEM", 55, 77], ["sialadenitis", "PROBLEM", 79, 91], ["hepatitis", "PROBLEM", 93, 102], ["enteritis", "PROBLEM", 104, 113], ["acute pancreatitis", "PROBLEM", 119, 137], ["ZIKV", "PROBLEM", 174, 178], ["other flavivirus infections", "PROBLEM", 182, 209], ["Macnamara", "TEST", 443, 452], ["organs", "ANATOMY", 22, 28], ["acute", "OBSERVATION_MODIFIER", 38, 43], ["tubulitis", "OBSERVATION", 44, 53], ["interstitial", "ANATOMY_MODIFIER", 55, 67], ["nephritis", "OBSERVATION", 68, 77], ["sialadenitis", "OBSERVATION", 79, 91], ["hepatitis", "OBSERVATION", 93, 102], ["enteritis", "OBSERVATION", 104, 113], ["acute", "OBSERVATION_MODIFIER", 119, 124], ["pancreatitis", "OBSERVATION", 125, 137], ["flavivirus", "OBSERVATION", 188, 198]]], ["These potential complications may be increasingly recognized as the ZIKV epidemic continues to expand into developed countries with a large ageing and immunosuppressed population.DiscussionFinally, our mouse model also provided a novel avenue for the evaluation of anti-ZIKV treatment.", [["mouse", "ORGANISM", 202, 207], ["anti-ZIKV", "CANCER", 265, 274], ["mouse", "SPECIES", 202, 207], ["mouse", "SPECIES", 202, 207], ["anti-ZIKV", "SPECIES", 265, 274], ["These potential complications", "PROBLEM", 0, 29], ["the ZIKV epidemic", "PROBLEM", 64, 81], ["a large ageing", "TREATMENT", 132, 146], ["immunosuppressed population", "TREATMENT", 151, 178], ["the evaluation", "TEST", 247, 261], ["anti-ZIKV treatment", "TREATMENT", 265, 284], ["complications", "OBSERVATION", 16, 29], ["large", "OBSERVATION_MODIFIER", 134, 139]]], ["Type I interferons have broad-spectrum antiviral activities including those against ZIKV, but type I interferon-signaling-/receptor-deficient mice were not suitable for evaluation of the effects of recombinant type I interferons.", [["Type I interferons", "GENE_OR_GENE_PRODUCT", 0, 18], ["ZIKV", "GENE_OR_GENE_PRODUCT", 84, 88], ["type I interferon-signaling-/receptor", "GENE_OR_GENE_PRODUCT", 94, 131], ["mice", "ORGANISM", 142, 146], ["type I interferons", "GENE_OR_GENE_PRODUCT", 210, 228], ["Type I interferons", "PROTEIN", 0, 18], ["interferon", "PROTEIN", 101, 111], ["recombinant type I interferons", "PROTEIN", 198, 228], ["mice", "SPECIES", 142, 146], ["ZIKV", "SPECIES", 84, 88], ["mice", "SPECIES", 142, 146], ["Type I interferons", "PROBLEM", 0, 18], ["broad-spectrum antiviral activities", "TREATMENT", 24, 59], ["ZIKV", "PROBLEM", 84, 88], ["type I interferon", "TREATMENT", 94, 111], ["deficient mice", "PROBLEM", 132, 146], ["evaluation", "TEST", 169, 179], ["recombinant type I interferons", "TREATMENT", 198, 228]]], ["We therefore evaluated the antiviral effects of two commercially available preparations of recombinant type I interferons in this new mouse model (Hamel et al., 2015, Zumla et al., 2016, Chan et al., 2013, Chan et al., 2015b).", [["type I interferons", "GENE_OR_GENE_PRODUCT", 103, 121], ["mouse", "ORGANISM", 134, 139], ["recombinant type I interferons", "PROTEIN", 91, 121], ["mouse", "SPECIES", 134, 139], ["mouse", "SPECIES", 134, 139], ["recombinant type I interferons", "TREATMENT", 91, 121]]], ["We showed that the early use of either drug was associated with improved clinical outcome with no fatality (100% fatality in untreated mice), markedly decreased inflammatory response after dexamethasone withdrawal, and reduced viral loads in various tissues of the mice as compared to those of the untreated mice.", [["tissues", "ANATOMY", 250, 257], ["dexamethasone", "CHEMICAL", 189, 202], ["dexamethasone", "CHEMICAL", 189, 202], ["mice", "ORGANISM", 135, 139], ["dexamethasone", "SIMPLE_CHEMICAL", 189, 202], ["tissues", "TISSUE", 250, 257], ["mice", "ORGANISM", 265, 269], ["mice", "ORGANISM", 308, 312], ["mice", "SPECIES", 135, 139], ["mice", "SPECIES", 265, 269], ["mice", "SPECIES", 308, 312], ["mice", "SPECIES", 135, 139], ["mice", "SPECIES", 265, 269], ["mice", "SPECIES", 308, 312], ["fatality", "PROBLEM", 98, 106], ["markedly decreased inflammatory response", "PROBLEM", 142, 182], ["dexamethasone withdrawal", "PROBLEM", 189, 213], ["reduced viral loads", "PROBLEM", 219, 238], ["decreased", "OBSERVATION_MODIFIER", 151, 160], ["inflammatory response", "OBSERVATION", 161, 182], ["viral loads", "OBSERVATION", 227, 238]]], ["The viral load reductions were especially significant in the early phase of the disease (5 dpi), when the mice were on dexamethasone.", [["dexamethasone", "CHEMICAL", 119, 132], ["dexamethasone", "CHEMICAL", 119, 132], ["mice", "ORGANISM", 106, 110], ["dexamethasone", "SIMPLE_CHEMICAL", 119, 132], ["mice", "SPECIES", 106, 110], ["mice", "SPECIES", 106, 110], ["The viral load reductions", "TEST", 0, 25], ["dexamethasone", "TREATMENT", 119, 132], ["viral load", "OBSERVATION", 4, 14], ["early phase", "OBSERVATION_MODIFIER", 61, 72]]], ["These findings suggested that the early use of recombinant interferons might help to control viral replication during the initial phase of infection, and prevent the subsequent development of severe complications related to an exaggerated immune response in the presence of high viral loads as seen in the untreated mice.", [["infection", "DISEASE", 139, 148], ["mice", "ORGANISM", 316, 320], ["recombinant interferons", "PROTEIN", 47, 70], ["mice", "SPECIES", 316, 320], ["mice", "SPECIES", 316, 320], ["recombinant interferons", "TREATMENT", 47, 70], ["viral replication", "TREATMENT", 93, 110], ["infection", "PROBLEM", 139, 148], ["severe complications", "PROBLEM", 192, 212], ["an exaggerated immune response", "PROBLEM", 224, 254], ["high viral loads", "PROBLEM", 274, 290], ["infection", "OBSERVATION", 139, 148], ["severe", "OBSERVATION_MODIFIER", 192, 198], ["complications", "OBSERVATION", 199, 212], ["exaggerated", "OBSERVATION_MODIFIER", 227, 238], ["immune response", "OBSERVATION", 239, 254], ["high viral loads", "OBSERVATION", 274, 290]]], ["It is important to further confirm these results in our mouse model using different ZIKV strains and in clinical trials because ZIKV antagonizes mouse STAT2 less efficiently than human STAT2, and thus may be more susceptible to type I interferons in mice (Grant et al., 2016).", [["mouse", "ORGANISM", 56, 61], ["ZIKV", "ORGANISM", 128, 132], ["mouse", "ORGANISM", 145, 150], ["STAT2", "GENE_OR_GENE_PRODUCT", 151, 156], ["human", "ORGANISM", 179, 184], ["STAT2", "GENE_OR_GENE_PRODUCT", 185, 190], ["type I interferons", "GENE_OR_GENE_PRODUCT", 228, 246], ["mice", "ORGANISM", 250, 254], ["ZIKV", "PROTEIN", 128, 132], ["STAT2", "PROTEIN", 151, 156], ["human STAT2", "PROTEIN", 179, 190], ["type I interferons", "PROTEIN", 228, 246], ["mouse", "SPECIES", 56, 61], ["mouse", "SPECIES", 145, 150], ["human", "SPECIES", 179, 184], ["mice", "SPECIES", 250, 254], ["mouse", "SPECIES", 56, 61], ["ZIKV", "SPECIES", 84, 88], ["ZIKV", "SPECIES", 128, 132], ["mouse", "SPECIES", 145, 150], ["human", "SPECIES", 179, 184], ["mice", "SPECIES", 250, 254], ["our mouse model", "TREATMENT", 52, 67], ["different ZIKV strains", "TREATMENT", 74, 96], ["clinical trials", "TREATMENT", 104, 119], ["ZIKV antagonizes mouse STAT2", "TREATMENT", 128, 156]]], ["While most patients with mild ZIKV infection may not require systemic interferon treatment, clinical trials should be considered to evaluate the benefits of the early use of interferon treatment in patients at risk of developing severe ZIKV-associated complications, such as those with underlying comorbidities (Sarmiento-Ospina et al., 2016).", [["ZIKV infection", "DISEASE", 30, 44], ["interferon", "CHEMICAL", 174, 184], ["patients", "ORGANISM", 11, 19], ["interferon", "GENE_OR_GENE_PRODUCT", 174, 184], ["patients", "ORGANISM", 198, 206], ["interferon", "PROTEIN", 70, 80], ["interferon", "PROTEIN", 174, 184], ["patients", "SPECIES", 11, 19], ["patients", "SPECIES", 198, 206], ["ZIKV", "SPECIES", 30, 34], ["ZIKV", "SPECIES", 236, 240], ["mild ZIKV infection", "PROBLEM", 25, 44], ["systemic interferon treatment", "TREATMENT", 61, 90], ["clinical trials", "TREATMENT", 92, 107], ["interferon treatment", "TREATMENT", 174, 194], ["developing severe ZIKV-associated complications", "PROBLEM", 218, 265], ["underlying comorbidities", "PROBLEM", 286, 310], ["mild", "OBSERVATION_MODIFIER", 25, 29], ["ZIKV", "OBSERVATION", 30, 34], ["severe", "OBSERVATION_MODIFIER", 229, 235], ["ZIKV", "OBSERVATION", 236, 240], ["complications", "OBSERVATION", 252, 265]]], ["The increased risk of fetal loss and low birth weight associated with interferon therapy in the first trimester of pregnancy may be outweighed by the risk of congenital malformations due to ZIKV infection.", [["fetal", "ANATOMY", 22, 27], ["fetal loss", "DISEASE", 22, 32], ["birth weight", "DISEASE", 41, 53], ["interferon", "CHEMICAL", 70, 80], ["congenital malformations", "DISEASE", 158, 182], ["ZIKV infection", "DISEASE", 190, 204], ["fetal", "ANATOMICAL_SYSTEM", 22, 27], ["interferon", "GENE_OR_GENE_PRODUCT", 70, 80], ["congenital malformations", "PATHOLOGICAL_FORMATION", 158, 182], ["interferon", "PROTEIN", 70, 80], ["ZIKV", "SPECIES", 190, 194], ["fetal loss", "PROBLEM", 22, 32], ["low birth weight", "PROBLEM", 37, 53], ["interferon therapy", "TREATMENT", 70, 88], ["congenital malformations", "PROBLEM", 158, 182], ["ZIKV infection", "PROBLEM", 190, 204], ["increased", "OBSERVATION_MODIFIER", 4, 13], ["risk", "OBSERVATION_MODIFIER", 14, 18], ["fetal loss", "OBSERVATION", 22, 32], ["congenital", "OBSERVATION", 158, 168], ["ZIKV infection", "OBSERVATION", 190, 204]]], ["The optimal timing of treatment commencement should be further investigated as late commencement of interferon treatment may be useless or deleterious and should be avoided (Solomon et al., 2003).DiscussionIn summary, this novel mouse model is useful for investigating host immune response-associated damage of and evaluating countermeasures for ZIKV infection.", [["interferon", "CHEMICAL", 100, 110], ["infection", "DISEASE", 351, 360], ["mouse", "ORGANISM", 229, 234], ["ZIKV", "ORGANISM", 346, 350], ["interferon", "PROTEIN", 100, 110], ["mouse", "SPECIES", 229, 234], ["mouse", "SPECIES", 229, 234], ["ZIKV", "SPECIES", 346, 350], ["treatment commencement", "TREATMENT", 22, 44], ["interferon treatment", "TREATMENT", 100, 120], ["ZIKV infection", "PROBLEM", 346, 360]]], ["Inflammation of different visceral organs may be important complications of ZIKV that should be further studied in infected humans.", [["visceral organs", "ANATOMY", 26, 41], ["Inflammation", "DISEASE", 0, 12], ["visceral organs", "ORGAN", 26, 41], ["ZIKV", "ORGANISM", 76, 80], ["humans", "ORGANISM", 124, 130], ["humans", "SPECIES", 124, 130], ["ZIKV", "SPECIES", 76, 80], ["humans", "SPECIES", 124, 130], ["Inflammation of different visceral organs", "PROBLEM", 0, 41], ["ZIKV", "PROBLEM", 76, 80], ["different", "ANATOMY_MODIFIER", 16, 25], ["visceral", "ANATOMY_MODIFIER", 26, 34], ["organs", "ANATOMY", 35, 41], ["ZIKV", "OBSERVATION", 76, 80], ["infected", "OBSERVATION", 115, 123]]], ["Long-term monitoring of the testicular function of ZIKV-infected male patients should be considered.", [["testicular", "ANATOMY", 28, 38], ["ZIKV-infected", "DISEASE", 51, 64], ["testicular", "ORGAN", 28, 38], ["ZIKV", "ORGANISM", 51, 55], ["patients", "ORGANISM", 70, 78], ["patients", "SPECIES", 70, 78], ["ZIKV", "SPECIES", 51, 55], ["ZIKV", "PROBLEM", 51, 55], ["testicular", "ANATOMY", 28, 38]]], ["Clinical trials should be considered for evaluating the effects of recombinant interferon treatments in patients at high risk for ZIKV-associated complications when the potential benefits may outweight the side effects of treatment.DiscussionThe following are the supplementary data related to this article.Author ContributionJFWC, AJZ, CCSC, and KYY designed the study.", [["patients", "ORGANISM", 104, 112], ["patients", "SPECIES", 104, 112], ["ZIKV", "SPECIES", 130, 134], ["Clinical trials", "TREATMENT", 0, 15], ["recombinant interferon treatments", "TREATMENT", 67, 100], ["ZIKV", "PROBLEM", 130, 134], ["associated complications", "PROBLEM", 135, 159], ["treatment", "TREATMENT", 222, 231], ["the study", "TEST", 360, 369]]], ["AJZ, CCSC, HZ, and VKMP performed infections.", [["HZ", "DISEASE", 11, 13], ["infections", "DISEASE", 34, 44], ["AJZ", "SIMPLE_CHEMICAL", 0, 3], ["HZ", "PROBLEM", 11, 13], ["VKMP", "PROBLEM", 19, 23], ["infections", "PROBLEM", 34, 44], ["infections", "OBSERVATION", 34, 44]]], ["CCYY, JOLT, KKHC, and KHC prepared virus stocks and viral titrations.", [["CCYY", "SIMPLE_CHEMICAL", 0, 4], ["KKHC", "TREATMENT", 12, 16], ["KHC", "TREATMENT", 22, 25], ["virus stocks", "TREATMENT", 35, 47], ["viral titrations", "TREATMENT", 52, 68], ["JOLT", "ANATOMY", 6, 10], ["viral titrations", "OBSERVATION", 52, 68]]], ["AJZ, WWNM, VKMP, and RKHAY prepared histology and immunohistochemistry slides.", [["AJZ", "SIMPLE_CHEMICAL", 0, 3], ["AJZ", "PROTEIN", 0, 3], ["WWNM", "PROTEIN", 5, 9], ["VKMP", "PROTEIN", 11, 15], ["RKHAY", "PROTEIN", 21, 26], ["immunohistochemistry slides", "TEST", 50, 77]]], ["CCYY, KMT, ZZ, and JPC performed viral load studies.", [["KMT", "GENE_OR_GENE_PRODUCT", 6, 9], ["ZZ", "GENE_OR_GENE_PRODUCT", 11, 13], ["CCYY", "PROTEIN", 0, 4], ["KMT", "PROTEIN", 6, 9], ["ZZ", "PROTEIN", 11, 13], ["JPC", "PROTEIN", 19, 22], ["KMT", "TEST", 6, 9], ["JPC", "TREATMENT", 19, 22], ["viral load studies", "TEST", 33, 51]]], ["JFWC, AJZ, RKHAY, VKMP, and KYY acquired images at the microscope, analyzed, and quantified the data.", [["JFWC", "PROTEIN", 0, 4], ["AJZ", "PROTEIN", 6, 9], ["RKHAY", "PROTEIN", 11, 16], ["VKMP", "PROTEIN", 18, 22], ["KYY", "PROTEIN", 28, 31], ["JFWC", "TEST", 0, 4], ["VKMP", "TEST", 18, 22], ["the microscope", "TEST", 51, 65]]], ["The funding sources had no role in study design, data collection, analysis or interpretation or writing of the report.", [["data collection", "TEST", 49, 64], ["analysis", "TEST", 66, 74]]], ["The corresponding authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.", [["the study", "TEST", 61, 70]]]], "4d259054b0f0e246ce38666cc139a96359d4303b": [["All rights reserved convalescent plasma, obtainable by plasmapheresis of recovered COVID 19 attacks, who would be volunteering to donate plasma or immunoglobulin-containing fractions has been proposed and implemented with success in COVID 19 cases (Chen et al, 2020; Shen et al, 2020 ; WHO, 2020; Casadevall et al, 2020; Seghatchian et al, 2020) .", [["plasma", "ANATOMY", 33, 39], ["plasma", "ANATOMY", 137, 143], ["convalescent", "ORGANISM", 20, 32], ["plasma", "ORGANISM_SUBSTANCE", 33, 39], ["plasma", "ORGANISM_SUBSTANCE", 137, 143], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 147, 161], ["immunoglobulin", "PROTEIN", 147, 161], ["convalescent plasma", "TEST", 20, 39], ["plasmapheresis", "TREATMENT", 55, 69], ["immunoglobulin", "TREATMENT", 147, 161]]], ["Specific requirements and standards for preparation, qualification, storage, and distribution of these blood preparations need to be fully explored.", [["blood", "ANATOMY", 103, 108], ["blood", "ORGANISM_SUBSTANCE", 103, 108], ["these blood preparations", "TREATMENT", 97, 121]]], ["An administration of volumes ranging from 200 to 600 mL of immune plasma (8-10 mL/Kg) once per day and up to three-seven consecutive days is generally recommended to be safe.", [["immune plasma", "ANATOMY", 59, 72], ["plasma", "ORGANISM_SUBSTANCE", 66, 72], ["An administration of volumes", "TREATMENT", 0, 28], ["immune plasma", "TREATMENT", 59, 72]]], ["However, some technical issues still need to be solved such as the optimal threshold of serum titer of specific neutralizing antibodies (> 160 or > 320 by EIA method) in the preparation and the real utility of performing a pathogen (viral) inactivation treatment of such products.", [["serum", "ANATOMY", 88, 93], ["serum", "ORGANISM_SUBSTANCE", 88, 93], ["neutralizing antibodies", "PROTEIN", 112, 135], ["some technical issues", "PROBLEM", 9, 30], ["serum titer", "TEST", 88, 99], ["specific neutralizing antibodies", "TEST", 103, 135], ["a pathogen (viral) inactivation treatment", "TREATMENT", 221, 262], ["such products", "TREATMENT", 266, 279]]], ["In fact, critically ill COVID 19 patients as well as those in early phases of the disease might be excellent candidates for passive immunotherapy, and further randomized clinical trials for addressing its clinical usefulness in various patient subcategories.", [["patients", "ORGANISM", 33, 41], ["patient", "ORGANISM", 236, 243], ["patients", "SPECIES", 33, 41], ["patient", "SPECIES", 236, 243], ["the disease", "PROBLEM", 78, 89], ["passive immunotherapy", "TREATMENT", 124, 145], ["disease", "OBSERVATION", 82, 89]]], ["The immunocompromised status associated with haematological malignancies may enhance the risk of COVID-19 infections.", [["haematological malignancies", "ANATOMY", 45, 72], ["haematological malignancies", "DISEASE", 45, 72], ["infections", "DISEASE", 106, 116], ["malignancies", "CANCER", 60, 72], ["The immunocompromised status", "PROBLEM", 0, 28], ["haematological malignancies", "PROBLEM", 45, 72], ["COVID-19 infections", "PROBLEM", 97, 116], ["immunocompromised", "OBSERVATION", 4, 21], ["infections", "OBSERVATION", 106, 116]]], ["Based on this consideration, it might be postulated that either the preventive or the therapeutic use of convalescent plasma may be beneficial in chemotherapy-treated cancer patients, possibly mitigating the impact of COVID-19 (Dholaria B, et al, 2020) .", [["plasma", "ANATOMY", 118, 124], ["cancer", "ANATOMY", 167, 173], ["cancer", "DISEASE", 167, 173], ["COVID-19", "CHEMICAL", 218, 226], ["convalescent", "ORGANISM", 105, 117], ["plasma", "ORGANISM_SUBSTANCE", 118, 124], ["cancer", "CANCER", 167, 173], ["patients", "ORGANISM", 174, 182], ["patients", "SPECIES", 174, 182], ["convalescent plasma", "TREATMENT", 105, 124], ["chemotherapy", "TREATMENT", 146, 158], ["COVID", "TEST", 218, 223]]], ["However, the incidence and potential predictive parameters of mortality of COVID 19 in patients with haematological malignancies is still matter of investigation (Seghatchan et al, 2020).", [["haematological malignancies", "ANATOMY", 101, 128], ["haematological malignancies", "DISEASE", 101, 128], ["patients", "ORGANISM", 87, 95], ["haematological malignancies", "CANCER", 101, 128], ["patients", "SPECIES", 87, 95], ["COVID", "TREATMENT", 75, 80], ["haematological malignancies", "PROBLEM", 101, 128], ["malignancies", "OBSERVATION", 116, 128]]], ["Moreover, gene response, differing types of immunities, underlying conditions or life style behaviours in male and female, and races such as African (having 4 times more fatal outcomes than other populations) could be exposed to an increased risk for COVID 19-related complications.", [["underlying conditions", "PROBLEM", 56, 77], ["COVID 19-related complications", "PROBLEM", 251, 281], ["increased", "OBSERVATION_MODIFIER", 232, 241]]]], "PMC7335699": [["IntroductionThe COVID-19 pandemic has significant implications for the diagnosis and management of patients with gastrointestinal conditions including inflammatory bowel disease (IBD).1 Healthcare systems have had to adapt rapidly to maintain provision of core services and reduce unintended consequences from the necessary diversion of resources to focus on the pandemic.", [["gastrointestinal", "ANATOMY", 113, 129], ["bowel", "ANATOMY", 164, 169], ["inflammatory bowel disease", "DISEASE", 151, 177], ["IBD", "DISEASE", 179, 182], ["patients", "ORGANISM", 99, 107], ["bowel", "ORGAN", 164, 169], ["patients", "SPECIES", 99, 107], ["management", "TREATMENT", 85, 95], ["gastrointestinal conditions", "PROBLEM", 113, 140], ["inflammatory bowel disease (IBD)", "PROBLEM", 151, 183], ["core services", "TREATMENT", 256, 269], ["unintended consequences", "PROBLEM", 281, 304], ["gastrointestinal", "ANATOMY", 113, 129], ["inflammatory", "OBSERVATION_MODIFIER", 151, 163], ["bowel", "ANATOMY", 164, 169], ["disease", "OBSERVATION", 170, 177]]], ["The continued accumulation of cases positive for SARS-CoV-2 and the intervention from national governments to enforce strict social isolation (\u2018shielding\u2019) and distancing have necessitated IBD services to dramatically changing and restructuring the way they provide care for IBD patients.2 In addition, the rapid increase in COVID-19 hospitalisations along with restrictions in endoscopic and surgical facilities has resulted in the redeployment of clinicians and nurses to front-line services to care for these patients with resultant impact on the delivery of IBD care.3 In IBD, delays in diagnosis and therapy can have serious consequences including the need for emergency surgery.4", [["SARS", "DISEASE", 49, 53], ["IBD", "DISEASE", 275, 278], ["IBD", "DISEASE", 576, 579], ["patients", "ORGANISM", 279, 287], ["patients", "ORGANISM", 512, 520], ["patients", "SPECIES", 279, 287], ["patients", "SPECIES", 512, 520], ["SARS-CoV", "SPECIES", 49, 57], ["SARS", "PROBLEM", 49, 53], ["the intervention", "TREATMENT", 64, 80], ["strict social isolation (\u2018shielding\u2019)", "TREATMENT", 118, 155], ["IBD services", "TREATMENT", 189, 201], ["IBD patients", "TREATMENT", 275, 287], ["COVID", "TEST", 325, 330], ["IBD care", "TREATMENT", 562, 570], ["IBD", "PROBLEM", 576, 579], ["therapy", "TREATMENT", 605, 612], ["serious consequences", "PROBLEM", 622, 642], ["emergency surgery", "TREATMENT", 666, 683], ["accumulation", "OBSERVATION_MODIFIER", 14, 26], ["rapid", "OBSERVATION_MODIFIER", 307, 312], ["increase", "OBSERVATION_MODIFIER", 313, 321], ["IBD", "OBSERVATION", 576, 579]]]], "102b103fbaf7dcd8f4f68ef9650d7e8443e17a1b": [["Single-Family Room Design in the NeonatalIntensive Care Unit-Challenges and OpportunitiesRobert D. White, MDThe trend toward single-family room (SFR) design in the neonatal intensive care unit (NICU) has been driven by a growing understanding of the developmental needs of preterm infants, a desire to provide environments that support and encourage family participation, and infection control considerations.", [["infection", "DISEASE", 376, 385], ["infants", "ORGANISM", 281, 288], ["infants", "SPECIES", 281, 288], ["infection control considerations", "PROBLEM", 376, 408]]], ["SFR design offers many potential benefits, but also requires substantial change in the NICU culture, as well as additional space and technology when compared to an open ward.", [["the NICU culture", "TEST", 83, 99], ["substantial", "OBSERVATION_MODIFIER", 61, 72], ["change", "OBSERVATION", 73, 79]]], ["There are many good reasons for this, some of which remain valid, but most can no longer be invoked.", [["many", "OBSERVATION_MODIFIER", 10, 14], ["good", "OBSERVATION_MODIFIER", 15, 19]]], ["In this article, we will explore the reasons single-family rooms (SFR) are growing in popularity as new NICUs are being built and discuss how the desirable features of the open ward can be incorporated into SFR design in order to maximize benefits to babies, families, and caregivers alike.Why Change?Benefit to BabiesWhy Change?The most compelling evidence that has driven the interest in SFR design is the increasing awareness of how important the sensory environment is to the premature newborn who is in a critical stage of brain growth and development.", [["brain", "ANATOMY", 528, 533], ["brain", "ORGAN", 528, 533]]], ["1,2 During the third trimester, the infant's brain increases in mass by 400%, comparable to the 400% growth seen in the entire period from term to adulthood.", [["brain", "ANATOMY", 45, 50], ["infant", "ORGANISM", 36, 42], ["brain", "ORGAN", 45, 50], ["infant", "SPECIES", 36, 42], ["mass", "PROBLEM", 64, 68], ["brain", "ANATOMY", 45, 50], ["increases", "OBSERVATION_MODIFIER", 51, 60], ["mass", "OBSERVATION", 64, 68]]], ["Most neurons are formed by the end of the second trimester, but only limited dendritic connections are present.", [["neurons", "ANATOMY", 5, 12], ["dendritic", "ANATOMY", 77, 86], ["neurons", "CELL", 5, 12], ["dendritic connections", "MULTI-TISSUE_STRUCTURE", 77, 98], ["dendritic connections", "OBSERVATION", 77, 98]]], ["These proliferate during the third trimester in all areas of the brain but especially in the auditory cortex, where learning of phonemes and voice inflection is already taking place.", [["brain", "ANATOMY", 65, 70], ["auditory cortex", "ANATOMY", 93, 108], ["brain", "ORGAN", 65, 70], ["auditory cortex", "MULTI-TISSUE_STRUCTURE", 93, 108], ["These proliferate", "PROBLEM", 0, 17], ["voice inflection", "PROBLEM", 141, 157], ["proliferate", "OBSERVATION", 6, 17], ["brain", "ANATOMY", 65, 70], ["auditory cortex", "ANATOMY", 93, 108]]], ["3, 4 The fetus is primed to receive multisensory input from the mother-smell, taste, tactile, pain, movement, temperature change, light, and auditory input are all detected and elicit a response in the fetus, and in the preterm infant as well.", [["fetus", "ANATOMY", 9, 14], ["fetus", "ANATOMY", 202, 207], ["pain", "DISEASE", 94, 98], ["fetus", "ORGANISM", 9, 14], ["fetus", "ORGAN", 202, 207], ["multisensory input", "TREATMENT", 36, 54], ["pain", "PROBLEM", 94, 98], ["temperature change, light, and auditory input", "PROBLEM", 110, 155], ["fetus", "ANATOMY", 202, 207]]], ["In the open ward setting, even when the baby is in an incubator, many of these sensory stimuli are different in character, timing, and context than they are in utero.", [["these sensory stimuli", "TEST", 73, 94], ["sensory stimuli", "OBSERVATION", 79, 94]]], ["To some extent this is unavoidable, but the presence of the infant in an open ward, where shielding from activity in the adjacent bed space with its attendant noise and lights is incomplete at best, is now understood to be less than optimal from a developmental standpoint.Why Change?A second benefit to babies offered by SFR design is increased access to their parents, especially for intimate contact including skin-to-skin care.", [["skin", "ANATOMY", 413, 417], ["skin", "ANATOMY", 421, 425], ["babies", "ORGANISM", 304, 310], ["skin", "ORGAN", 413, 417], ["skin", "ORGAN", 421, 425], ["infant", "SPECIES", 60, 66], ["skin care", "TREATMENT", 421, 430], ["some extent", "OBSERVATION_MODIFIER", 3, 14], ["unavoidable", "OBSERVATION", 23, 34], ["skin", "ANATOMY", 413, 417], ["skin", "ANATOMY", 421, 425]]], ["Although it is possible to facilitate skin-toskin care in an open ward, both space and privacy issues limit many parents from taking full advantage of this technique.", [["skin", "ANATOMY", 38, 42], ["skin", "ORGAN", 38, 42], ["skin-toskin care", "TREATMENT", 38, 54], ["this technique", "TREATMENT", 151, 165], ["skin", "ANATOMY", 38, 42]]], ["6 It is not difficult to imagine how uncomfortable some parents (especially fathers) might be to sing a lullaby, read a children's story, or discuss sensitive matters with the medical staff in an open ward, or how much more likely this would be to occur in the SFR setting.", [["children", "ORGANISM", 120, 128], ["children", "SPECIES", 120, 128]]], ["Evidence for the value of skin-to-skin care in particular is now growing rapidly, [7] [8] [9] and it is also intuitive to understand how much more suitable the mother's arms would be than the incubator or warming bed with regard to all the desired sensory stimuli.", [["skin", "ANATOMY", 26, 30], ["skin", "ANATOMY", 34, 38], ["skin", "ORGAN", 26, 30], ["skin", "ORGAN", 34, 38], ["skin", "ANATOMY", 26, 30], ["skin", "ANATOMY", 34, 38]]], ["10 Finally, SFR design offers significant potential value to infants for infection control.", [["infection", "DISEASE", 73, 82], ["infants", "ORGANISM", 61, 68], ["infants", "SPECIES", 61, 68], ["infection control", "TREATMENT", 73, 90], ["infection", "OBSERVATION", 73, 82]]], ["Hospital-acquired infections remain a major cause of death, disability, and cost in premature babies.", [["infections", "DISEASE", 18, 28], ["death", "DISEASE", 53, 58], ["disability", "DISEASE", 60, 70], ["babies", "ORGANISM", 94, 100], ["acquired infections", "PROBLEM", 9, 28], ["death", "PROBLEM", 53, 58], ["cost in premature babies", "PROBLEM", 76, 100], ["infections", "OBSERVATION", 18, 28]]], ["The initial all-private room NICU was constructed in the 1980s in Brest, France, for infection control purposes and recent pandemics of severe acute respiratory syndrome and influenza, as well as local outbreaks of methicillin-resistant Staphylococcus aureus and multiple-resistant Gram-negative bacteria, have emphasized the importance of considering this an important issue in NICU design.", [["infection", "DISEASE", 85, 94], ["acute respiratory syndrome", "DISEASE", 143, 169], ["influenza", "DISEASE", 174, 183], ["methicillin", "CHEMICAL", 215, 226], ["Staphylococcus aureus", "DISEASE", 237, 258], ["methicillin", "CHEMICAL", 215, 226], ["methicillin-resistant Staphylococcus aureus", "ORGANISM", 215, 258], ["Staphylococcus aureus", "SPECIES", 237, 258], ["Staphylococcus aureus", "SPECIES", 237, 258], ["infection control purposes", "TREATMENT", 85, 111], ["severe acute respiratory syndrome", "PROBLEM", 136, 169], ["influenza", "PROBLEM", 174, 183], ["methicillin-resistant Staphylococcus aureus", "PROBLEM", 215, 258], ["multiple-resistant Gram-negative bacteria", "PROBLEM", 263, 304], ["severe", "OBSERVATION_MODIFIER", 136, 142], ["acute", "OBSERVATION_MODIFIER", 143, 148], ["respiratory syndrome", "OBSERVATION", 149, 169], ["Staphylococcus aureus", "OBSERVATION", 237, 258], ["resistant", "OBSERVATION_MODIFIER", 272, 281], ["negative bacteria", "OBSERVATION", 287, 304]]], ["Hospital-acquired infection has been reduced in the adult setting through the use of private rooms, 11 and since it is now clear that the incubator is an insufficient barrier to acquisition of nosocomial organisms, the SFR is an attractive way to address this problem.Benefits to FamiliesThe interest in SFR design has also been driven to a large extent by the evidence that families benefit from this environment in comparison to the open ward.", [["infection", "DISEASE", 18, 27], ["acquired infection", "PROBLEM", 9, 27], ["nosocomial organisms", "PROBLEM", 193, 213], ["infection", "OBSERVATION", 18, 27], ["reduced", "OBSERVATION_MODIFIER", 37, 44]]], ["Increased parental satisfaction in a SFR is clear, but families have also been found to participate more actively in medical discussions 5, 6 and become more comfortable and competent in the care of their infants.", [["infants", "ORGANISM", 205, 212], ["infants", "SPECIES", 205, 212], ["clear", "OBSERVATION", 44, 49]]], ["Clinical experience has shown that families feel more welcome in the SFR setting, and they perceive that their babies receive better care.", [["babies", "ORGANISM", 111, 117]]], ["With good design, nurses and other caregivers are provided a space where their needs for a supportive sensory environment-which are quite different from those of the baby-can be met.", [["baby", "ORGANISM", 166, 170]]], ["While they are at the bedside, of course, the sensory environment must be first of all suitable to the needs of the baby, but increasingly many elements of care (eg, charting, preparation of medications and feedings, team report) can and in many cases should be performed away from the bedside.", [["baby", "ORGANISM", 116, 120], ["medications", "TREATMENT", 191, 202], ["feedings", "TREATMENT", 207, 215]]], ["In these areas, lighting (especially daylight and access to nature), sound (eg, conversation, music), and other stimuli that would not be appropriate at the bedside can be allowed and even encouraged to the extent that it improves the well-being and performance of caregivers.", [["areas", "OBSERVATION_MODIFIER", 9, 14]]], ["Like families, caregivers appreciate and will readily take advantage of the opportunity to personalize their work environments.Communication/SafetyOpen-ward NICU design was essential in the era before central monitors and wireless technology became available.", [["wireless technology", "TEST", 222, 241]]], ["Although technology is now available to assist in these needs, it is not yet optimal.Communication/Safety\"Baby-to-nurse\" communication refers to transmission of alarms from monitors that track physiological parameters in the baby, as well as alarms from medical equipment such as ventilators, IV pumps, incubators, and more.", [["baby", "ORGANISM_SUBDIVISION", 225, 229], ["medical equipment", "TREATMENT", 254, 271], ["ventilators", "TREATMENT", 280, 291], ["IV pumps", "TREATMENT", 293, 301], ["incubators", "TREATMENT", 303, 313]]], ["Monitor information can now be sent from a baby's bedside to a monitor at any other bedside, to a central monitor, as well as to a wireless communication device carried by caregivers.", [["a wireless communication device", "TREATMENT", 129, 160]]], ["These devices can be programmed to also send monitor information to other caregivers in the NICU if the primary caregiver is unable to immediately respond.", [["These devices", "TREATMENT", 0, 13]]], ["Currently, though, most medical devices cannot be networked with the monitor alarms, so an \"infusion complete\" or \"occlusion\" alarm from an IV pump, or alarms of similar importance from ventilators and incubators are readily transmitted only by auditory means.", [["the monitor alarms", "TEST", 65, 83], ["an \"infusion complete\"", "TREATMENT", 88, 110], ["an IV pump", "TREATMENT", 137, 147], ["ventilators", "TREATMENT", 186, 197]]], ["Although this situation would rarely endanger an infant (if an infant was in immediate danger, parameters from the monitor such as heart rate or oxygen saturation would also go into alarm mode), it does create significant anxiety for caregivers and family members and noxious auditory stimulus to the infant if the alarms are not immediately recognized.Communication/Safety\"Nurse-to-nurse\" communication is taken for granted in an open ward NICU-it happens naturally and almost continually, and of course includes respiratory therapists, physicians, and other medical professionals.", [["heart", "ANATOMY", 131, 136], ["oxygen", "CHEMICAL", 145, 151], ["anxiety", "DISEASE", 222, 229], ["oxygen", "CHEMICAL", 145, 151], ["heart", "ORGAN", 131, 136], ["oxygen", "SIMPLE_CHEMICAL", 145, 151], ["infant", "ORGANISM", 301, 307], ["infant", "SPECIES", 49, 55], ["infant", "SPECIES", 63, 69], ["the monitor", "TEST", 111, 122], ["heart rate", "TEST", 131, 141], ["oxygen saturation", "TEST", 145, 162], ["significant anxiety", "PROBLEM", 210, 229], ["noxious auditory stimulus", "TEST", 268, 293]]], ["5 A challenge in either setting is the appropriate venue for teaching rounds.", [["A challenge", "TREATMENT", 2, 13]]], ["While work rounds that may include only a few members of the medical team and the family are facilitated by the SFR, 6 bedside rounds that involve large numbers of the medical team have drawbacks in both the SFR and open ward settings.", [["open ward settings", "TREATMENT", 216, 234]]], ["5 Good design and family support programs such as those offered by the March of Dimes can assure that these 84 Volume 10, Number 2, www.nainr.com opportunities are productive, but require active involvement of someone with the responsibility for family support to insure that they occur.Communication/SafetyTo some extent, all of these communication issues have an impact on patient safety, which relies both on good alarms as well as good communication amongst the medical team and between the medical team and the family.", [["patient", "ORGANISM", 375, 382], ["patient", "SPECIES", 375, 382], ["family support programs", "TREATMENT", 18, 41], ["family support", "TREATMENT", 246, 260], ["productive", "OBSERVATION_MODIFIER", 164, 174]]], ["Visibility is a particular challenge with SFR design, as are the inherently increased distances between beds and from beds to unit support areas.CostConstruction costs of SFR NICUs have been estimated to be 5% greater than comparable open ward designed NICUs.", [["increased", "OBSERVATION_MODIFIER", 76, 85]]], ["Usually more space is designated at the bedside for family support and storage of frequently-used supplies and less space elsewhere in the NICU for these functions than in an open ward.", [["family support", "TREATMENT", 52, 66]]], ["Of equal or greater concern is the question of whether ongoing costs, especially for labor, are higher in the SFR NICU; this question is less easy to quantify.", [["ongoing costs", "PROBLEM", 55, 68], ["labor", "PROBLEM", 85, 90]]], ["On the other hand, if SFR design can reduce hospitalacquired infection, increase family participation, facilitating earlier discharge in some cases, and improve neurodevelopment of the infant, SFR might actually reduce health care costs.LayoutThe most critical feature to successful SFR design is to carefully identify central gathering areas for staff and families that have easy visual and physical access to clusters of at least 8 and preferably 12 or more rooms, as well as ready access to daylight and support areas.", [["infection", "DISEASE", 61, 70], ["infant", "ORGANISM", 185, 191], ["infant", "SPECIES", 185, 191], ["hospitalacquired infection", "PROBLEM", 44, 70], ["infection", "OBSERVATION", 61, 70]]], ["This is very difficult to accomplish with gross square footage (total floor space, including support areas, divided by the number of beds) of less than 500 square feet per bed or in a structure which is relatively long and narrow.", [["gross square footage", "PROBLEM", 42, 62], ["total floor space", "TREATMENT", 64, 81], ["support areas", "TREATMENT", 93, 106], ["narrow", "OBSERVATION_MODIFIER", 223, 229]]], ["Optimal square footage to avoid undesirable compromises to some aspects of care is usually around 750 gross square feet per bed; this could be somewhat more or less depending on the services housed and the flexibility of the building footprint.LayoutDesign of the SFR itself typically includes a family area at the rear of the room, a patient care space in the center of the room, and an area for handwashing, charting, supplies, waste containers, and other support materials at the front of the room.", [["patient", "ORGANISM", 335, 342], ["patient", "SPECIES", 335, 342], ["undesirable compromises", "PROBLEM", 32, 55]]], ["This layout provides privacy for the family, maximizes space available for care of the infant, and allows for easy stocking and removal of materials without disturbing those in the room.LayoutWhereas typical floor plans of NICUs show only an infant bed in each care area, good design requires that the care area be designed to facilitate the ongoing presence of the family at the bedside, ideally in skin-to-skin contact with all but the most unstable infants.", [["skin", "ANATOMY", 400, 404], ["skin", "ANATOMY", 408, 412], ["skin", "ORGAN", 400, 404], ["skin", "ORGAN", 408, 412], ["infants", "ORGANISM", 452, 459], ["infant", "SPECIES", 87, 93], ["infant", "SPECIES", 242, 248], ["infants", "SPECIES", 452, 459], ["easy stocking and removal of materials", "TREATMENT", 110, 148], ["skin", "ANATOMY", 400, 404], ["skin", "ANATOMY", 408, 412]]], ["The provision of a bathroom in each SFR is controversial; so is the availability of a TV or DVD player, although these devices have great potential for education, relaxation, and allowing families to stay in touch with the outside world, and can be used with headphones to avoid an adverse impact on the infant.LayoutThe front portion of the room also deserves careful attention.", [["infant", "SPECIES", 304, 310], ["headphones", "TREATMENT", 259, 269]]], ["Is the sink large enough to permit good scrubbing, without counters or items nearby that could be contaminated by splashing? 12, 13 Can supplies be stocked and trash and soiled linens be removed easily and quietly?", [["trash and soiled linens", "TREATMENT", 160, 183], ["sink large", "OBSERVATION_MODIFIER", 7, 17], ["good", "OBSERVATION_MODIFIER", 35, 39], ["scrubbing", "OBSERVATION", 40, 49]]], ["Is it easy to see what is going on in the room from a central point but also possible to provide visual privacy when needed?LayoutThere are a number of other design features, both of the SFR and the NICU as a whole that should be planned carefully, [13] [14] [15] but those are not unique to the SFR design and are beyond the scope of this paper.Communication/SafetyAs noted earlier, technology is now available to support good communication where physical and visual access are limited.", [["[13] [14] [15]", "SIMPLE_CHEMICAL", 249, 263], ["visual privacy", "TREATMENT", 97, 111]]], ["Several problems remain, though, that require careful planning.", [["Several problems", "PROBLEM", 0, 16]]], ["Because of the need to hear non-networked alarms, rooms should be designed so that this sound can be transmitted to the central nursing area when the SFR door is open without other barriers or competing noise that could interfere with the ability of the nurse to hear the alarm.", [["central", "ANATOMY_MODIFIER", 120, 127]]], ["In some situations, though, (e.g., an infant in an open crib or skin-to-skin without medical devices, hospice care, or 1:1 nursing), closing the door could be acceptable and even desirable.", [["skin", "ANATOMY", 64, 68], ["skin", "ANATOMY", 72, 76], ["skin", "ORGAN", 64, 68], ["skin", "ORGAN", 72, 76], ["medical devices", "TREATMENT", 85, 100], ["hospice care", "TREATMENT", 102, 114], ["skin", "ANATOMY", 64, 68], ["skin", "ANATOMY", 72, 76]]], ["The \"nurse call\" button should be easily accessible both to parents who may be holding the baby at the bedside and to caregivers at any point of care; this might require two such buttons in some settings.Communication/SafetyPersonal communication devices used by nurses should be easy to use in a hands-free mode both for convenience and for infection control purposes, and should not themselves be a source of noise.", [["infection", "DISEASE", 342, 351], ["Communication/SafetyPersonal communication devices", "TREATMENT", 204, 254], ["infection control purposes", "TREATMENT", 342, 368]]], ["With convergence of technology, it is also feasible that these devices could soon provide visual access to the SFR and the infant bedside.Communication/SafetyOperational Strategies SFR design facilitates extensive family presence and involvement in care, and also requires recognition of aspects of collaborative nursing care that were common but often not formalized in open ward designs.", [["these devices", "TREATMENT", 57, 70], ["collaborative nursing care", "TREATMENT", 299, 325], ["open ward designs", "TREATMENT", 371, 388]]], ["If caregivers typically help one another during an IV start, when weighing an infant, or when performing respiratory care, how can that teamwork be formalized in a way that provides the least stress for the infant, and the greatest efficiency for the staff?", [["infant", "SPECIES", 207, 213], ["an IV start", "TREATMENT", 48, 59]]], ["If responding quickly to saturation alarms is important to limit complications of oxygen toxicity or deprivation, how can caregivers best assist one another, and empower parents to become a part of the care team in this regard?", [["oxygen", "CHEMICAL", 82, 88], ["toxicity", "DISEASE", 89, 97], ["oxygen", "CHEMICAL", 82, 88], ["oxygen", "SIMPLE_CHEMICAL", 82, 88], ["oxygen toxicity", "PROBLEM", 82, 97]]], ["Further consideration of these topics is beyond the scope of this paper but presents fertile ground for future discussion and clinical research.Does It Really Matter?Clear evidence that SFR design improves the outcomes for babies is still lacking.", [["babies", "ORGANISM", 223, 229]]], ["Surveys done in SFR units show that the great majority of families prefer the SFR and that most nurses believe it is the best environment of care for the infant.", [["infant", "ORGANISM", 154, 160], ["infant", "SPECIES", 154, 160], ["Surveys", "TEST", 0, 7]]], ["16 A comprehensive study is underway at Women & Infants Hospital of Rhode Island to evaluate the long-term impact on infants cared for in an SFR compared to those treated in an open ward.", [["infants", "ORGANISM", 117, 124], ["Women", "SPECIES", 40, 45], ["infants", "SPECIES", 117, 124], ["A comprehensive study", "TEST", 3, 24]]], ["In the meantime, the best evidence currently available comes from Sweden, where a randomized controlled trial of 365 families showed that preterm infants cared for in a setting where the family was present and providing skin-toskin care on an almost continuous basis required approximately 5 days less of intensive care, on average, and were discharged home 5 days earlier than those who were cared for in an area where parents were welcome at all times but their overnight stay was quite limited.", [["skin", "ANATOMY", 220, 224], ["infants", "ORGANISM", 146, 153], ["skin", "ORGAN", 220, 224], ["infants", "SPECIES", 146, 153], ["skin-toskin care", "TREATMENT", 220, 236], ["skin", "ANATOMY", 220, 224]]], ["Skin-to-skin care was instituted in both groups but particularly facilitated in the group that had continuous access for the parents.", [["Skin", "ANATOMY", 0, 4], ["skin", "ANATOMY", 8, 12], ["Skin", "ORGAN", 0, 4], ["skin", "ORGAN", 8, 12], ["skin care", "TREATMENT", 8, 17], ["skin", "ANATOMY", 8, 12]]], ["17 This group is planning to obtain long-term follow-up of these infants, but even the short-term data would indicate that significant costsavings can be derived by designing and operating a NICU where the environment of the baby and parents is more nurturing than the open ward design would allow.", [["infants", "ORGANISM", 65, 72], ["infants", "SPECIES", 65, 72]]]], "PMC7323040": [["INTRODUCTIONCOVID\u201019 lung disease is caused by SARS\u2010CoV\u20102, a RNA virus member of coronavirus family of viruses.1The most common clinical symptom is fever (in almost 90% of cases).", [["lung", "ANATOMY", 21, 25], ["lung disease", "DISEASE", 21, 33], ["fever", "DISEASE", 148, 153], ["lung", "ORGAN", 21, 25], ["SARS\u2010CoV\u20102", "ORGANISM", 47, 57], ["coronavirus", "ORGANISM", 81, 92], ["SARS\u2010CoV", "SPECIES", 47, 55], ["19 lung disease", "PROBLEM", 18, 33], ["SARS", "PROBLEM", 47, 51], ["The most common clinical symptom", "PROBLEM", 112, 144], ["fever", "PROBLEM", 148, 153], ["lung", "ANATOMY", 21, 25], ["disease", "OBSERVATION", 26, 33], ["most common", "OBSERVATION_MODIFIER", 116, 127]]], ["Brugada syndrome (BrS) is an inherited arrhythmic disease characterized by the type 1 Brugada ECG pattern in the right precordial leads of the ECG (coved type ST\u2010elevation and T\u2010wave inversion in lead V1 and/or V2) and an increased risk for ventricular fibrillation and sudden cardiac death.2ECG manifestations of BrS may be uncovered during fever.CASE REPORTA 52\u2010yearold male with no history of familiar sudden death arrived at our Emergency Department of Cittadella General Hospital after syncope with loss of consciousness (40 seconds) and spams occurred at bed during high fever (39.5\u00b0C).", [["right precordial", "ANATOMY", 113, 129], ["ventricular", "ANATOMY", 241, 252], ["cardiac", "ANATOMY", 277, 284], ["spams", "ANATOMY", 543, 548], ["Brugada syndrome", "DISEASE", 0, 16], ["BrS", "DISEASE", 18, 21], ["arrhythmic disease", "DISEASE", 39, 57], ["Brugada", "DISEASE", 86, 93], ["ventricular fibrillation", "DISEASE", 241, 265], ["sudden cardiac death", "DISEASE", 270, 290], ["BrS", "DISEASE", 314, 317], ["fever", "DISEASE", 342, 347], ["sudden death", "DISEASE", 405, 417], ["syncope", "DISEASE", 491, 498], ["loss of consciousness", "DISEASE", 504, 525], ["spams", "DISEASE", 543, 548], ["fever", "DISEASE", 577, 582], ["ventricular", "MULTI-TISSUE_STRUCTURE", 241, 252], ["cardiac", "ORGAN", 277, 284], ["Brugada syndrome", "PROBLEM", 0, 16], ["an inherited arrhythmic disease", "PROBLEM", 26, 57], ["the type 1 Brugada ECG pattern", "PROBLEM", 75, 105], ["the ECG", "TEST", 139, 146], ["type ST\u2010elevation", "PROBLEM", 154, 171], ["T\u2010wave inversion in lead V1", "PROBLEM", 176, 203], ["an increased risk", "PROBLEM", 219, 236], ["ventricular fibrillation", "PROBLEM", 241, 265], ["sudden cardiac death", "PROBLEM", 270, 290], ["BrS", "PROBLEM", 314, 317], ["fever", "PROBLEM", 342, 347], ["familiar sudden death", "PROBLEM", 396, 417], ["syncope", "PROBLEM", 491, 498], ["loss of consciousness", "PROBLEM", 504, 525], ["spams", "PROBLEM", 543, 548], ["high fever", "PROBLEM", 572, 582], ["arrhythmic disease", "OBSERVATION", 39, 57], ["right", "ANATOMY_MODIFIER", 113, 118], ["precordial", "ANATOMY_MODIFIER", 119, 129], ["increased", "OBSERVATION_MODIFIER", 222, 231], ["ventricular", "ANATOMY", 241, 252], ["fibrillation", "OBSERVATION", 253, 265], ["cardiac", "ANATOMY", 277, 284], ["death", "OBSERVATION", 285, 290]]], ["He began to suffer from dyspnea and fever 10 days before.", [["dyspnea", "DISEASE", 24, 31], ["fever", "DISEASE", 36, 41], ["dyspnea", "PROBLEM", 24, 31], ["fever", "PROBLEM", 36, 41], ["dyspnea", "OBSERVATION", 24, 31], ["fever", "OBSERVATION", 36, 41]]], ["Few days before another syncope occurred during high fever after a hot shower.", [["syncope", "DISEASE", 24, 31], ["fever", "DISEASE", 53, 58], ["another syncope", "PROBLEM", 16, 31], ["high fever", "PROBLEM", 48, 58]]], ["The thoracic high\u2010resolution computed tomography demonstrated bilateral multiple ground\u2010glass opacities.", [["thoracic", "ANATOMY", 4, 12], ["opacities", "DISEASE", 94, 103], ["The thoracic high\u2010resolution computed tomography", "TEST", 0, 48], ["bilateral multiple ground\u2010glass opacities", "PROBLEM", 62, 103], ["thoracic", "ANATOMY", 4, 12], ["bilateral", "ANATOMY_MODIFIER", 62, 71], ["multiple", "OBSERVATION_MODIFIER", 72, 80], ["ground\u2010glass opacities", "OBSERVATION", 81, 103]]], ["The nose\u2010pharyngeal swab resulted positive for SARS\u2010CoV\u20102 by PCR study.", [["nose\u2010pharyngeal swab", "ANATOMY", 4, 24], ["SARS", "DISEASE", 47, 51], ["nose\u2010pharyngeal swab", "ORGANISM_SUBSTANCE", 4, 24], ["SARS\u2010CoV", "SPECIES", 47, 55], ["The nose\u2010pharyngeal swab", "TEST", 0, 24], ["SARS", "PROBLEM", 47, 51], ["PCR study", "TEST", 61, 70]]], ["The 12\u2010lead ECG presented a \u201ccoved\u2010type\u201d aspect in leads V1 and V2 at the fourth intercostal space and a first\u2010degree atrio\u2010ventricular block (Figure 1).", [["fourth intercostal space", "ANATOMY", 74, 98], ["atrio\u2010ventricular", "ANATOMY", 118, 135], ["intercostal", "MULTI-TISSUE_STRUCTURE", 81, 92], ["The 12\u2010lead ECG", "TEST", 0, 15], ["a first\u2010degree atrio\u2010ventricular block", "PROBLEM", 103, 141], ["V1", "ANATOMY_MODIFIER", 57, 59], ["V2", "ANATOMY_MODIFIER", 64, 66], ["fourth intercostal space", "ANATOMY", 74, 98], ["atrio\u2010ventricular block", "OBSERVATION", 118, 141]]], ["The C\u2010reactive protein was 160.7 mg/L and the troponin level was normal.CASE REPORTThe patients started treatment with a combination of high\u2010flow oxygen inhalation, amoxycillin/clavulanic acid, low molecular weight heparin, and paracetamol.", [["oxygen", "CHEMICAL", 146, 152], ["amoxycillin/clavulanic acid", "CHEMICAL", 165, 192], ["heparin", "CHEMICAL", 215, 222], ["paracetamol", "CHEMICAL", 228, 239], ["oxygen", "CHEMICAL", 146, 152], ["amoxycillin", "CHEMICAL", 165, 176], ["clavulanic acid", "CHEMICAL", 177, 192], ["paracetamol", "CHEMICAL", 228, 239], ["C\u2010reactive", "GENE_OR_GENE_PRODUCT", 4, 14], ["troponin", "GENE_OR_GENE_PRODUCT", 46, 54], ["patients", "ORGANISM", 87, 95], ["oxygen", "SIMPLE_CHEMICAL", 146, 152], ["amoxycillin", "SIMPLE_CHEMICAL", 165, 176], ["clavulanic acid", "SIMPLE_CHEMICAL", 177, 192], ["low molecular weight heparin", "SIMPLE_CHEMICAL", 194, 222], ["paracetamol", "SIMPLE_CHEMICAL", 228, 239], ["C\u2010reactive protein", "PROTEIN", 4, 22], ["troponin", "PROTEIN", 46, 54], ["patients", "SPECIES", 87, 95], ["The C\u2010reactive protein", "TEST", 0, 22], ["the troponin level", "TEST", 42, 60], ["treatment", "TREATMENT", 104, 113], ["high\u2010flow oxygen inhalation", "TREATMENT", 136, 163], ["amoxycillin", "TREATMENT", 165, 176], ["clavulanic acid", "TREATMENT", 177, 192], ["low molecular weight heparin", "TREATMENT", 194, 222], ["paracetamol", "TREATMENT", 228, 239], ["normal", "OBSERVATION", 65, 71]]], ["During the eight days hospital stay, the ECG was continuously monitored: the patient did not experience either syncope or ventricular arrhythmias.", [["ventricular", "ANATOMY", 122, 133], ["syncope", "DISEASE", 111, 118], ["ventricular arrhythmias", "DISEASE", 122, 145], ["patient", "ORGANISM", 77, 84], ["ventricular", "ORGAN", 122, 133], ["patient", "SPECIES", 77, 84], ["the ECG", "TEST", 37, 44], ["syncope", "PROBLEM", 111, 118], ["ventricular arrhythmias", "PROBLEM", 122, 145], ["ventricular", "ANATOMY", 122, 133], ["arrhythmias", "OBSERVATION", 134, 145]]], ["As soon as the temperature went down, the 12\u2010lead ECG resumed a normal aspect, maintaining a long PR interval (0.230 seconds) (Figure 2).", [["PR", "PROTEIN", 98, 100], ["the temperature", "TEST", 11, 26], ["the 12\u2010lead ECG", "TEST", 38, 53], ["a long PR interval", "PROBLEM", 91, 109], ["normal", "OBSERVATION", 64, 70]]], ["While awaiting for the results of the genetic screening for pathogenic mutation of SCN5A, he received a subcutaneous implantable cardioverter\u2010defibrillator (Emblem S\u2010ICD, Model 209; Boston Scientific) after the resolution of COVID\u201019 disease.DISCUSSIONUp to 30% of patients with BrS carry a loss\u2010of\u2010function pathogenic variant (mutation) in SCN5A, the gene that encodes the cardiac sodium channel.", [["subcutaneous", "ANATOMY", 104, 116], ["cardiac", "ANATOMY", 374, 381], ["COVID", "DISEASE", 225, 230], ["BrS", "DISEASE", 279, 282], ["sodium", "CHEMICAL", 382, 388], ["sodium", "CHEMICAL", 382, 388], ["patients", "ORGANISM", 265, 273], ["SCN5A", "GENE_OR_GENE_PRODUCT", 341, 346], ["SCN5A", "DNA", 83, 88], ["SCN5A", "DNA", 341, 346], ["cardiac sodium channel", "PROTEIN", 374, 396], ["patients", "SPECIES", 265, 273], ["the genetic screening", "TEST", 34, 55], ["pathogenic mutation of SCN5A", "PROBLEM", 60, 88], ["a subcutaneous implantable cardioverter\u2010defibrillator", "TREATMENT", 102, 155], ["COVID\u201019 disease", "PROBLEM", 225, 241], ["a loss\u2010of\u2010function pathogenic variant (mutation) in SCN5A", "PROBLEM", 289, 346], ["cardiac", "ANATOMY", 374, 381], ["sodium channel", "OBSERVATION", 382, 396]]], ["The ECG manifestations of BrS may be uncovered during fever, and fever has been unequivocally associated with life\u2010threatening arrhythmic events in these patients.3In fact, sodium channel function is sensitive to temperature: in particular temperature may accelerate inactivation and/or decrease sodium channel expression at higher temperatures.4At this moment, we do not know if the virus itself could interact directly with the myocardial ion channels and provoke the ECG modification typical of BrS.", [["myocardial", "ANATOMY", 430, 440], ["BrS", "DISEASE", 26, 29], ["fever", "DISEASE", 54, 59], ["fever", "DISEASE", 65, 70], ["sodium", "CHEMICAL", 173, 179], ["sodium", "CHEMICAL", 296, 302], ["sodium", "CHEMICAL", 173, 179], ["sodium", "CHEMICAL", 296, 302], ["patients", "ORGANISM", 154, 162], ["sodium channel", "SIMPLE_CHEMICAL", 173, 187], ["sodium", "SIMPLE_CHEMICAL", 296, 302], ["myocardial", "MULTI-TISSUE_STRUCTURE", 430, 440], ["myocardial ion channels", "PROTEIN", 430, 453], ["patients", "SPECIES", 154, 162], ["BrS.", "SPECIES", 498, 502], ["The ECG", "TEST", 0, 7], ["BrS", "PROBLEM", 26, 29], ["fever", "PROBLEM", 54, 59], ["fever", "PROBLEM", 65, 70], ["life\u2010threatening arrhythmic events", "PROBLEM", 110, 144], ["sodium channel function", "TEST", 173, 196], ["decrease sodium channel expression", "PROBLEM", 287, 321], ["the virus", "PROBLEM", 380, 389]]], ["In the setting of fever, the presence of a pathogenic variant in SCN5A seems to be significantly correlated with the occurrence of life\u2010threatening arrhythmic events.3,4The decision to implant or not an implantable cardioverter\u2010defibrillator in BrS patients with syncope during high fever is still debated, because the nature of the syncope is unknown (arrhythmias, hypotension?).", [["fever", "DISEASE", 18, 23], ["3,4", "CHEMICAL", 166, 169], ["BrS", "DISEASE", 245, 248], ["syncope", "DISEASE", 263, 270], ["high fever", "DISEASE", 278, 288], ["syncope", "DISEASE", 333, 340], ["arrhythmias", "DISEASE", 353, 364], ["hypotension", "DISEASE", 366, 377], ["SCN5A", "GENE_OR_GENE_PRODUCT", 65, 70], ["patients", "ORGANISM", 249, 257], ["SCN5A", "DNA", 65, 70], ["patients", "SPECIES", 249, 257], ["fever", "PROBLEM", 18, 23], ["a pathogenic variant in SCN5A", "PROBLEM", 41, 70], ["life\u2010threatening arrhythmic events", "PROBLEM", 131, 165], ["an implantable cardioverter\u2010defibrillator", "TREATMENT", 200, 241], ["syncope", "PROBLEM", 263, 270], ["high fever", "PROBLEM", 278, 288], ["the syncope", "PROBLEM", 329, 340], ["arrhythmias", "PROBLEM", 353, 364], ["hypotension", "PROBLEM", 366, 377], ["fever", "OBSERVATION", 18, 23], ["pathogenic variant", "OBSERVATION", 43, 61], ["SCN5A", "OBSERVATION", 65, 70], ["syncope", "OBSERVATION", 333, 340]]], ["Nevertheless, after having discussed with the patient the risk\u2010benefit ratio of this choice, we implanted a subcutaneous implantable cardioverter\u2010defibrillator.DISCUSSIONRecently, a consensus of experts in inherited arrhythmic syndromes suggested to immediately attend the emergency department patients with BrS who develop high fever (>38.5\u00b0C) despite paracetamol treatment if: (a) they had a sodium channel disease, (b) are under 26 years old or over 70 years, (c) had a spontaneous type 1 Brugada pattern and/or cardiac syncope.4Assessment at the Emergency Department should include an ECG and monitoring for arrhythmia if the ECG shows the type 1 Brugada ECG pattern, until fever and/or the ECG pattern resolves.", [["subcutaneous", "ANATOMY", 108, 120], ["cardiac", "ANATOMY", 515, 522], ["arrhythmic syndromes", "DISEASE", 216, 236], ["BrS", "DISEASE", 308, 311], ["fever", "DISEASE", 329, 334], ["paracetamol", "CHEMICAL", 353, 364], ["sodium", "CHEMICAL", 394, 400], ["Brugada", "DISEASE", 492, 499], ["cardiac syncope", "DISEASE", 515, 530], ["arrhythmia", "DISEASE", 612, 622], ["Brugada", "DISEASE", 651, 658], ["fever", "DISEASE", 678, 683], ["paracetamol", "CHEMICAL", 353, 364], ["sodium", "CHEMICAL", 394, 400], ["patient", "ORGANISM", 46, 53], ["patients", "ORGANISM", 294, 302], ["paracetamol", "SIMPLE_CHEMICAL", 353, 364], ["sodium", "SIMPLE_CHEMICAL", 394, 400], ["cardiac", "ORGAN", 515, 522], ["patient", "SPECIES", 46, 53], ["patients", "SPECIES", 294, 302], ["a subcutaneous implantable cardioverter\u2010defibrillator", "TREATMENT", 106, 159], ["inherited arrhythmic syndromes", "PROBLEM", 206, 236], ["high fever", "PROBLEM", 324, 334], ["paracetamol treatment", "TREATMENT", 353, 374], ["a sodium channel disease", "PROBLEM", 392, 416], ["a spontaneous type 1 Brugada pattern", "PROBLEM", 471, 507], ["cardiac syncope", "PROBLEM", 515, 530], ["an ECG", "TEST", 586, 592], ["monitoring", "TEST", 597, 607], ["arrhythmia", "PROBLEM", 612, 622], ["the ECG", "TEST", 626, 633], ["the type 1 Brugada ECG pattern", "PROBLEM", 640, 670], ["fever", "PROBLEM", 678, 683], ["the ECG pattern", "TEST", 691, 706], ["cardiac", "ANATOMY", 515, 522], ["syncope", "OBSERVATION", 523, 530]]], ["According to our experience, this advice should be extended to all patients with high fever and syncope, even if previous ECG appeared normal.DISCUSSIONTransient appearance of \u201ccoved\u2010type\u201d aspect in leads V1 and V2 mimicking ST elevation myocardial infarction is an additional diagnostic and therapeutic challenge in COVID\u201019 patients presenting with chest pain, as recently reported.5", [["myocardial", "ANATOMY", 238, 248], ["chest", "ANATOMY", 351, 356], ["fever", "DISEASE", 86, 91], ["syncope", "DISEASE", 96, 103], ["myocardial infarction", "DISEASE", 238, 259], ["chest pain", "DISEASE", 351, 361], ["patients", "ORGANISM", 67, 75], ["myocardial", "MULTI-TISSUE_STRUCTURE", 238, 248], ["patients", "ORGANISM", 326, 334], ["chest", "ORGANISM_SUBDIVISION", 351, 356], ["patients", "SPECIES", 67, 75], ["patients", "SPECIES", 326, 334], ["high fever", "PROBLEM", 81, 91], ["syncope", "PROBLEM", 96, 103], ["previous ECG", "TEST", 113, 125], ["V2 mimicking ST elevation myocardial infarction", "PROBLEM", 212, 259], ["chest pain", "PROBLEM", 351, 361], ["normal", "OBSERVATION", 135, 141], ["myocardial", "ANATOMY", 238, 248], ["infarction", "OBSERVATION", 249, 259], ["chest", "ANATOMY", 351, 356]]]], "PMC6355779": [["IntroductionSpinal Cord Injury Without Radiographic Abnormality (SCIWORA) was coined by Pang in 1982 for children who sustained a traumatic spinal cord injury (SCI) without radiographic evidence of an adjacent spinal column injury to explain the SCI [1].", [["spinal cord", "ANATOMY", 140, 151], ["spinal column", "ANATOMY", 210, 223], ["cord injury", "DISEASE", 147, 158], ["SCI", "DISEASE", 160, 163], ["SCI", "DISEASE", 246, 249], ["children", "ORGANISM", 105, 113], ["spinal cord", "ORGANISM_SUBDIVISION", 140, 151], ["children", "SPECIES", 105, 113], ["IntroductionSpinal Cord Injury", "PROBLEM", 0, 30], ["Radiographic Abnormality", "PROBLEM", 39, 63], ["a traumatic spinal cord injury", "PROBLEM", 128, 158], ["an adjacent spinal column injury", "PROBLEM", 198, 230], ["Cord", "ANATOMY", 19, 23], ["Injury", "OBSERVATION", 24, 30], ["Without", "UNCERTAINTY", 31, 38], ["traumatic", "OBSERVATION_MODIFIER", 130, 139], ["spinal cord", "ANATOMY", 140, 151], ["injury", "OBSERVATION", 152, 158], ["spinal", "ANATOMY", 210, 216], ["column injury", "OBSERVATION", 217, 230]]], ["SCIWORA has the built-in assumption \u201cwhere the SCI occurs, there the spinal column injury occurs\u201d (or thereabouts).", [["spinal column", "ANATOMY", 69, 82], ["SCI", "DISEASE", 47, 50], ["the spinal column injury", "PROBLEM", 65, 89], ["SCI", "OBSERVATION", 47, 50], ["spinal column", "ANATOMY", 69, 82]]], ["Since SCIWORA pre-dates widespread magnetic resonance imaging (MRI) use, many believed MRI would provide a missing nearby soft-tissue explanation, and it did, but not for all, and SCIWORA persisted.", [["soft-tissue", "ANATOMY", 122, 133], ["tissue", "TISSUE", 127, 133], ["magnetic resonance imaging", "TEST", 35, 61], ["MRI", "TEST", 63, 66], ["MRI", "TEST", 87, 90]]], ["Though some recommend terms like SCIWONA (spinal cord injury without neuroradiologic abnormality) for modern cases without explanation despite all studies including MRI, the term has not caught on and SCIWORA continues to be applied loosely to all such cases [2, 3].IntroductionThis paper challenges the assumption in traumatic SCI, which led to the SCIWORA hypothesis, i.e., the notion we call \u201clocality\u201d that states if any SCI occurs, then any causal spinal column injury must be in the immediate vicinity.", [["spinal cord", "ANATOMY", 42, 53], ["spinal column", "ANATOMY", 453, 466], ["cord injury", "DISEASE", 49, 60], ["neuroradiologic abnormality", "DISEASE", 69, 96], ["SCI", "DISEASE", 328, 331], ["SCI", "DISEASE", 425, 428], ["spinal cord", "ORGAN", 42, 53], ["SCIWONA (spinal cord injury", "PROBLEM", 33, 60], ["neuroradiologic abnormality", "PROBLEM", 69, 96], ["all studies", "TEST", 143, 154], ["MRI", "TEST", 165, 168], ["SCIWORA", "TREATMENT", 201, 208], ["traumatic SCI", "PROBLEM", 318, 331], ["any causal spinal column injury", "PROBLEM", 442, 473], ["spinal cord", "ANATOMY", 42, 53], ["traumatic SCI", "OBSERVATION", 318, 331], ["spinal column", "ANATOMY", 453, 466]]], ["Thus, to explain cases of SCI when no local spinal column injury is present, the SCIWORA hypothesis postulates that the pediatric spinal column is inherently lax, i.e., the spinal column has more physiologic flexibility than the spinal cord.", [["spinal column", "ANATOMY", 44, 57], ["spinal column", "ANATOMY", 130, 143], ["spinal column", "ANATOMY", 173, 186], ["spinal cord", "ANATOMY", 229, 240], ["SCI", "DISEASE", 26, 29], ["spinal column", "MULTI-TISSUE_STRUCTURE", 44, 57], ["spinal cord", "ORGAN", 229, 240], ["local spinal column injury", "PROBLEM", 38, 64], ["spinal column", "ANATOMY", 44, 57], ["injury", "OBSERVATION", 58, 64], ["spinal column", "ANATOMY", 130, 143], ["lax", "OBSERVATION", 158, 161], ["spinal column", "ANATOMY", 173, 186], ["physiologic flexibility", "OBSERVATION", 196, 219], ["spinal cord", "ANATOMY", 229, 240]]], ["We present a case series misdiagnosed as SCIWORA to demonstrate the existence of non-locality, meaning the SCI and the spinal column uncoupling or damage need not occur in the same location (Fig. 1).", [["spinal column", "ANATOMY", 119, 132], ["non-locality", "DISEASE", 81, 93], ["SCI", "DISEASE", 107, 110], ["non-locality", "PROBLEM", 81, 93], ["the SCI", "PROBLEM", 103, 110], ["the spinal column uncoupling", "PROBLEM", 115, 143], ["damage", "PROBLEM", 147, 153], ["spinal column", "ANATOMY", 119, 132]]], ["So long as even one of these cases is true, then the real existence of non-locality is demonstrated, even if the majority of spinal column and spinal cord injuries do occur adjacent to one another.", [["spinal column", "ANATOMY", 125, 138], ["spinal cord", "ANATOMY", 143, 154], ["non-locality", "DISEASE", 71, 83], ["cord injuries", "DISEASE", 150, 163], ["spinal column", "MULTI-TISSUE_STRUCTURE", 125, 138], ["spinal cord", "ORGAN", 143, 154], ["spinal column", "PROBLEM", 125, 138], ["spinal cord injuries", "PROBLEM", 143, 163], ["spinal column", "ANATOMY", 125, 138], ["spinal cord", "ANATOMY", 143, 154]]], ["Last, the medical literature that has been cited as evidence for the SCIWORA hypothesis is examined for its actual supporting content.MethodsRancho Los Amigos is a National Rehabilitation Center for SCIs, pediatric and adult, and the spine team reviews and consults with each admission.", [["the SCIWORA hypothesis", "PROBLEM", 65, 87], ["spine", "ANATOMY", 234, 239]]], ["SCI consults for the last 5 years (2012\u20132017) were screened for a diagnosis of SCIWORA.", [["SCI", "DISEASE", 0, 3], ["SCIWORA", "DISEASE", 79, 86]]], ["All SCIWORA cases underwent chart and radiographic review to determine accuracy or consistency with the diagnosis and whether the assumption of locality (i.e. that the spinal column injury, when identifiable, must occur near the level of the spinal cord injury) was confirmed.", [["spinal column", "ANATOMY", 168, 181], ["spinal cord", "ANATOMY", 242, 253], ["cord injury", "DISEASE", 249, 260], ["spinal cord", "ORGAN", 242, 253], ["radiographic review", "TEST", 38, 57], ["the spinal column injury", "PROBLEM", 164, 188], ["the spinal cord injury", "PROBLEM", 238, 260], ["spinal column", "ANATOMY", 168, 181], ["spinal cord", "ANATOMY", 242, 253]]], ["Neurological levels and severity of impairment were graded according to the American Spinal Injury Association International Standards for Neurological Classification of Spinal Cord Injury ASIA/ISCoS [4].", [["Spinal", "ANATOMY", 170, 176], ["Spinal Injury", "DISEASE", 85, 98], ["Spinal Cord Injury", "DISEASE", 170, 188], ["Neurological levels", "TEST", 0, 19], ["severity of impairment", "PROBLEM", 24, 46], ["Spinal Cord Injury", "PROBLEM", 170, 188], ["Spinal", "ANATOMY", 85, 91], ["Spinal Cord", "ANATOMY", 170, 181]]], ["All patients sustained an American Spinal Injury Association Impairment Scale (AIS) grade of A and are referred to as \u201ccomplete\u201d hereafter.", [["Spinal Injury", "DISEASE", 35, 48], ["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["an American Spinal Injury", "PROBLEM", 23, 48], ["Spinal", "ANATOMY", 35, 41], ["Injury", "OBSERVATION", 42, 48]]], ["Institutional Review Board approval was obtained.Case 1 ::: ResultsA 4-year-old male forward-facing rear passenger restrained in a child\u2019s seat was injured when the vehicle hit a tree at freeway speeds.", [["child", "SPECIES", 131, 136]]], ["A C1\u20132 distraction injury caused a T2 complete paraplegia and was mislabeled a T2 SCIWORA as the treating physicians saw no evidence of spinal column injury near T2.", [["spinal column", "ANATOMY", 136, 149], ["paraplegia", "DISEASE", 47, 57], ["spinal column", "MULTI-TISSUE_STRUCTURE", 136, 149], ["A C1\u20132 distraction injury", "PROBLEM", 0, 25], ["a T2 complete paraplegia", "PROBLEM", 33, 57], ["spinal column injury", "PROBLEM", 136, 156], ["distraction injury", "OBSERVATION", 7, 25], ["complete", "OBSERVATION_MODIFIER", 38, 46], ["paraplegia", "OBSERVATION", 47, 57], ["no evidence of", "UNCERTAINTY", 121, 135], ["spinal", "ANATOMY", 136, 142], ["column injury", "OBSERVATION", 143, 156]]], ["The patient was sent to our facility with an unstable C1\u20132 ligamentous injury above his T2 SCI level.", [["ligamentous", "ANATOMY", 59, 70], ["patient", "ORGANISM", 4, 11], ["ligamentous", "ORGAN", 59, 70], ["patient", "SPECIES", 4, 11], ["an unstable C1\u20132 ligamentous injury", "PROBLEM", 42, 77], ["ligamentous", "ANATOMY", 59, 70], ["injury", "OBSERVATION", 71, 77]]], ["The case has been previously reported and some of the images reproduced herein (Figs.", [["the images", "TEST", 50, 60]]], ["The patient underwent successful C1\u20132 posterior spinal fusion to prevent subsequent risk of a secondary translation event at C1\u20132 which might render a C2 level SCI.CASE 2 ::: ResultsA 2-year-old girl in a forward-facing child\u2019s seat in a sudden deceleration MVC sustained a C6\u20137 distractive flexion injury with C2 complete SCI without nearby C2 level spinal column disruption locally on CT or MRI.", [["spinal", "ANATOMY", 48, 54], ["spinal column", "ANATOMY", 351, 364], ["SCI", "DISEASE", 160, 163], ["SCI", "DISEASE", 323, 326], ["patient", "ORGANISM", 4, 11], ["girl", "ORGANISM", 195, 199], ["child", "ORGANISM", 220, 225], ["patient", "SPECIES", 4, 11], ["girl", "SPECIES", 195, 199], ["successful C1\u20132 posterior spinal fusion", "TREATMENT", 22, 61], ["a secondary translation event", "PROBLEM", 92, 121], ["a sudden deceleration MVC", "PROBLEM", 236, 261], ["a C6\u20137 distractive flexion injury", "PROBLEM", 272, 305], ["C2 complete SCI", "PROBLEM", 311, 326], ["nearby C2 level spinal column disruption", "PROBLEM", 335, 375], ["CT", "TEST", 387, 389], ["MRI", "TEST", 393, 396], ["posterior", "ANATOMY_MODIFIER", 38, 47], ["spinal", "ANATOMY", 48, 54], ["fusion", "OBSERVATION", 55, 61], ["secondary translation", "OBSERVATION", 94, 115], ["SCI", "OBSERVATION", 323, 326], ["spinal column", "ANATOMY", 351, 364]]], ["In addition, there was no C6\u20137 spinal cord injury adjacent to the C6\u20137 spinal column injury on CT or MRI (Fig. 4).CASE 3 ::: ResultsA twelve-year-old restrained rear passenger with shoulder harness was involved in a high-speed sudden deceleration MVC.", [["C6\u20137 spinal cord", "ANATOMY", 26, 42], ["C6\u20137 spinal column", "ANATOMY", 66, 84], ["shoulder", "ANATOMY", 181, 189], ["cord injury", "DISEASE", 38, 49], ["spinal cord", "ORGAN", 31, 42], ["shoulder", "ORGANISM_SUBDIVISION", 181, 189], ["C6\u20137 spinal cord injury", "PROBLEM", 26, 49], ["the C6\u20137 spinal column injury", "PROBLEM", 62, 91], ["CT", "TEST", 95, 97], ["MRI", "TEST", 101, 104], ["sudden deceleration MVC", "PROBLEM", 227, 250], ["no", "UNCERTAINTY", 23, 25], ["spinal cord", "ANATOMY", 31, 42], ["injury", "OBSERVATION", 43, 49], ["C6\u20137", "ANATOMY_MODIFIER", 66, 70], ["spinal", "ANATOMY", 71, 77], ["column", "ANATOMY_MODIFIER", 78, 84], ["injury", "OBSERVATION", 85, 91], ["shoulder", "ANATOMY", 181, 189]]], ["She sustained a distractive-flexion C2 hangman\u2019s fracture (traumatic spondylolisthesis) and T2 clinical and radiologic SCI without evidence of T2 spinal column injury (Fig. 5).CASE 4 ::: ResultsA 65-year-old man in a sudden deceleration MVC sustained a T11\u201312 distraction injury with a C8 SCI without evidence of spinal column disruption about the level of the SCI and has been previously reported (Fig. 6) [6].Case 5 ::: ResultsA 24-year-old male MCA victim sustained a violent L2\u20133 distraction injury with clinical T9 SCI without nearby T9 spinal column disruption (Fig. 7).Case 6 ::: ResultsA 23-year-old female restrained passenger involved in a high-speed MVC sustained a distractive-flexion C2 hangman\u2019s fracture with a T1 cervicothoracic spinal cord injury without evidence spinal column osteoligamentous damage near the cervicothoracic junction and nearly identical to Case 3 (Fig. 8)DiscussionBorrowing from a similar concept in quantum mechanics, this series illustrates an effect we call \u201cnon-locality, \u201dmeaning a traumatic SCI may occur away from its causal spinal column injury, using a light fixture analogy and 6 representative cases (Fig. 1).", [["T2 spinal column", "ANATOMY", 143, 159], ["spinal column", "ANATOMY", 313, 326], ["MCA", "ANATOMY", 448, 451], ["T9 spinal column", "ANATOMY", 539, 555], ["cervicothoracic spinal cord", "ANATOMY", 729, 756], ["spinal column", "ANATOMY", 781, 794], ["cervicothoracic junction", "ANATOMY", 828, 852], ["spinal column", "ANATOMY", 1070, 1083], ["fracture", "DISEASE", 49, 57], ["traumatic spondylolisthesis", "DISEASE", 59, 86], ["SCI", "DISEASE", 119, 122], ["MVC", "DISEASE", 237, 240], ["SCI", "DISEASE", 289, 292], ["SCI", "DISEASE", 361, 364], ["MCA", "DISEASE", 448, 451], ["distraction injury", "DISEASE", 484, 502], ["SCI", "DISEASE", 520, 523], ["fracture", "DISEASE", 710, 718], ["cord injury", "DISEASE", 752, 763], ["SCI", "DISEASE", 1035, 1038], ["man", "ORGANISM", 208, 211], ["female", "ORGANISM", 608, 614], ["cord", "ORGAN", 752, 756], ["man", "SPECIES", 208, 211], ["a distractive-flexion C2 hangman\u2019s fracture", "PROBLEM", 14, 57], ["traumatic spondylolisthesis)", "PROBLEM", 59, 87], ["T2 clinical and radiologic SCI", "PROBLEM", 92, 122], ["T2 spinal column injury", "PROBLEM", 143, 166], ["a sudden deceleration MVC", "PROBLEM", 215, 240], ["a T11\u201312 distraction injury", "PROBLEM", 251, 278], ["a C8 SCI", "PROBLEM", 284, 292], ["spinal column disruption", "PROBLEM", 313, 337], ["a violent L2\u20133 distraction injury", "PROBLEM", 469, 502], ["clinical T9 SCI", "PROBLEM", 508, 523], ["nearby T9 spinal column disruption", "PROBLEM", 532, 566], ["a distractive-flexion C2 hangman\u2019s fracture", "PROBLEM", 675, 718], ["a T1 cervicothoracic spinal cord injury", "PROBLEM", 724, 763], ["spinal column osteoligamentous damage", "PROBLEM", 781, 818], ["a traumatic SCI", "PROBLEM", 1023, 1038], ["its causal spinal column injury", "PROBLEM", 1059, 1090], ["a light fixture analogy", "TREATMENT", 1098, 1121], ["fracture", "OBSERVATION", 49, 57], ["traumatic", "OBSERVATION_MODIFIER", 59, 68], ["spondylolisthesis", "OBSERVATION", 69, 86], ["without evidence of", "UNCERTAINTY", 123, 142], ["T2", "ANATOMY_MODIFIER", 143, 145], ["spinal", "ANATOMY", 146, 152], ["column", "ANATOMY_MODIFIER", 153, 159], ["injury", "OBSERVATION", 160, 166], ["T11", "ANATOMY", 253, 256], ["distraction injury", "OBSERVATION", 260, 278], ["C8 SCI", "ANATOMY", 286, 292], ["without evidence of", "UNCERTAINTY", 293, 312], ["spinal", "ANATOMY", 313, 319], ["column", "ANATOMY_MODIFIER", 320, 326], ["disruption", "OBSERVATION", 327, 337], ["SCI", "ANATOMY", 361, 364], ["MCA", "ANATOMY", 448, 451], ["T9 SCI", "ANATOMY", 517, 523], ["T9", "ANATOMY_MODIFIER", 539, 541], ["spinal", "ANATOMY", 542, 548], ["column", "ANATOMY_MODIFIER", 549, 555], ["fracture", "OBSERVATION", 710, 718], ["cervicothoracic", "ANATOMY_MODIFIER", 729, 744], ["spinal cord", "ANATOMY", 745, 756], ["injury", "OBSERVATION", 757, 763], ["spinal", "ANATOMY", 781, 787], ["column", "ANATOMY_MODIFIER", 788, 794], ["cervicothoracic junction", "ANATOMY", 828, 852], ["spinal column", "ANATOMY", 1070, 1083]]], ["If unconvinced by these cases, another example of the non-locality phenomenon has been present in the literature involving flexion-distraction Salter\u2013Harris I odontoid fractures in children [7].", [["fractures", "DISEASE", 168, 177], ["children", "ORGANISM", 181, 189], ["children", "SPECIES", 181, 189], ["the non-locality phenomenon", "PROBLEM", 50, 77], ["Harris I odontoid fractures", "PROBLEM", 150, 177], ["odontoid", "ANATOMY", 159, 167], ["fractures", "OBSERVATION", 168, 177]]], ["In 55 cases, 15 had SCI: 8 (53%) occurred non-locally at the cervicothoracic junction, and 7 (47%) occurred locally about C2.", [["cervicothoracic junction", "ANATOMY", 61, 85], ["SCI", "DISEASE", 20, 23], ["cervicothoracic junction", "MULTI-TISSUE_STRUCTURE", 61, 85], ["cervicothoracic junction", "ANATOMY", 61, 85]]], ["Non-local cervicothoracic SCI was more common than local C2 SCI.", [["cervicothoracic", "ANATOMY", 10, 25], ["SCI", "DISEASE", 26, 29], ["SCI", "DISEASE", 60, 63], ["Non-local cervicothoracic SCI", "PROBLEM", 0, 29], ["cervicothoracic SCI", "ANATOMY", 10, 29], ["C2 SCI", "ANATOMY", 57, 63]]], ["Though most SCIs, in general, result from a local spinal column injury, it appears that SCI may also result from a distant osteoligamentous uncoupling of the spinal column.", [["spinal column", "ANATOMY", 50, 63], ["osteoligamentous", "ANATOMY", 123, 139], ["spinal column", "ANATOMY", 158, 171], ["SCIs", "DISEASE", 12, 16], ["SCI", "DISEASE", 88, 91], ["SCIs", "CANCER", 12, 16], ["spinal column", "MULTI-TISSUE_STRUCTURE", 50, 63], ["spinal column", "MULTI-TISSUE_STRUCTURE", 158, 171], ["a local spinal column injury", "PROBLEM", 42, 70], ["SCI", "PROBLEM", 88, 91], ["a distant osteoligamentous uncoupling of the spinal column", "PROBLEM", 113, 171], ["most SCIs", "OBSERVATION_MODIFIER", 7, 16], ["spinal", "ANATOMY", 50, 56], ["column injury", "OBSERVATION", 57, 70], ["SCI", "OBSERVATION", 88, 91], ["distant", "OBSERVATION_MODIFIER", 115, 122], ["osteoligamentous uncoupling", "OBSERVATION", 123, 150], ["spinal", "ANATOMY", 158, 164], ["column", "ANATOMY_MODIFIER", 165, 171]]], ["With a positive case for non-locality in place, real explanatory power for previously mislabeled SCIWORA cases like these is available.DiscussionSCIWORA appears to have been born not simply from our early inability to visualize spinal column damage radiographically, but also from our failure to recognize non-locality.", [["spinal column", "ANATOMY", 228, 241], ["previously mislabeled SCIWORA cases", "PROBLEM", 75, 110], ["spinal column damage radiographically", "PROBLEM", 228, 265], ["our failure", "PROBLEM", 281, 292], ["spinal column", "ANATOMY", 228, 241]]], ["Pang has stated that any osteoligamentous MRI change seen for a SCIWORA \u201ccorresponds exactly to the level of the neurological lesion in each case\u201d (p.", [["neurological lesion", "ANATOMY", 113, 132], ["neurological lesion", "DISEASE", 113, 132], ["any osteoligamentous MRI change", "PROBLEM", 21, 52], ["the neurological lesion", "PROBLEM", 109, 132], ["neurological", "ANATOMY", 113, 125], ["lesion", "OBSERVATION", 126, 132]]], ["From the assumption of locality-only effects, SCIWORA and its theories about the pediatric spinal column being more lax than the spinal cord were postulated in order to explain the missing spinal column damage that should have otherwise been expected.", [["spinal column", "ANATOMY", 91, 104], ["spinal cord", "ANATOMY", 129, 140], ["spinal column", "ANATOMY", 189, 202], ["spinal column", "MULTI-TISSUE_STRUCTURE", 91, 104], ["spinal cord", "ORGAN", 129, 140], ["SCIWORA", "TREATMENT", 46, 53], ["the missing spinal column damage", "PROBLEM", 177, 209], ["locality", "OBSERVATION", 23, 31], ["pediatric", "ANATOMY_MODIFIER", 81, 90], ["spinal column", "ANATOMY", 91, 104], ["spinal cord", "ANATOMY", 129, 140], ["spinal", "ANATOMY", 189, 195], ["column damage", "OBSERVATION", 196, 209]]], ["Even at face value, however, children have far fewer spinal cord injuries than adults despite much more vigorous physical activity, daily falls and so forth which presents common sense empirical evidence against such theories.DiscussionGiven this, we set out to find the actual empirical evidence in the scientific literature that was used to justify the claims of SCIWORA.", [["spinal cord", "ANATOMY", 53, 64], ["cord injuries", "DISEASE", 60, 73], ["children", "ORGANISM", 29, 37], ["spinal cord", "ORGANISM_SUBDIVISION", 53, 64], ["children", "SPECIES", 29, 37], ["far fewer spinal cord injuries", "PROBLEM", 43, 73], ["spinal cord", "ANATOMY", 53, 64], ["injuries", "OBSERVATION", 65, 73]]], ["The general claim that children\u2019s spines are inherently lax such that the spinal column can stretch more than the spinal cord prior to disruption;Discussion-and-Discussion2.", [["spines", "ANATOMY", 34, 40], ["spinal column", "ANATOMY", 74, 87], ["spinal cord", "ANATOMY", 114, 125], ["children", "ORGANISM", 23, 31], ["spines", "MULTI-TISSUE_STRUCTURE", 34, 40], ["spinal cord", "ORGAN", 114, 125], ["children", "SPECIES", 23, 31], ["inherently lax", "PROBLEM", 45, 59], ["spinal column", "ANATOMY", 74, 87], ["spinal cord", "ANATOMY", 114, 125]]], ["The specific claim that the spinal column can stretch 2 inches (5.08 cm) while the spinal cord can stretch only 1/4 inch (0.64 cm) prior to disruption.DiscussionReferences of all PubMed articles with Spinal Cord Injury Without Radiographic Abnormality in the title for the last 10 years plus any written by Pang were traced back to their origin looking for any study along the path with the actual empirical data to support either of the claims.DiscussionFor the specific claim that the spinal column may stretch physiologically up to 2 inches (5.08 cm) without disruption while the spinal cord may only stretch up to 1/4 inch (0.64 cm, eight times less) before disruption, all reference trails lead to a single case series about 6 SCI breech births by Leventhal in 1960 [9].", [["spinal column", "ANATOMY", 28, 41], ["spinal cord", "ANATOMY", 83, 94], ["spinal column", "ANATOMY", 487, 500], ["spinal cord", "ANATOMY", 583, 594], ["Cord Injury", "DISEASE", 207, 218], ["SCI", "DISEASE", 732, 735], ["Leventhal", "CHEMICAL", 753, 762], ["spinal cord", "ORGAN", 83, 94], ["spinal cord", "ORGAN", 583, 594], ["disruption", "PROBLEM", 140, 150], ["Spinal Cord Injury", "PROBLEM", 200, 218], ["Radiographic Abnormality", "PROBLEM", 227, 251], ["any study", "TEST", 357, 366], ["disruption while the spinal cord", "PROBLEM", 562, 594], ["disruption", "PROBLEM", 662, 672], ["spinal column", "ANATOMY", 28, 41], ["spinal cord", "ANATOMY", 83, 94], ["Spinal Cord", "ANATOMY", 200, 211], ["spinal column", "ANATOMY", 487, 500], ["spinal cord", "ANATOMY", 583, 594]]], ["One baby died and underwent autopsy.", [["baby", "ORGANISM", 4, 8], ["autopsy", "TEST", 28, 35]]], ["A single sentence in the discussion then appears in the entire 4-page paper making the claim: \u201cIt was shown in the autopsy specimen that this column can be stretched 2 inches and the cervical cord pulled down 1/4 inch\u201d without any description of the methods employed.DiscussionFor the general claim, 11 terminal references emerged, which were grouped into the following 4 categories excluding dead ends: (1) parallel breech births [10, 11], (2) normal pediatric spinal and radiographic anatomy and variants [12\u201315], (3) adults with cervical stenosis sustaining a SCI due to ligamentum flavum buckling after a hyper-extension injury, but some without spinal column injury [16, 17], and (4) case series without static x-ray evidence to explain some SCIs (Table 1) [18\u201320].", [["cervical cord", "ANATOMY", 183, 196], ["spinal", "ANATOMY", 462, 468], ["cervical", "ANATOMY", 532, 540], ["ligamentum flavum", "ANATOMY", 574, 591], ["spinal column", "ANATOMY", 650, 663], ["cervical stenosis", "DISEASE", 532, 549], ["SCI", "DISEASE", 563, 566], ["ligamentum flavum buckling", "DISEASE", 574, 600], ["hyper-extension injury", "DISEASE", 609, 631], ["SCIs", "DISEASE", 747, 751], ["cervical cord", "TISSUE", 183, 196], ["spinal", "ORGAN", 462, 468], ["cervical", "ORGAN", 532, 540], ["the cervical cord", "PROBLEM", 179, 196], ["parallel breech births", "PROBLEM", 408, 430], ["radiographic anatomy", "TEST", 473, 493], ["variants", "TEST", 498, 506], ["cervical stenosis", "PROBLEM", 532, 549], ["a SCI", "PROBLEM", 561, 566], ["ligamentum flavum buckling", "PROBLEM", 574, 600], ["a hyper-extension injury", "PROBLEM", 607, 631], ["spinal column injury", "PROBLEM", 650, 670], ["case series", "TEST", 689, 700], ["static x-ray", "TEST", 709, 721], ["cervical cord", "ANATOMY", 183, 196], ["spinal", "ANATOMY", 462, 468], ["cervical", "ANATOMY", 532, 540], ["stenosis", "OBSERVATION", 541, 549], ["SCI", "ANATOMY", 563, 566], ["ligamentum flavum", "ANATOMY", 574, 591], ["buckling", "OBSERVATION", 592, 600], ["without", "UNCERTAINTY", 642, 649], ["spinal", "ANATOMY", 650, 656], ["column", "ANATOMY_MODIFIER", 657, 663]]], ["The remaining citations terminated in the following 2 basic ways: (1) dead-end--the terminal reference does not make or suggest the original claim being traced, (2) case series of children--some with SCI, but without a local spinal column injury seen on radiographic analysis as seen, for example, in Pang\u2019s articles [1, 8, 21\u201326].", [["spinal column", "ANATOMY", 225, 238], ["SCI", "DISEASE", 200, 203], ["children", "ORGANISM", 180, 188], ["children", "SPECIES", 180, 188], ["SCI", "PROBLEM", 200, 203], ["a local spinal column injury", "PROBLEM", 217, 245], ["radiographic analysis", "TEST", 254, 275], ["spinal column", "ANATOMY", 225, 238], ["injury", "OBSERVATION", 239, 245]]], ["A SCIWORA label is given, but no evidence for its validity.", [["no evidence for", "UNCERTAINTY", 30, 45]]], ["Rather, SCIWORA and differential stretch is assumed a priori without ever demonstrating its truth.", [["SCIWORA", "DNA", 8, 15]]], ["Three recurrent terminal articles are illustrative and included in Table 1 [18\u201320].DiscussionThus, little, if any, genuine or empirical evidence appears to exist for the SCIWORA hypothesis and its idea about the differential stretch between the spinal column and spinal cord.", [["spinal column", "ANATOMY", 245, 258], ["spinal cord", "ANATOMY", 263, 274], ["spinal column", "MULTI-TISSUE_STRUCTURE", 245, 258], ["spinal cord", "ORGAN", 263, 274], ["Three recurrent terminal articles", "PROBLEM", 0, 33], ["the SCIWORA hypothesis", "PROBLEM", 166, 188], ["the differential stretch between the spinal column and spinal cord", "PROBLEM", 208, 274], ["recurrent", "OBSERVATION_MODIFIER", 6, 15], ["terminal", "OBSERVATION_MODIFIER", 16, 24], ["articles", "OBSERVATION", 25, 33], ["spinal column", "ANATOMY", 245, 258], ["spinal cord", "ANATOMY", 263, 274]]], ["Rather, it starts with the assumption of locality and then infers SCIWORA when a certain radiologic modality was not sensitive enough to detect the explanation -or- non-locality was not recognized while the explanation was present all along.", [["SCIWORA", "DNA", 66, 73]]], ["In point of fact, in his original 1982 article, Pang describes a case of L2 flexion-distraction lap-belt fracture and a T6 SCIWORA [1].", [["fracture", "DISEASE", 105, 113], ["L2 flexion-distraction lap", "TREATMENT", 73, 99], ["belt fracture", "PROBLEM", 100, 113], ["L2 flexion", "ANATOMY", 73, 83], ["distraction lap", "OBSERVATION", 84, 99], ["fracture", "OBSERVATION", 105, 113], ["T6", "ANATOMY", 120, 122]]], ["This L2,T6 mismatch distraction injury was likely similar to our case 5 (L2,T9 mismatch), i.e., a non-local SCI above the spinal column uncoupling.", [["spinal column", "ANATOMY", 122, 135], ["SCI", "DISEASE", 108, 111], ["T6 mismatch distraction injury", "PROBLEM", 8, 38], ["L2,T9 mismatch", "TREATMENT", 73, 87], ["a non-local SCI above the spinal column uncoupling", "PROBLEM", 96, 146], ["L2", "ANATOMY", 5, 7], ["T6", "ANATOMY", 8, 10], ["mismatch distraction", "OBSERVATION", 11, 31], ["T9", "ANATOMY", 76, 78], ["non-local SCI", "OBSERVATION", 98, 111], ["spinal column", "ANATOMY", 122, 135]]], ["If correct, then the L2,T6 case was neither a SCIWORA (nor a SCIWONA) since the entire column injury causing the SCI was visible on CT and MRI, just unrecognized for non-locality.", [["SCI", "DISEASE", 113, 116], ["the entire column injury", "PROBLEM", 76, 100], ["the SCI", "PROBLEM", 109, 116], ["CT", "TEST", 132, 134], ["MRI", "TEST", 139, 142], ["non-locality", "PROBLEM", 166, 178], ["L2", "ANATOMY", 21, 23], ["T6", "ANATOMY", 24, 26], ["column", "OBSERVATION_MODIFIER", 87, 93], ["injury", "OBSERVATION", 94, 100], ["SCI", "ANATOMY", 113, 116]]], ["There are likely many cases mislabeled throughout the literature and we wonder if difficult to accept theories about perfectly self-reducing spinal dislocation are not the product of the assumption of local effects only.", [["spinal", "ANATOMY", 141, 147], ["dislocation", "DISEASE", 148, 159], ["spinal", "ORGAN", 141, 147], ["perfectly self-reducing spinal dislocation", "PROBLEM", 117, 159], ["likely", "UNCERTAINTY", 10, 16], ["many", "OBSERVATION_MODIFIER", 17, 21], ["cases", "OBSERVATION", 22, 27], ["spinal", "ANATOMY", 141, 147], ["dislocation", "OBSERVATION", 148, 159], ["local effects", "OBSERVATION", 201, 214]]], ["Of special note, we commonly receive adults with acquired degenerative stenosis and limited space available for the cord who have sustained a hyperextension SCI after a simple fall.", [["cord", "ANATOMY", 116, 120], ["degenerative stenosis", "DISEASE", 58, 79], ["SCI", "DISEASE", 157, 160], ["cord", "ORGAN", 116, 120], ["acquired degenerative stenosis", "PROBLEM", 49, 79], ["a hyperextension SCI", "PROBLEM", 140, 160], ["a simple fall", "PROBLEM", 167, 180], ["degenerative", "OBSERVATION_MODIFIER", 58, 70], ["stenosis", "OBSERVATION", 71, 79], ["cord", "ANATOMY", 116, 120], ["hyperextension SCI", "OBSERVATION", 142, 160]]], ["Since there is often no spinal column disruption, by definition, this may be called a SCIWORA or SCIWONA.", [["spinal column", "ANATOMY", 24, 37], ["spinal column disruption", "PROBLEM", 24, 48], ["no", "UNCERTAINTY", 21, 23], ["spinal", "ANATOMY", 24, 30], ["column disruption", "OBSERVATION", 31, 48]]], ["The acquired local stenosis and sudden ligamentum flavum buckling at the extreme of physiologic motion during the fall is the culprit and has long been known [17].", [["ligamentum flavum", "ANATOMY", 39, 56], ["stenosis", "DISEASE", 19, 27], ["ligamentum flavum", "MULTI-TISSUE_STRUCTURE", 39, 56], ["The acquired local stenosis", "PROBLEM", 0, 27], ["sudden ligamentum flavum buckling", "PROBLEM", 32, 65], ["the fall", "PROBLEM", 110, 118], ["local", "OBSERVATION_MODIFIER", 13, 18], ["stenosis", "OBSERVATION", 19, 27], ["sudden", "OBSERVATION_MODIFIER", 32, 38], ["ligamentum flavum", "ANATOMY", 39, 56], ["buckling", "OBSERVATION", 57, 65], ["extreme", "OBSERVATION_MODIFIER", 73, 80], ["physiologic motion", "OBSERVATION", 84, 102]]], ["Again, it is a satisfactory explanation to guide treatment that is desired.", [["treatment", "TREATMENT", 49, 58]]], ["Though SCIWORA is not disputed absolutely, non-local distraction injury will often suffice once locality is relinquished.", [["non-local distraction injury", "PROBLEM", 43, 71], ["not disputed", "UNCERTAINTY", 18, 30], ["non-local distraction", "OBSERVATION", 43, 64]]], ["For alleged remaining SCIWORAs, an adequate explanation, not a diagnostic label, is wanting.DiscussionThe clinical concern of a SCIWORA misdiagnosis is inappropriate management like over-bracing or under-operating including unnecessary cost, risk, or detriment in terms of pressure ulcer risk or encumbrance to rehabilitation of a SCI patient.", [["ulcer", "ANATOMY", 282, 287], ["ulcer", "DISEASE", 282, 287], ["SCI", "DISEASE", 331, 334], ["ulcer", "PATHOLOGICAL_FORMATION", 282, 287], ["patient", "ORGANISM", 335, 342], ["patient", "SPECIES", 335, 342], ["a SCIWORA misdiagnosis", "PROBLEM", 126, 148], ["inappropriate management", "TREATMENT", 152, 176], ["bracing", "TREATMENT", 187, 194], ["pressure ulcer risk", "PROBLEM", 273, 292], ["ulcer", "OBSERVATION", 282, 287]]], ["Three of our six cases had SCI below the spinal column injury with risk of subsequent higher level SCI if the unstable level were not treated appropriately (three cases had complete SCI above the column injury, so neurologic risk was less critical except had they been incomplete).", [["spinal column", "ANATOMY", 41, 54], ["neurologic", "ANATOMY", 214, 224], ["SCI", "DISEASE", 27, 30], ["SCI", "DISEASE", 99, 102], ["SCI", "DISEASE", 182, 185], ["spinal column", "MULTI-TISSUE_STRUCTURE", 41, 54], ["SCI", "PROBLEM", 27, 30], ["the spinal column injury", "PROBLEM", 37, 61], ["subsequent higher level SCI", "PROBLEM", 75, 102], ["complete SCI", "PROBLEM", 173, 185], ["the column injury", "PROBLEM", 192, 209], ["neurologic risk", "PROBLEM", 214, 229], ["spinal column", "ANATOMY", 41, 54], ["column", "ANATOMY", 196, 202]]], ["Misunderstanding the injuries led to over-bracing and additional cost.", [["injuries", "DISEASE", 21, 29], ["the injuries", "PROBLEM", 17, 29], ["bracing", "TREATMENT", 42, 49], ["injuries", "OBSERVATION", 21, 29]]], ["An additional consideration is the occasional recurrence of SCIWORA reported [23, 25].", [["SCIWORA", "DISEASE", 60, 67], ["occasional", "OBSERVATION_MODIFIER", 35, 45], ["recurrence", "OBSERVATION", 46, 56]]], ["As only a peripheral theory, recurrence might signal non-locality.", [["a peripheral theory", "PROBLEM", 8, 27], ["recurrence might signal non-locality", "PROBLEM", 29, 65], ["peripheral", "ANATOMY_MODIFIER", 10, 20], ["recurrence", "OBSERVATION", 29, 39], ["non-locality", "OBSERVATION_MODIFIER", 53, 65]]], ["If a distant spinal column injury was not treated, and did not heal, then ongoing instability may be the cause for SCI recurrence, especially in children with daily falls and play.", [["spinal column", "ANATOMY", 13, 26], ["SCI", "DISEASE", 115, 118], ["falls", "DISEASE", 165, 170], ["spinal column", "MULTI-TISSUE_STRUCTURE", 13, 26], ["children", "ORGANISM", 145, 153], ["children", "SPECIES", 145, 153], ["a distant spinal column injury", "PROBLEM", 3, 33], ["ongoing instability", "PROBLEM", 74, 93], ["SCI recurrence", "PROBLEM", 115, 129], ["distant", "OBSERVATION_MODIFIER", 5, 12], ["spinal", "ANATOMY", 13, 19], ["column injury", "OBSERVATION", 20, 33], ["recurrence", "OBSERVATION", 119, 129]]], ["Treatment of non-local injuries might prevent many SCIWORA recurrences.DiscussionAs a point of final clarification, there are a myriad of terms which have emerged around SCIWORA, including SCIWORET (SCI without radiographic evidence of trauma), SCIWOCTET (SCI without CT evidence of trauma) and SCIWONA which are variably applied to pediatric and adult patients [2, 27, 28].", [["injuries", "DISEASE", 23, 31], ["SCIWORA", "DISEASE", 51, 58], ["SCI", "DISEASE", 199, 202], ["trauma", "DISEASE", 236, 242], ["SCI", "DISEASE", 256, 259], ["trauma", "DISEASE", 283, 289], ["patients", "ORGANISM", 353, 361], ["patients", "SPECIES", 353, 361], ["non-local injuries", "PROBLEM", 13, 31], ["many SCIWORA recurrences", "PROBLEM", 46, 70], ["trauma", "PROBLEM", 236, 242], ["SCIWOCTET (SCI", "PROBLEM", 245, 259], ["trauma", "PROBLEM", 283, 289], ["SCIWONA", "TREATMENT", 295, 302], ["non-local injuries", "OBSERVATION", 13, 31], ["many", "OBSERVATION_MODIFIER", 46, 50], ["SCIWORA", "OBSERVATION_MODIFIER", 51, 58], ["recurrences", "OBSERVATION", 59, 70]]], ["These terms appear misguided when applied to the explanation for a SCI.", [["SCI", "DISEASE", 67, 70], ["a SCI", "PROBLEM", 65, 70], ["misguided", "OBSERVATION", 19, 28], ["SCI", "OBSERVATION", 67, 70]]], ["Rather, the studies using these terms are assessing the sensitivity of various individual radiographic modalities (e.g., static radiographs, CT, MRI, dynamic radiographs) or their combination in determining the explanation or cause for the SCI.", [["SCI", "DISEASE", 240, 243], ["the studies", "TEST", 8, 19], ["static radiographs", "TEST", 121, 139], ["CT", "TEST", 141, 143], ["MRI", "TEST", 145, 148], ["dynamic radiographs", "TEST", 150, 169], ["the SCI", "PROBLEM", 236, 243], ["SCI", "OBSERVATION", 240, 243]]], ["In some cases, the explanation is a genuine spinal column injury, in others it is ligamentum flavum buckling in the setting of degenerative stenosis, or a large disc herniation, or even underlying congenital or pathologic states of the spinal column.", [["spinal column", "ANATOMY", 44, 57], ["ligamentum flavum", "ANATOMY", 82, 99], ["disc", "ANATOMY", 161, 165], ["spinal column", "ANATOMY", 236, 249], ["ligamentum flavum buckling", "DISEASE", 82, 108], ["degenerative stenosis", "DISEASE", 127, 148], ["disc herniation", "DISEASE", 161, 176], ["spinal column", "MULTI-TISSUE_STRUCTURE", 236, 249], ["a genuine spinal column injury", "PROBLEM", 34, 64], ["ligamentum flavum buckling", "PROBLEM", 82, 108], ["degenerative stenosis", "PROBLEM", 127, 148], ["a large disc herniation", "PROBLEM", 153, 176], ["underlying congenital or pathologic states of the spinal column", "PROBLEM", 186, 249], ["spinal", "ANATOMY", 44, 50], ["column injury", "OBSERVATION", 51, 64], ["ligamentum flavum", "ANATOMY", 82, 99], ["buckling", "OBSERVATION", 100, 108], ["degenerative", "OBSERVATION_MODIFIER", 127, 139], ["stenosis", "OBSERVATION", 140, 148], ["large", "OBSERVATION_MODIFIER", 155, 160], ["disc", "ANATOMY", 161, 165], ["herniation", "OBSERVATION", 166, 176], ["congenital", "OBSERVATION", 197, 207], ["pathologic", "OBSERVATION", 211, 221], ["spinal", "ANATOMY", 236, 242], ["column", "ANATOMY_MODIFIER", 243, 249]]], ["In this way, these studies are useful to help reduce over-utilization of additional radiologic studies while understanding the limits of detection for any one modality in the evaluation of SCI patients.", [["SCI", "DISEASE", 189, 192], ["patients", "ORGANISM", 193, 201], ["patients", "SPECIES", 193, 201], ["these studies", "TEST", 13, 26], ["additional radiologic studies", "TEST", 73, 102], ["the evaluation", "TEST", 171, 185]]], ["However, the problem is the SCI patients who seemingly have no explanation on any of our radiologic studies.", [["SCI", "DISEASE", 28, 31], ["patients", "ORGANISM", 32, 40], ["patients", "SPECIES", 32, 40], ["our radiologic studies", "TEST", 85, 107]]], ["To these, the SCIWORA hypothesis about the differential stretch between the spinal column and spinal cord, especially in pediatric patients, has formed and embedded itself in the literature, never having been empirically verified, but merely inferred from various case series where a certain radiologic modality was not sensitive enough to detect the explanation -or- non-locality was not recognized while the explanation was present all along.DiscussionTo further complicate terminology, some authors have included the presence, absence or type of findings of cord damage on the MRI as part of the diagnostic criteria for SCIWORA [2, 8, 21].", [["spinal column", "ANATOMY", 76, 89], ["spinal cord", "ANATOMY", 94, 105], ["cord", "ANATOMY", 561, 565], ["cord damage", "DISEASE", 561, 572], ["spinal column", "MULTI-TISSUE_STRUCTURE", 76, 89], ["spinal cord", "ORGAN", 94, 105], ["patients", "ORGANISM", 131, 139], ["cord", "TISSUE", 561, 565], ["patients", "SPECIES", 131, 139], ["the SCIWORA hypothesis", "PROBLEM", 10, 32], ["the differential stretch between the spinal column and spinal cord", "PROBLEM", 39, 105], ["cord damage", "PROBLEM", 561, 572], ["the MRI", "TEST", 576, 583], ["differential stretch", "OBSERVATION", 43, 63], ["spinal column", "ANATOMY", 76, 89], ["spinal cord", "ANATOMY", 94, 105], ["cord", "ANATOMY", 561, 565], ["damage", "OBSERVATION", 566, 572]]], ["Again, this is not relevant as what needs to be explained is not cord damage as seen on MRI, but why the clinical cord syndrome exists at all after a trauma, whether seen on MRI or not.", [["cord", "ANATOMY", 65, 69], ["cord", "ANATOMY", 114, 118], ["cord damage", "DISEASE", 65, 76], ["cord syndrome", "DISEASE", 114, 127], ["trauma", "DISEASE", 150, 156], ["cord", "TISSUE", 65, 69], ["cord", "ORGAN", 114, 118], ["cord damage", "PROBLEM", 65, 76], ["MRI", "TEST", 88, 91], ["the clinical cord syndrome", "PROBLEM", 101, 127], ["a trauma", "PROBLEM", 148, 156], ["MRI", "TEST", 174, 177], ["cord", "ANATOMY", 65, 69], ["damage", "OBSERVATION", 70, 76], ["cord", "ANATOMY", 114, 118], ["syndrome", "OBSERVATION", 119, 127]]], ["In case 1 that we present, initial MRI did not reveal cord damage at T2 even though the patient was clinically a complete T2 paraplegic.", [["cord", "ANATOMY", 54, 58], ["cord damage", "DISEASE", 54, 65], ["cord", "TISSUE", 54, 58], ["patient", "ORGANISM", 88, 95], ["patient", "SPECIES", 88, 95], ["initial MRI", "TEST", 27, 38], ["cord damage at T2", "PROBLEM", 54, 71], ["a complete T2 paraplegic", "PROBLEM", 111, 135], ["cord", "ANATOMY", 54, 58], ["damage", "OBSERVATION", 59, 65]]], ["Follow-up MRI at 2 weeks revealed abundant cord damage and he remained a T2 complete paraplegic.", [["cord", "ANATOMY", 43, 47], ["cord damage", "DISEASE", 43, 54], ["cord", "TISSUE", 43, 47], ["Follow-up MRI", "TEST", 0, 13], ["abundant cord damage", "PROBLEM", 34, 54], ["a T2 complete paraplegic", "PROBLEM", 71, 95], ["abundant", "OBSERVATION_MODIFIER", 34, 42], ["cord", "ANATOMY", 43, 47], ["damage", "OBSERVATION", 48, 54], ["paraplegic", "OBSERVATION", 85, 95]]], ["What was lacking was the explanation for the cord injury which was present as a non-local and radiologically evident spinal column disruption all along.", [["cord", "ANATOMY", 45, 49], ["spinal column", "ANATOMY", 117, 130], ["cord injury", "DISEASE", 45, 56], ["cord", "TISSUE", 45, 49], ["the cord injury", "PROBLEM", 41, 56], ["a non-local and radiologically evident spinal column disruption", "PROBLEM", 78, 141], ["cord", "ANATOMY", 45, 49], ["injury", "OBSERVATION", 50, 56], ["spinal", "ANATOMY", 117, 123], ["column disruption", "OBSERVATION", 124, 141]]], ["Attempts to classify SCI recovery based on MRI cord signal findings are useful, but have no bearing on the cause of the injury in the first place or the SCIWORA hypothesis itself.DiscussionThis paper has some important limitations, though we submit that once one agrees that even a single legitimate case of non-locality has occurred, then its real existence is verified.", [["cord", "ANATOMY", 47, 51], ["SCI", "DISEASE", 21, 24], ["non-locality", "DISEASE", 308, 320], ["cord", "ORGAN", 47, 51], ["SCI recovery", "TEST", 21, 33], ["MRI cord signal findings", "TEST", 43, 67], ["the injury", "PROBLEM", 116, 126], ["non-locality", "PROBLEM", 308, 320], ["cord", "ANATOMY", 47, 51], ["injury", "OBSERVATION", 120, 126]]], ["It may be limited by the initial 10-year time frame selected, the keywords used, or the degree to which the authors were able to read, trace, and adequately survey, interpret, and represent the hundreds of articles examined in reference to the claims under scrutiny.DiscussionIn conclusion, SCI may occur at a level noncontiguous with the causal spinal column injury occurring via a distraction mechanism, what we call non-locality.", [["spinal column", "ANATOMY", 346, 359], ["SCI", "DISEASE", 291, 294], ["spinal column", "MULTI-TISSUE_STRUCTURE", 346, 359], ["the causal spinal column injury", "PROBLEM", 335, 366], ["a distraction mechanism", "TREATMENT", 381, 404], ["spinal column", "ANATOMY", 346, 359]]], ["Consideration of these injuries may prevent unnecessary or incorrect bracing or treatment for presumed SCIWORA instability at the level of SCI, sparing additional cost, risk, and discomfort while fostering a proper search for (including complete spinal imaging), and treatment of, the actual causative spinal column injury which may exist elsewhere.", [["spinal", "ANATOMY", 246, 252], ["spinal column", "ANATOMY", 302, 315], ["injuries", "DISEASE", 23, 31], ["SCI", "DISEASE", 139, 142], ["spinal column", "MULTI-TISSUE_STRUCTURE", 302, 315], ["these injuries", "PROBLEM", 17, 31], ["incorrect bracing", "TREATMENT", 59, 76], ["treatment", "TREATMENT", 80, 89], ["SCIWORA instability", "PROBLEM", 103, 122], ["SCI", "PROBLEM", 139, 142], ["discomfort", "PROBLEM", 179, 189], ["complete spinal imaging", "TEST", 237, 260], ["treatment", "TREATMENT", 267, 276], ["the actual causative spinal column injury", "PROBLEM", 281, 322], ["SCI", "ANATOMY", 139, 142], ["spinal", "ANATOMY", 302, 308], ["column injury", "OBSERVATION", 309, 322]]], ["This awareness may facilitate our search for adequate explanations for difficult to understand cases rather than mere or mysterious assignment as spinal cord injuries without (neuro)-radiographic abnormality.", [["spinal cord", "ANATOMY", 146, 157], ["cord injuries", "DISEASE", 153, 166], ["cord", "ORGAN", 153, 157], ["spinal cord injuries", "PROBLEM", 146, 166], ["radiographic abnormality", "PROBLEM", 183, 207], ["spinal cord", "ANATOMY", 146, 157]]]], "PMC7175829": [["EinleitungDas Bundesland Nordrhein-Westfalen (NRW) ist von der COVID-19-Pandemie schwer betroffen.", [["EinleitungDas Bundesland Nordrhein-Westfalen (NRW) ist von der COVID-19-Pandemie schwer betroffen", "SPECIES", 0, 97], ["EinleitungDas", "TEST", 0, 13], ["Westfalen (NRW)", "TREATMENT", 35, 50], ["COVID", "TEST", 63, 68], ["Pandemie schwer betroffen", "TREATMENT", 72, 97]]], ["In der Folgezeit wurde NRW ein Hotspot f\u00fcr COVID-19 und war bis vor wenigen Tagen das Bundesland mit den meisten gemeldeten F\u00e4llen [1].", [["COVID", "TEST", 43, 48]]], ["Die COVID-19-Pandemie stellt insbesondere die innerklinische Akut- und Notfallmedizin vor neue, bisher ungekannte Herausforderungen.", [["Die COVID-19-Pandemie stellt insbesondere die innerklinische Akut- und Notfallmedizin vor neue", "SPECIES", 0, 94], ["COVID", "TEST", 4, 9], ["Akut", "TEST", 61, 65]]], ["Die Dynamik der Entwicklung und die Anpassung der Strukturen in der Patientenversorgung sind f\u00fcr Notaufnahmen und Intensivstationen weltweit eine neue Erfahrung [2].", [["Notaufnahmen", "TREATMENT", 97, 109]]], ["Im Folgenden m\u00f6chten wir chronologisch \u00fcber unsere bisherigen Erfahrungen mit dem neuen Coronavirus SARS-CoV\u20112 (\u201esevere acute respiratory syndrome coronavirus 2\u201c) und \u00fcber die daraus resultierenden Ma\u00dfnahmen der interdisziplin\u00e4ren Notaufnahme des Universit\u00e4tsklinikums M\u00fcnster (UKM) berichten.EinleitungDie Notaufnahme wurde erstmalig Ende Januar mit dem Thema SARS-CoV\u20112 konfrontiert.", [["respiratory syndrome coronavirus", "DISEASE", 126, 158], ["Im Folgenden m\u00f6chten wir chronologisch \u00fcber unsere bisherigen Erfahrungen mit dem neuen Coronavirus SARS-CoV\u20112 (\u201esevere acute respiratory syndrome coronavirus 2\u201c) und \u00fcber die daraus resultierenden Ma\u00dfnahmen der interdisziplin\u00e4ren Notaufnahme des Universit\u00e4tsklinikums M\u00fcnster (UKM) berichten", "SPECIES", 0, 292], ["EinleitungDie Notaufnahme wurde erstmalig Ende Januar mit dem Thema SARS-CoV\u20112 konfrontiert", "SPECIES", 293, 384], ["chronologisch", "TEST", 25, 38], ["Coronavirus SARS", "PROBLEM", 88, 104], ["acute respiratory syndrome coronavirus", "PROBLEM", 120, 158], ["EinleitungDie", "TEST", 293, 306]]], ["Am 23.01.2020 meldete sich eine Patientin nach R\u00fcckkehr von einer Dienstreise nach China telefonisch beim diensthabenden Internisten und schilderte Husten, Abgeschlagenheit und Gliederschmerzen \u2013 letztlich war SARS-CoV\u20112 jedoch nicht nachweisbar.", [["China telefonisch beim diensthabenden Internisten und schilderte Husten, Abgeschlagenheit und Gliederschmerzen \u2013 letztlich war SARS-CoV\u20112 jedoch nicht nachweisbar", "SPECIES", 83, 245], ["meldete sich", "TREATMENT", 14, 26]]], ["Am Folgetag finalisierten wir eine erste Verfahrensanweisung zum Transport von Blutproben, Hygienema\u00dfnahmen und Isolationsm\u00f6glichkeiten von fraglich infizierten Reiser\u00fcckkehrern.", [["Am Folgetag finalisierten wir eine erste Verfahrensanweisung zum Transport von Blutproben, Hygienema\u00dfnahmen und Isolationsm\u00f6glichkeiten von fraglich infizierten Reiser\u00fcckkehrern", "SPECIES", 0, 177], ["Hygienema\u00dfnahmen", "TREATMENT", 91, 107]]], ["Zeitgleich wurde im Notaufnahmeteam ein erstes Flussschema zum Umgang mit SARS-CoV-2-Verdachtsf\u00e4llen kommuniziert.", [["Zeitgleich wurde im Notaufnahmeteam ein erstes Flussschema zum Umgang mit SARS-CoV-2-Verdachtsf\u00e4llen kommuniziert", "SPECIES", 0, 113], ["Zeitgleich wurde", "TREATMENT", 0, 16], ["CoV", "TEST", 79, 82], ["Verdachtsf\u00e4llen kommuniziert", "TREATMENT", 85, 113]]], ["Ferner etablierten wir einen UKM-internen E\u2011Mail-Verteiler zu SARS-CoV\u20112, um einen reibungslosen Informationsfluss zwischen den Fachdisziplinen Notfallaufnahme, Virologie, Hygiene und Mikrobiologie zu gew\u00e4hrleisten und insbesondere die Meldung von klinischen Verdachtsf\u00e4llen als auch labordiagnostisch best\u00e4tigter F\u00e4lle beim Gesundheitsamt sicherzustellen.", [["Ferner etablierten wir einen UKM-internen E\u2011Mail-Verteiler zu SARS-CoV\u20112, um einen reibungslosen Informationsfluss zwischen den Fachdisziplinen Notfallaufnahme, Virologie, Hygiene und Mikrobiologie zu gew\u00e4hrleisten und insbesondere die Meldung von klinischen Verdachtsf\u00e4llen als auch labordiagnostisch best\u00e4tigter F\u00e4lle beim Gesundheitsamt sicherzustellen", "SPECIES", 0, 355]]], ["Vermerkt wurden Name des Patienten, Symptome, Kontaktdaten und die Anamnese, die den Abstrich begr\u00fcndete.EinleitungAb dem 01.02.2020 war dann eine PCR-Testung auf SARS-CoV\u20112 in der Virologie des UKM verf\u00fcgbar, nachdem Positivkontrollen aus der Charit\u00e9 zur Etablierung beigebracht wurden.", [["EinleitungAb dem 01.02.2020 war dann eine PCR-Testung auf SARS-CoV\u20112 in der Virologie des UKM verf\u00fcgbar, nachdem Positivkontrollen aus der Charit\u00e9 zur Etablierung beigebracht wurden", "SPECIES", 105, 286], ["EinleitungAb dem", "TEST", 105, 121], ["eine PCR", "TEST", 142, 150], ["auf SARS", "TEST", 159, 167]]], ["Verdachtsf\u00e4lle (zu diesem Zeitpunkt ausschlie\u00dflich China-R\u00fcckkehrer [3]) wurden zun\u00e4chst ab dem 03.02.2020 in der RTW-Halle der Notaufnahme durch das ge\u00f6ffnete Autofenster ersteingesch\u00e4tzt, abgestrichen und \u2013 wenn vertretbar \u2013 unmittelbar in die h\u00e4usliche Quarant\u00e4ne geschickt.", [["Verdachtsf\u00e4lle (zu diesem Zeitpunkt ausschlie\u00dflich China-R\u00fcckkehrer [3]) wurden zun\u00e4chst ab dem 03.02.2020 in der RTW-Halle der Notaufnahme durch das ge\u00f6ffnete Autofenster ersteingesch\u00e4tzt, abgestrichen und \u2013 wenn vertretbar \u2013 unmittelbar in die h\u00e4usliche Quarant\u00e4ne geschickt", "SPECIES", 0, 276], ["zun\u00e4chst ab dem", "TREATMENT", 80, 95]]], ["3 Wochen bei Reiser\u00fcckkehrern aus China machbar und praktikabel.", [["Wochen bei Reiser\u00fcckkehrern aus China machbar und praktikabel", "SPECIES", 2, 63]]], ["Mit steigenden Fallzahlen von COVID-19-Patienten in Norditalien [4, 5] nach dem 21.02. und dem beginnenden COVID-19-Ausbruch im Kreis Heinsberg (NRW) kam es zu einem deutlichen Anstieg der Patientenvorstellungen zur Abkl\u00e4rung einer m\u00f6glichen SARS-CoV-2-Infektion.", [["Mit steigenden Fallzahlen von COVID-19-Patienten", "SPECIES", 0, 48], ["und dem beginnenden COVID-19-Ausbruch im Kreis Heinsberg (NRW) kam es zu einem deutlichen Anstieg der Patientenvorstellungen zur Abkl\u00e4rung einer m\u00f6glichen SARS-CoV", "SPECIES", 87, 250], ["COVID", "TEST", 107, 112], ["Infektion", "PROBLEM", 253, 262]]], ["Parallel dazu erschwerten unz\u00e4hlige Anrufe besorgter B\u00fcrger auf dem Telefon des diensthabenden Internisten die Patientenversorgung erheblich.", [["dazu erschwerten unz\u00e4hlige Anrufe besorgter B\u00fcrger auf dem Telefon des diensthabenden Internisten die Patientenversorgung erheblich", "SPECIES", 9, 140]]], ["Hierbei standen allgemeine Fragen zu SARS-CoV\u20112, Verhaltensweisen, aber auch Fragen zur Diagnostik im Vordergrund.", [["Hierbei standen allgemeine", "TREATMENT", 0, 26]]], ["Zum Schutz des Personals erfolgt die Kommunikation mit m\u00f6glichen Infizierten \u00fcber eine Gegensprechanlage bei geschlossenem Fenster.", [["Zum Schutz des Personals erfolgt die Kommunikation mit m\u00f6glichen Infizierten \u00fcber eine Gegensprechanlage bei geschlossenem Fenster", "SPECIES", 0, 130], ["Zum Schutz des", "TREATMENT", 0, 14]]], ["Diese orientiert sich an den g\u00fcltigen Empfehlungen des Robert Koch-Instituts (RKI) in Form eines adaptierten Flussschemas (Abb.", [["Diese orientiert sich an den g\u00fcltigen Empfehlungen des Robert Koch-Instituts (RKI)", "SPECIES", 0, 82]]], ["Zur Dokumentation wurde im Krankenhausinformationssystem (KIS; in unseren Fall AGFA Orbis, Agfa HealthCare GmbH, Bonn, Deutschland) das \u201eCorona-Anamnese-MS\u201c(CAMS\u2011)Formular etabliert.", [["Zur Dokumentation wurde im Krankenhausinformationssystem (KIS; in unseren Fall AGFA Orbis, Agfa HealthCare GmbH, Bonn, Deutschland) das \u201eCorona-Anamnese-MS\u201c(CAMS\u2011)Formular etabliert", "SPECIES", 0, 181], ["KIS", "TEST", 58, 61], ["Orbis", "TEST", 84, 89], ["Corona", "TEST", 137, 143]]], ["Dieses dient als zentrales Kommunikationsinstrument zwischen der Virologie, der Hygiene und dem \u00e4rztlichen Personal der Testungsstelle.", [["Dieses dient als zentrales Kommunikationsinstrument zwischen der Virologie, der Hygiene und dem \u00e4rztlichen Personal der Testungsstelle", "SPECIES", 0, 134]]], ["Zudem erm\u00f6glicht es die Dokumentation der telefonischen Befundmitteilung und dient schlie\u00dflich als Kurzarztbrief (Abb.", [["Zudem erm\u00f6glicht es die Dokumentation der telefonischen Befundmitteilung und dient schlie\u00dflich als Kurzarztbrief", "SPECIES", 0, 112], ["Zudem erm\u00f6glicht", "TREATMENT", 0, 16]]], ["Der Abstrich wurde au\u00dferhalb des Containers durch eine Pflegekraft in entsprechender Schutzkleidung (Schutzkittel, Einmalhandschuhe, FFP2-Maske und Schutzbrille) durchgef\u00fchrt.", [["Der Abstrich wurde au\u00dferhalb des", "TREATMENT", 0, 32], ["FFP2", "TREATMENT", 133, 137]]], ["Aufgrund der sehr fr\u00fchzeitig verf\u00fcgbaren Testung konnten wir gl\u00fccklicherweise ein Welle von 35 positiven Ischgl-R\u00fcckreisenden abfangen, die alle einen Super-spreader-Ph\u00e4notyp zeigten [6].Etablierung einer Coronateststelle und -hotlineAufgrund der Vielzahl der Anrufe im Coronacontainer konnte nach einem Aufruf durch den Studiendekan der Medizinischen Fakult\u00e4t M\u00fcnster kurzfristig eine studentische Telefonhotline aufgebaut werden.", [["Aufgrund der sehr fr\u00fchzeitig verf\u00fcgbaren Testung konnten wir gl\u00fccklicherweise ein Welle von 35 positiven Ischgl-R\u00fcckreisenden abfangen, die alle einen Super-spreader-Ph\u00e4notyp zeigten", "SPECIES", 0, 182], ["Aufgrund", "TEST", 0, 8], ["Testung", "TEST", 41, 48], ["konnten", "TEST", 49, 56], ["Ischgl", "TEST", 105, 111], ["Aufgrund der Vielzahl der Anrufe im Coronacontainer konnte nach einem", "TREATMENT", 234, 303]]], ["Nach z\u00fcgiger Einarbeitung, t\u00e4glich aktualisierten Flussschemata sowie engmaschiger \u00e4rztlicher Betreuung standen den Anrufern vor\u00fcbergehend bis zu 3 Medizinstudierende gleichzeitig (2-Schicht-System) in der Zeit von 08.00\u201320.00 Uhr an 7 Tagen in der Woche kompetent zur Verf\u00fcgung (Abb.", [["Nach z\u00fcgiger", "TREATMENT", 0, 12], ["t\u00e4glich aktualisierten Flussschemata sowie engmaschiger", "TREATMENT", 27, 82]]], ["3).Etablierung einer Coronateststelle und -hotlineIn Erwartung einer weiteren Zunahme von Verdachtsf\u00e4llen erfolgte am 15.03. der Entschluss zur Etablierung eines 3\u2011spurigen Drive-in-Container-Parks mit deutlich besserer Zuwegung (Abb.", [["der Entschluss zur Etablierung eines 3\u2011spurigen Drive-in-Container-Parks mit deutlich besserer Zuwegung", "SPECIES", 125, 228], ["der Entschluss zur Etablierung eines", "TREATMENT", 125, 161]]], ["Die Sondierung der Abstrichindikation, Terminierung und Einweisung in das Drive-in-Konzept erfolgt durch die Studenten der Hotline.Etablierung einer Coronateststelle und -hotlineMit Etablierung der SARS-CoV-2-PCR wurde fortw\u00e4hrend die Logistik des Probentransfers zum (dezentral gelegenen) Institut f\u00fcr Virologie optimiert.", [["Die Sondierung der Abstrichindikation, Terminierung und Einweisung in das Drive-in-Konzept erfolgt durch die Studenten der Hotline", "SPECIES", 0, 130], ["Etablierung einer Coronateststelle und -hotlineMit Etablierung der SARS-CoV-2-PCR wurde fortw\u00e4hrend die Logistik des Probentransfers zum (dezentral gelegenen) Institut f\u00fcr Virologie optimiert", "SPECIES", 131, 322], ["Etablierung", "TEST", 131, 142], ["der SARS", "TEST", 194, 202], ["CoV", "TEST", 203, 206], ["PCR wurde", "TREATMENT", 209, 218], ["zum (dezentral gelegenen", "TREATMENT", 264, 288]]], ["Eine 2\u2011st\u00fcndliche Abholung und zahlreiche kleine Verbesserungen (\u201efast track\u201c f\u00fcr eilige Proben) erm\u00f6glichen derzeit eine realistische \u201eturnaround time\u201c von ca.", [["Eine 2\u2011st\u00fcndliche Abholung", "TREATMENT", 0, 26]]], ["Ebenfalls durch das Containerteam erfolgt die telefonische Benachrichtigung der Patienten sp\u00e4testens am Folgetag, auch am Wochenende.Diagnostik und Allokation von Verdachtsf\u00e4llenDurch die neu geschaffenen Anlaufstellen f\u00fcr fraglich SARS-CoV-2-Infizierte wurde die Notfallaufnahme deutlich entlastet.", [["Diagnostik", "TEST", 133, 143], ["Anlaufstellen", "TEST", 205, 218], ["fraglich SARS", "PROBLEM", 223, 236], ["CoV", "TEST", 237, 240], ["Infizierte", "TREATMENT", 243, 253]]], ["Die B\u00fcrger verhielten sich erstaunlich diszipliniert und besch\u00e4ftigten die Notaufnahme nicht mit Krankheitsbildern, die fach\u00e4rztlich ambulant betreut werden k\u00f6nnen.", [["Die B\u00fcrger verhielten sich erstaunlich diszipliniert und besch\u00e4ftigten die Notaufnahme nicht mit Krankheitsbildern, die fach\u00e4rztlich ambulant betreut werden k\u00f6nnen", "SPECIES", 0, 163]]], ["Da die Kapazit\u00e4t der vorhandenen Isolationszimmer mit Druckumkehr daf\u00fcr nicht ausreichte, wurden zun\u00e4chst 3 regul\u00e4re Untersuchungsr\u00e4ume, im Verlauf dann 2 weitere Observationszimmer auf Unterdruck umgestellt.", [["Da die Kapazit\u00e4t", "TREATMENT", 0, 16]]], ["Hier k\u00f6nnen bisher nahezu alle h\u00f6hergradigen Verdachtsf\u00e4lle isoliert werden.", [["Hier k\u00f6nnen", "TEST", 0, 11]]], ["Um Verdachtsf\u00e4lle im KIS, wie dies bereits f\u00fcr MRSA-Besiedlung etc. \u00fcblich ist, hervorzuheben, f\u00fchrten wir eine farbliche Kennung ein.", [["MRSA", "SPECIES", 47, 51], ["MRSA", "PROBLEM", 47, 51], ["MRSA", "OBSERVATION", 47, 51]]], ["Nachdem uns anf\u00e4nglich noch ein positiver Alternativbefund (z.", [["Nachdem", "TREATMENT", 0, 7]]], ["B. Influenza A, humanes Metapneumovirus oder Respiratory Syncytial Virus) in der Point-of-Care-PCR-Diagnostik (FilmArray\u00ae Respiratory Panel, BioMerieux, N\u00fcrtingen, Deutschland) zum Verzicht auf eine SARS-CoV-2-Diagnostik ermutigte, erschien uns diese Praxis mit steigenden Zahlen positiver Ergebnisse im Coronacontainer sehr bald zu unsicher.", [["Respiratory Syncytial Virus", "DISEASE", 45, 72], ["B. Influenza A", "ORGANISM", 0, 14], ["humanes Metapneumovirus oder Respiratory Syncytial Virus", "ORGANISM", 16, 72], ["B. Influenza", "SPECIES", 0, 12], ["B. Influenza A", "SPECIES", 0, 14], ["Verzicht auf eine SARS-CoV-2-Diagnostik ermutigte, erschien uns diese Praxis mit steigenden Zahlen positiver Ergebnisse im Coronacontainer sehr bald zu unsicher", "SPECIES", 181, 341], ["Influenza", "PROBLEM", 3, 12], ["humanes Metapneumovirus", "TREATMENT", 16, 39], ["Respiratory Syncytial Virus", "PROBLEM", 45, 72], ["PCR", "TEST", 95, 98], ["Diagnostik", "TEST", 99, 109], ["FilmArray", "TEST", 111, 120], ["Respiratory Panel", "TEST", 122, 139], ["BioMerieux", "TEST", 141, 151], ["N\u00fcrtingen", "TEST", 153, 162], ["Deutschland", "TEST", 164, 175], ["zum", "TEST", 177, 180], ["Verzicht", "TEST", 181, 189], ["CoV", "TEST", 204, 207], ["Diagnostik ermutigte", "TREATMENT", 210, 230]]], ["Die vom RKI publizierten Kriterien zur Testung bei begr\u00fcndeten Verdachtsf\u00e4llen (ehemals Kriterium 1 und 2) waren f\u00fcr den regul\u00e4ren Betrieb in der Notaufnahme jedoch nicht hinreichend praktikabel, da auch Patienten ohne Reiseanamnese oder Kontakt zu einem COVID-19-Fall von den Fachabteilungen nicht ohne SARS-CoV-2-Testung auf die Stationen \u00fcbernommen wurden.", [["Die vom RKI publizierten Kriterien zur Testung bei begr\u00fcndeten Verdachtsf\u00e4llen (ehemals Kriterium 1 und 2) waren f\u00fcr den regul\u00e4ren Betrieb in der Notaufnahme jedoch nicht hinreichend praktikabel, da auch Patienten ohne Reiseanamnese oder Kontakt zu einem COVID-19-Fall von den Fachabteilungen nicht ohne SARS-CoV-2-Testung auf die Stationen \u00fcbernommen wurden", "SPECIES", 0, 358], ["Die", "PROBLEM", 0, 3], ["Kriterien zur Testung bei begr\u00fcndeten Verdachtsf\u00e4llen (ehemals Kriterium", "TREATMENT", 25, 97], ["Reiseanamnese", "TEST", 219, 232], ["COVID", "TEST", 255, 260]]], ["Daher wurden bald alle Patienten mit Fieber oder respiratorischen Symptomen vor Hospitalisierung auf SARS-CoV\u20112 getestet und bis zum Eintreffen eines negativen Ergebnisses (formal: nicht nachweisbar, nnw) isoliert.", [["Daher wurden bald alle Patienten mit Fieber oder respiratorischen Symptomen vor Hospitalisierung auf SARS-CoV\u20112 getestet und bis zum Eintreffen eines negativen Ergebnisses (formal: nicht nachweisbar, nnw) isoliert", "SPECIES", 0, 213], ["auf SARS", "TEST", 97, 105]]], ["Zum Screening implementierten wir einen Fragebogen, der h\u00e4ufige Symptome (Fieber, Husten, Dyspnoe, Myalgien, Halsschmerzen, Diarrh\u00f6, Geruchs- und Geschmacksver\u00e4nderungen), Reiseanamnese und COVID-19-Kontakte abfragt und verpflichtend von den Triagemitarbeitern ausgef\u00fcllt wird.", [["Reiseanamnese und COVID-19-Kontakte abfragt und verpflichtend von den Triagemitarbeitern ausgef\u00fcllt wird", "SPECIES", 172, 276], ["Zum Screening", "TEST", 0, 13], ["Dyspnoe", "TREATMENT", 90, 97], ["Myalgien", "TREATMENT", 99, 107], ["Halsschmerzen", "TREATMENT", 109, 122], ["COVID", "TEST", 190, 195]]], ["Sobald eines der Kriterien positiv beantwortet wird, erfolgen umgehend eine Schutzisolation und eine PCR-Testung.Diagnostik und Allokation von Verdachtsf\u00e4llenF\u00fcr Verdachtsf\u00e4lle liegen spezielle COVID-Aufnahme-Pakete (EKG-Elektroden, Labor-Monovetten, periphere Verweilkan\u00fcle, Rachenabstrich, Blutkultuflaschen etc.) bereit, damit die Aufnahme m\u00f6glichst zeitnah en bloc und dementsprechend ressourcenschonend durchgef\u00fchrt werden kann.", [["Diagnostik", "TEST", 113, 123], ["Verdachtsf\u00e4llenF\u00fcr", "TEST", 143, 161], ["Verdachtsf\u00e4lle", "TEST", 162, 176], ["liegen", "TEST", 177, 183], ["spezielle", "TEST", 184, 193], ["COVID", "TEST", 194, 199], ["Aufnahme", "TEST", 200, 208], ["EKG", "TEST", 217, 220], ["Elektroden", "TREATMENT", 221, 231], ["Labor", "PROBLEM", 233, 238], ["Monovetten", "TREATMENT", 239, 249], ["periphere Verweilkan\u00fcle", "TREATMENT", 251, 274], ["Rachenabstrich", "TREATMENT", 276, 290], ["zeitnah en bloc", "TREATMENT", 353, 368]]], ["Zur Absch\u00e4tzung des Krankheitsverlaufs wurde im Labor-Order-Entry-Modul f\u00fcr die Notaufnahme ein Laborstandard \u201eCOVID-19 Evaluation\u201c mit Differenzialblutbild, Ferritin, Interleukin\u20116, Procalcitonin, LDH, D\u2011Dimeren und hochsensitivem Troponin hinterlegt.", [["Zur Absch\u00e4tzung des Krankheitsverlaufs wurde im Labor-Order-Entry-Modul f\u00fcr die Notaufnahme ein Laborstandard \u201eCOVID-19", "SPECIES", 0, 119], ["COVID", "TEST", 111, 116], ["Evaluation", "TEST", 120, 130], ["Ferritin", "TEST", 158, 166], ["Interleukin\u20116", "TEST", 168, 181], ["Procalcitonin", "TEST", 183, 196], ["LDH", "TEST", 198, 201], ["D\u2011Dimeren", "TEST", 203, 212], ["Troponin", "TEST", 232, 240]]], ["Auch wenn eine multinationale Validierung dieser Parameter noch aussteht, wird dieses Aufnahmelabor bei allen SARS-CoV-2-positiven Patienten sowie bei allen harten Verdachtsf\u00e4llen abgenommen [7\u20139].Diagnostik und Allokation von Verdachtsf\u00e4llenZur Vermeidung unn\u00f6tiger Verz\u00f6gerung von Diagnostik und Therapie wurden ab dem 16.03. mit allen Funktionsabteilungen intensive Gespr\u00e4che bez\u00fcglich der Gew\u00e4hrleistung einer schnellen und dennoch f\u00fcr alle Beteiligten sicheren Versorgung von COVID-19-(Verdachts\u2011)Patienten gef\u00fchrt: u. a.", [["wird dieses Aufnahmelabor bei allen SARS-CoV-2-positiven Patienten sowie bei allen harten Verdachtsf\u00e4llen abgenommen", "SPECIES", 74, 190], ["Allokation von Verdachtsf\u00e4llenZur Vermeidung unn\u00f6tiger Verz\u00f6gerung von Diagnostik und Therapie wurden ab dem 16.03", "SPECIES", 212, 326], ["mit allen Funktionsabteilungen intensive Gespr\u00e4che bez\u00fcglich der Gew\u00e4hrleistung einer schnellen und dennoch f\u00fcr alle Beteiligten sicheren Versorgung von COVID-19-(Verdachts\u2011)Patienten gef\u00fchrt: u. a.", "SPECIES", 328, 526], ["CoV", "TEST", 115, 118], ["Diagnostik", "TEST", 197, 207], ["ab dem", "TEST", 314, 320], ["COVID", "TEST", 481, 486]]], ["Neben der Erstellung spezifischer SOP wurden spezielle COVID-19-Telefonnummern in den entsprechenden Abteilungen abgesprochen und transparent an alle Beteiligten kommuniziert.", [["Neben der Erstellung spezifischer SOP wurden spezielle COVID-19-Telefonnummern in den entsprechenden Abteilungen abgesprochen und transparent an alle Beteiligten kommuniziert", "SPECIES", 0, 174], ["COVID", "TEST", 55, 60], ["Telefonnummern", "TREATMENT", 64, 78]]], ["Dies gew\u00e4hrleistet eine unmittelbare Erreichbarkeit der COVID-19-Verantwortlichen der jeweiligen Abteilung.", [["Dies gew\u00e4hrleistet eine unmittelbare Erreichbarkeit der COVID-19-Verantwortlichen der jeweiligen", "SPECIES", 0, 96]]], ["In den entsprechenden Anforderungsformularen des Krankenhausinformationssystems wurde bei der Abfrage der \u201eInfektiosit\u00e4t\u201c eine eigene \u201echeckbox\u201c f\u00fcr V. a.", [["den entsprechenden Anforderungsformularen des Krankenhausinformationssystems wurde bei der Abfrage der \u201eInfektiosit\u00e4t\u201c eine eigene \u201echeckbox\u201c f\u00fcr V. a.", "SPECIES", 3, 154]]], ["COVID-19 erg\u00e4nzt.Diagnostik und Allokation von Verdachtsf\u00e4llenDie anf\u00e4nglich lange Dauer bis zum Erhalt der PCR-Ergebnisse f\u00fchrte schnell zu einer Stagnation des Patientenabstroms (engl.: \u201eexit block\u201c), da jeder Patient mit Fieber und/oder respiratorischen Symptomen bis zum negativen Befund auf der Notaufnahme in Isolation verblieb.", [["COVID-19 erg\u00e4nzt", "CHEMICAL", 0, 16], ["COVID", "PROTEIN", 0, 5], ["Allokation von Verdachtsf\u00e4llenDie anf\u00e4nglich lange Dauer bis zum Erhalt der PCR-Ergebnisse f\u00fchrte schnell zu einer Stagnation des Patientenabstroms (engl.: \u201eexit block\u201c), da jeder Patient mit Fieber und/oder respiratorischen Symptomen bis zum negativen Befund auf der Notaufnahme in Isolation verblieb", "SPECIES", 32, 333], ["COVID", "TEST", 0, 5], ["erg\u00e4nzt", "TREATMENT", 9, 16], ["Diagnostik", "TEST", 17, 27], ["bis", "TEST", 89, 92], ["zum", "TEST", 93, 96], ["Erhalt", "TEST", 97, 103], ["der PCR", "TEST", 104, 111], ["Ergebnisse f\u00fchrte schnell", "TREATMENT", 112, 137]]], ["Gepr\u00e4gt von den Berichten der italienischen Kollegen wurde ab dem 06.03. im Krisenstab des UKM die Einrichtung einer COVID-19-Station vorbereitet.", [["Gepr\u00e4gt von den Berichten der italienischen Kollegen wurde ab dem 06.03", "SPECIES", 0, 71], ["im Krisenstab des UKM die Einrichtung einer COVID-19-Station vorbereitet", "SPECIES", 73, 145]]], ["Innerhalb weniger Tage erfolgte eine bauliche Trennung der Station, die Klimaanlage wurde aufger\u00fcstet und ein \u00c4rzteteam, bestehend aus An\u00e4sthesisten und Internisten, wurde f\u00fcr einen Schichtdienst (2 OA+ 2-2-2) abgeordnet.", [["Innerhalb weniger", "SPECIES", 0, 17], ["Tage erfolgte eine bauliche Trennung der Station, die Klimaanlage wurde aufger\u00fcstet und ein \u00c4rzteteam, bestehend aus An\u00e4sthesisten und Internisten, wurde f\u00fcr einen Schichtdienst", "SPECIES", 18, 195]]], ["Mitarbeiter der Hygiene begleiteten den Umbau und trainierten die Anwendung der pers\u00f6nlichen Schutzausr\u00fcstung mit den Mitarbeitern.", [["Mitarbeiter der Hygiene begleiteten den Umbau und trainierten die Anwendung der pers\u00f6nlichen Schutzausr\u00fcstung mit den Mitarbeitern", "SPECIES", 0, 130]]], ["Somit stand ab dem 18.03.2020 eine Station mit 18 Monitorbettpl\u00e4tzen zur Verf\u00fcgung.", [["ab dem", "OBSERVATION", 12, 18]]], ["Bei Bedarf kann die Station modular auf bis zu 64 Betten erweitert werden.", [["Bei Bedarf kann die Station modular auf bis zu 64 Betten erweitert werden", "SPECIES", 0, 73]]], ["Zus\u00e4tzlich stehen 15 Isolationsbetten auf der Infektionsstation des Universit\u00e4tsklinikums zur Verf\u00fcgung.", [["Zus\u00e4tzlich stehen 15 Isolationsbetten auf der Infektionsstation des Universit\u00e4tsklinikums zur Verf\u00fcgung", "SPECIES", 0, 103], ["Zus\u00e4tzlich stehen", "TREATMENT", 0, 17]]], ["F\u00fcr schwerkranke COVID-19-Patienten wurde die internistische Intensivstation gesplittet und der Teil mit Schleusenzimmern vorsorglich freigehalten.", [["F\u00fcr schwerkranke COVID-19-Patienten wurde die internistische Intensivstation gesplittet und der Teil mit Schleusenzimmern vorsorglich freigehalten", "SPECIES", 0, 146]]], ["5) k\u00f6nnen COVID-19-(Verdachts\u2011)Patienten z\u00fcgig und f\u00fcr alle nachvollziehbar von der Notaufnahme auf die Infekt- oder Intensivstationen weiterverlegt werden, sodass die Handlungsf\u00e4higkeit der Notaufnahme weitestgehend gew\u00e4hrleitet ist.Diagnostik und Allokation von Verdachtsf\u00e4llenZusammenfassend verfahren wir zurzeit mit Verdachtsf\u00e4llen innerhalb der Notaufnahme wie folgt: Klinisch stabile Patienten werden nach Anamnese, Untersuchung, Blutentnahme und Einsendung eines Abstrichs auf SARS-CoV\u20112 nach Hause entlassen (Ergebnis wird telefonisch nachberichtet).", [["Allokation von Verdachtsf\u00e4llenZusammenfassend verfahren wir zurzeit mit Verdachtsf\u00e4llen innerhalb der Notaufnahme wie folgt: Klinisch stabile Patienten werden nach Anamnese, Untersuchung, Blutentnahme und Einsendung eines Abstrichs auf SARS-CoV\u20112 nach Hause entlassen", "SPECIES", 249, 516], ["k\u00f6nnen COVID", "TEST", 3, 15], ["Diagnostik und Allokation von Verdachtsf\u00e4llenZusammenfassend verfahren", "TREATMENT", 234, 304]]], ["Gerade bei schlechter Verf\u00fcgbarkeit bzw. langer \u201eturnaround time\u201c der PCR-Diagnostik hilft die CT-Diagnostik zur fr\u00fchzeitigen Diagnosestellung einer viralen Pneumonie.", [["Gerade bei schlechter Verf\u00fcgbarkeit bzw", "SPECIES", 0, 39], ["langer \u201eturnaround time\u201c der PCR-Diagnostik hilft die CT-Diagnostik zur fr\u00fchzeitigen Diagnosestellung einer viralen Pneumonie", "SPECIES", 41, 166], ["der PCR", "TEST", 66, 73], ["CT", "TEST", 95, 97], ["viralen Pneumonie", "PROBLEM", 149, 166], ["viralen Pneumonie", "OBSERVATION", 149, 166]]], ["Bei aktuell sehr schnell verf\u00fcgbarem PCR-Ergebnis (4\u20136 h) f\u00fchren wir bei uns derzeit CT nur bei negativem PCR-Ergebnis und weiterhin bestehendem Verdacht auf COVID-19 durch \u2013 die Patienten liegen zu diesem Zeitpunkt meist schon auf den Infektionsstationen.", [["Bei aktuell sehr schnell verf\u00fcgbarem PCR-Ergebnis (4\u20136 h) f\u00fchren wir bei uns derzeit CT nur bei negativem PCR-Ergebnis und weiterhin bestehendem Verdacht auf COVID-19 durch \u2013 die Patienten liegen zu diesem Zeitpunkt meist schon auf den Infektionsstationen", "SPECIES", 0, 255], ["Bei", "TEST", 0, 3], ["schnell", "TEST", 17, 24], ["verf\u00fcgbarem", "TEST", 25, 36], ["PCR", "TEST", 37, 40], ["Ergebnis", "TEST", 41, 49], ["f\u00fchren", "TEST", 58, 64], ["wir", "TEST", 65, 68], ["bei uns", "TEST", 69, 76], ["CT", "TEST", 85, 87], ["nur", "TEST", 88, 91], ["PCR", "TEST", 106, 109], ["Ergebnis", "TEST", 110, 118]]], ["Um zus\u00e4tzliche CT-Kapazit\u00e4ten zu schaffen, wurden unter anderem Untersuchungszeiten an Ger\u00e4ten reserviert, die normalerweise nicht in die Notfallversorgung integriert sind (z.", [["CT", "TEST", 15, 17], ["Kapazit\u00e4ten zu schaffen", "TREATMENT", 18, 41]]], ["B. SPECT-CT und PET-CT).Diagnostik und Allokation von Verdachtsf\u00e4llenAndersherum werden alle Notfallpatienten mit radiologischen Zeichen einer Pneumonie umgehend isoliert und mittels PCR getestet.", [["B. SPECT", "TEST", 0, 8], ["CT und PET-CT", "TEST", 9, 22]]], ["Bei konsequenter Anamneseerhebung und Isolation sowie Testung aller symptomatischen Patienten beschr\u00e4nkt sich diese nachtr\u00e4gliche Testung unserer Erfahrung nach auf seltene Zufallsbefunde (z.", [["Bei konsequenter Anamneseerhebung und Isolation sowie Testung aller symptomatischen Patienten beschr\u00e4nkt sich diese nachtr\u00e4gliche Testung unserer Erfahrung nach auf seltene Zufallsbefunde (z.", "SPECIES", 0, 191], ["Testung", "TEST", 54, 61]]], ["B. Pneumonie in der CT-Traumaspirale oder R\u00f6ntgen-Thorax bei Tumorsuche).", [["der CT", "TEST", 16, 22], ["Traumaspirale oder R\u00f6ntgen", "TREATMENT", 23, 49], ["Thorax", "ANATOMY", 50, 56]]], ["Intubierte, komat\u00f6se oder intoxikierte Patienten vom Rettungsdienst werden prophylaktisch schutzisoliert und abgestrichen.", [["Intubierte", "TREATMENT", 0, 10]]], ["Im Fall einer ohnehin notwendigen Schnittbildgebung wird diese gro\u00dfz\u00fcgig um eine Thorax-CT erweitert.", [["CT erweitert", "TEST", 88, 100], ["Thorax", "ANATOMY", 81, 87]]], ["Bislang kam es unter diesem Vorgehen noch zu keiner signifikanten Eintragung von SARS-CoV\u20112 auf die Bettenstationen.", [["Bislang kam es unter diesem Vorgehen noch zu keiner signifikanten Eintragung von SARS-CoV\u20112 auf die Bettenstationen", "SPECIES", 0, 115]]], ["Nat\u00fcrlich wurde im Krisenstab ein generelles PCR-Screening aller Neuaufnahmen intensiv diskutiert.", [["Nat\u00fcrlich wurde im Krisenstab ein generelles PCR-Screening aller Neuaufnahmen intensiv diskutiert", "SPECIES", 0, 97], ["Nat\u00fcrlich wurde", "TEST", 0, 15], ["PCR", "TEST", 45, 48], ["Screening", "TEST", 49, 58]]], ["In \u00dcbereinstimmung mit den RKI-Empfehlungen erfolgt in unserem Klinikum jedoch weiterhin keine generelle Testung asymptomatischer Patienten aufgrund der Scheinsicherheit eines negativen Ergebnisses (geringe Sensitivit\u00e4t) und zur Schonung der Testkapazit\u00e4ten.Patientenlenkung im Haus: Entlastung der NotaufnahmeDas UKM betreut aufgrund der Vielzahl an Spezialambulanzen und seiner hohen Bettenkapazit\u00e4t eine enorme Zahl an Patienten, die sich t\u00e4glich durch das Klinikum bewegen.", [["Empfehlungen erfolgt", "TREATMENT", 31, 51], ["an Spezialambulanzen und seiner", "TREATMENT", 348, 379]]], ["Insbesondere aus den Spezialambulanzen wurde eine Vielzahl von Fragen zum Umgang mit Reiser\u00fcckkehrern aus Risikogebieten und zu immunsupprimierten Patienten mit respiratorischer Symptomatik an die Notaufnahme herangetragen.", [["Insbesondere aus den Spezialambulanzen wurde eine Vielzahl von Fragen zum Umgang mit Reiser\u00fcckkehrern aus Risikogebieten und zu immunsupprimierten Patienten mit respiratorischer Symptomatik an die Notaufnahme herangetragen", "SPECIES", 0, 222], ["Insbesondere aus den Spezialambulanzen wurde", "TREATMENT", 0, 44]]], ["Zun\u00e4chst mussten wir notgedrungen die Einbestellung \u00fcberregionaler Spezialpatienten durch die jeweiligen Fachabteilungen sehr rasch unterbinden, sofern es sich nicht um einen medizinischen Notfall handelte, keine positive Risiko- oder Kontaktanamnese vorlag und das universit\u00e4re Leistungsspektrum nicht zwingend ben\u00f6tigt wurde.", [["Zun\u00e4chst mussten wir notgedrungen die Einbestellung \u00fcberregionaler Spezialpatienten durch die jeweiligen Fachabteilungen sehr rasch unterbinden, sofern es sich nicht um einen medizinischen Notfall handelte, keine positive Risiko- oder Kontaktanamnese vorlag und das universit\u00e4re Leistungsspektrum nicht zwingend ben\u00f6tigt wurde", "SPECIES", 0, 326], ["Zun\u00e4chst mussten wir", "TREATMENT", 0, 20]]], ["F\u00fcr den Umgang mit elektiven Patienten wurde am 13.03.2020 eine dementsprechende SOP zur Patientenlenkung erarbeitet.", [["F\u00fcr den Umgang mit elektiven Patienten wurde am 13.03", "SPECIES", 0, 53]]], ["Diese wurde, erg\u00e4nzt durch den Screeningbogen der Notaufnahme, an s\u00e4mtliche Pforten, Leitstellen, Ambulanzen und Pflegest\u00fctzpunkte verteilt und die Mitarbeiter entsprechend geschult.", [["erg\u00e4nzt durch den Screeningbogen der Notaufnahme, an s\u00e4mtliche Pforten, Leitstellen, Ambulanzen und Pflegest\u00fctzpunkte verteilt und die Mitarbeiter entsprechend geschult", "SPECIES", 13, 181], ["an s\u00e4mtliche Pforten", "TREATMENT", 63, 83], ["Ambulanzen", "TREATMENT", 98, 108]]], ["Durch diese Ma\u00dfnahmen konnte der zus\u00e4tzliche Zustrom von Patienten in die Notaufnahme effektiv reduziert werden.", [["Durch", "TREATMENT", 0, 5]]], ["Nachdem im Verlauf der Ambulanzbetrieb auf reine Notfallpatienten beschr\u00e4nkt wurde, nahmen die hausinternen Anfragen an die Notaufnahme nochmals deutlich ab und beschr\u00e4nken sich aktuell auf wenige Spezialf\u00e4lle bzw. -konstellationen.DiskussionTrotz (oder gerade wegen?) vieler Informations-E-Mails zu einzelnen SOP oder Ma\u00dfnahmen war die Durchdringung bei z.", [["Nachdem im Verlauf der Ambulanzbetrieb auf reine Notfallpatienten beschr\u00e4nkt wurde, nahmen die hausinternen Anfragen an die Notaufnahme nochmals deutlich ab und beschr\u00e4nken sich aktuell auf wenige Spezialf\u00e4lle bzw", "SPECIES", 0, 213], ["Nachdem", "TREATMENT", 0, 7], ["konstellationen", "TREATMENT", 216, 231]]], ["B. Hygienema\u00dfnahmen und \u201ephysical distancing\u201c im Team lange Zeit nicht zufriedenstellend.", [["B. Hygienema\u00dfnahmen und \u201ephysical distancing\u201c im Team lange Zeit nicht zufriedenstellend", "SPECIES", 0, 88]]], ["R\u00fcckblickend w\u00e4re eine fr\u00fchere und noch pers\u00f6nlichere Kommunikation zwischen dem Leitungsteam und den verschiedenen Berufsgruppen in der Notaufnahme notwendig gewesen, um den unterschiedlichen Kenntnisstand bez\u00fcglich der COVID-19-Pandemie anzugleichen.DiskussionObwohl wir fr\u00fchzeitig in zahlreichen Fachabteilungen COVID-Ansprechpartner finden konnten, wurde die Bedeutung der Pandemie f\u00fcr die dortigen Abl\u00e4ufe (auch unabh\u00e4ngig von Notf\u00e4llen) erst verz\u00f6gert wahrgenommen.", [["R\u00fcckblickend w\u00e4re eine fr\u00fchere und noch pers\u00f6nlichere Kommunikation zwischen dem Leitungsteam und den verschiedenen Berufsgruppen in der Notaufnahme notwendig gewesen, um den unterschiedlichen Kenntnisstand bez\u00fcglich der COVID-19-Pandemie anzugleichen", "SPECIES", 0, 251], ["DiskussionObwohl", "TREATMENT", 252, 268], ["fr\u00fchzeitig", "TREATMENT", 273, 283]]], ["Zum Beispiel ist die Problematik der operativen Versorgung von Verdachts- bzw.", [["Zum Beispiel ist die Problematik der operativen Versorgung von Verdachts- bzw", "SPECIES", 0, 77]]], ["COVID-F\u00e4llen erst mit 2 Wochen Versp\u00e4tung aufgegriffen worden.DiskussionObwohl wir alle im privaten Bereich schon sehr konkret an \u201ephysical distancing\u201c arbeiten, sa\u00dfen wir in der Notaufnahme retrospektiv zu lange in zu kleinen Arztzimmern zusammen.", [["DiskussionObwohl wir alle im privaten Bereich schon sehr konkret an \u201ephysical distancing\u201c arbeiten, sa\u00dfen wir in der Notaufnahme retrospektiv zu lange in zu kleinen Arztzimmern zusammen", "SPECIES", 62, 247], ["DiskussionObwohl", "TREATMENT", 62, 78]]], ["Aktuell ziehen wir in zus\u00e4tzliche B\u00fcros in einem Nachbarflur ein.", [["Aktuell ziehen wir", "TREATMENT", 0, 18]]], ["Zus\u00e4tzlich tragen seit Ende M\u00e4rz alle (!)", [["Zus\u00e4tzlich", "TREATMENT", 0, 10]]], ["Mitarbeiter im UKM einen Mund-Nasen-Schutz.DiskussionWir mussten feststellen, dass f\u00fcr die korrekte Verwendung der individuellen Schutzausr\u00fcstung erheblich mehr Schulungsbedarf besteht als geahnt.", [["Mitarbeiter", "TREATMENT", 0, 11]]], ["Ein Ansatz ist die wechselseitige Kontrolle im Rahmen des An- und Ablegens der Schutzkleidung.DiskussionDerzeit optimieren wir unsere bestehenden Ausfallskonzepte, um Pflegende und \u00c4rzte aus anderen Bereichen f\u00fcr den Einsatz in der Notaufnahme vorzubereiten.", [["Ein Ansatz ist die wechselseitige Kontrolle im Rahmen des An- und Ablegens der Schutzkleidung", "SPECIES", 0, 93], ["Ein Ansatz ist die", "TREATMENT", 0, 18], ["Kontrolle", "TREATMENT", 34, 43]]], ["Als Lehrnotaufnahme einer gro\u00dfen Uniklinik bestand zudem die M\u00f6glichkeit, innerhalb von nur 2 Tagen die Zahl der PJ-Studenten in der Notaufnahme von 4 auf 8 zu verdoppeln.", [["Lehrnotaufnahme einer gro\u00dfen Uniklinik bestand zudem die M\u00f6glichkeit, innerhalb von nur 2 Tagen die Zahl der PJ-Studenten in der Notaufnahme von 4 auf 8 zu verdoppeln", "SPECIES", 4, 170], ["Als Lehrnotaufnahme einer", "TREATMENT", 0, 25]]], ["Es besteht eine enge Kommunikation mit dem Dekanat der medizinischen Fakult\u00e4t zwecks Koordination weiterer studentischer Hilfskr\u00e4fte im Bedarfsfall.DiskussionEtwas Gutes hat die COVID-Pandemie zumindest mit sich gebracht \u2013 die Notaufnahme erf\u00e4hrt seit nunmehr 4 Wochen eine grandiose und extrem unb\u00fcrokratische Unterst\u00fctzung durch praktisch alle Bereiche des Unternehmens.", [["Koordination", "TEST", 85, 97], ["Pandemie zumindest mit sich gebracht", "TREATMENT", 184, 220]]], ["Egal ob neue PC oder Telefone, IT-Support, zus\u00e4tzliche Dienstleistungen oder Nachschub von knappen Verbrauchsmaterialien \u2013 die Wege sind deutlich k\u00fcrzer geworden und Probleme werden sehr zeitnah und pragmatisch gel\u00f6st (\u00dcbersicht siehe Tab.", [["Nachschub von knappen Verbrauchsmaterialien \u2013 die Wege sind deutlich k\u00fcrzer geworden und Probleme werden sehr zeitnah und pragmatisch gel\u00f6st", "SPECIES", 77, 217], ["Telefone", "TREATMENT", 21, 29], ["zus\u00e4tzliche", "TREATMENT", 43, 54]]]]}